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 28 
Enterovirus 71 (EV71) is a global infectious disease that affects millions of 29 
people. The virus is the main etiological agent for hand, foot and mouth 30 
disease with outbreaks and epidemics being reported globally. Infection 31 
can cause severe neurological, cardiac and respiratory problems in 32 
children under the age of 5. Despite on-going efforts, little is known about 33 
the pathogenesis of EV71, how the host immune system responds to the 34 
virus and the molecular mechanisms behind these responses.  35 
 36 
The aims of my project are: 37 
 38 
To establish an in vitro infection system to study EV71 viral kinetics to 39 
elucidate if there any difference between virus isolates that cause mild and 40 
neurotropic disease? 41 
 42 
To study the difference in infectivity and immune response in an ex vivo 43 
human blood infection system to see immune involvement plays a role in 44 
this neurotropism 45 
 46 
To assess the ability of the different isolates to infect and cross the blood 47 
brain barrier to see if neurovirulence increases the ability to infect or cross 48 
the blood brain barrier 49 
 50 
To study the inflammatory pathways involved in EV71 51 
immunopathogenesis to see if the different severities of disease induce 52 
different pathways. 53 
 54 
What I found: 55 
Virus isolates from patients with severe outcomes have higher levels of 56 
infectivity 57 
 58 
Only the isolates from the most severe patients can replicate in an ex vivo 59 
PBMC system 60 
 61 
CD4+ T Cells are the main instigators of EV71 replication in PBMCs 62 
 63 
Severe EV71 isolates show an increased ability to disrupt the BBB 64 
 65 
IL-36g could be a involved in a novel pathway related to infection severity 66 
 67 
 3 
Acknowledgements 68 
 69 
I would like to thank my supervisors Prof. Lisa Ng, Prof. Julian Hiscox, Dr 70 
Michael J. Griffiths and Prof. Tom Solomon for their support and for 71 
pushing me the whole way, I would not have made it this far without you. I 72 
would also like to thank all the LN Group members and the Brain Infection 73 
Group members for their constant support, help and hard work throughout 74 
this thesis.  75 
 76 
I would also like to thank several special people who, 77 
without them, I wouldn’t be here. 78 
 79 
My mum and dad. You have always supported me and pushed me to be 80 
the best I can, I wouldn’t have gotten this far without your help and support, 81 
and definitely your hospitality.   82 
 83 
Rachael, Matt, Frankie and Abby. You have always been there, whether 84 
as family, as a friend or just as someone to annoy. I couldn’t ask for better 85 
people to grow up with.  86 
 87 
Stavros. You have helped me so much throughout this PhD, but you were 88 
more than just a mentor, you were a friend, and then became family. I can 89 
never thank you enough. 90 
 91 
Cheryl. I don’t think I could have survived Singapore without you. You were 92 
always there, whether I needed to talk science, or anything else. Thanks 93 
so much twin.  94 
 95 
Hannah. I am so happy to have met you, you make every day feel better. 96 
Your constant encouragement and love have helped push me through this. 97 
I hope to return the favour soon.  98 
 4 
Table of Contents 99 
CHAPTER	1	.............................................................................................................................	11	 100 
INTRODUCTION	....................................................................................................................	11	 101 1.1.0	BACKGROUND	..............................................................................................................................	12	 102 1.2.0	EPIDEMIOLOGY	AND	SPREAD	...................................................................................................	14	 103 1.3.0	BIOLOGY	OF	EV71	.....................................................................................................................	18	 104 
1.3.1	Genome	Organisation	.........................................................................................................	18	 105 
1.3.2	Virus	life	cycle	.........................................................................................................................	20	 106 
1.3.3	Host	Receptors	.......................................................................................................................	22	 107 1.4.0	INFECTION	AND	IMMUNITY	......................................................................................................	24	 108 
1.4.1	Innate	Immunity	against	EV71	......................................................................................	25	 109 
1.4.2	EV71	and	host	replication	factors	.................................................................................	28	 110 
1.4.3	Adaptive	Immunity	and	EV71	.........................................................................................	29	 111 1.5.0	DECIPHERING	PATHOPHYSIOLOGY	USING	IN	VITRO	AND	IN	VIVO	MODELS	.......................	31	 112 
1.5.1	In	vitro	cellular	models	......................................................................................................	31	 113 
1.5.3	Ex	vivo	models	........................................................................................................................	32	 114 
1.5.4	In	vivo	animal	models	.........................................................................................................	34	 115 1.6.0	POTENTIAL	THERAPEUTICS	FOR	EV71	..................................................................................	37	 116 
1.6.1	Antivirals	..................................................................................................................................	37	 117 
1.6.3	Monoclonal	antibodies	.......................................................................................................	38	 118 
1.6.4	Vaccines	....................................................................................................................................	39	 119 1.7.0	THE	BLOOD-BRAIN	BARRIER	..................................................................................................	42	 120 1.8.0	CONCLUSION	................................................................................................................................	44	 121 
CHAPTER	2	.............................................................................................................................	45	 122 
PROJECT	AIMS	.......................................................................................................................	45	 123 
CHAPTER	3	.............................................................................................................................	47	 124 
 5 
MATERIALS	AND	METHODS	.............................................................................................	47	 125 3.1.0	CELL	CULTURE	............................................................................................................................	48	 126 
	3.1.1	Cells	used	.................................................................................................................................	48	 127 
3.1.2	Cell	passaging,	propagation	and	maintenance	.......................................................	49	 128 
3.1.3	Cell	seeding	..............................................................................................................................	51	 129 
3.1.4	Cell	freezing	.............................................................................................................................	52	 130 3.2.0	VIRUS	PRODUCTION	AND	TITRING	..........................................................................................	53	 131 
3.2.1	Virus	isolates	...........................................................................................................................	53	 132 
3.2.2	Viral	propagation	from	clinical	isolates	.....................................................................	53	 133 
3.2.3	Viral	propagation	.................................................................................................................	54	 134 
3.2.4	Viral	titration	.........................................................................................................................	54	 135 
3.2.5	Ultracentrifugation	..............................................................................................................	56	 136 3.3.0	CELL	VIABILITY	ASSAYS	............................................................................................................	57	 137 
3.3.1	CC50	............................................................................................................................................	57	 138 3.4.0	QRT-PCR	SET	UP	......................................................................................................................	58	 139 
3.4.1	Primer	and	probe	design	...................................................................................................	58	 140 
3.4.2	RNA	standard	production	.................................................................................................	60	 141 
3.4.3	Machine	set	up	and	program	..........................................................................................	64	 142 3.5.0	VIRAL	KINETICS	..........................................................................................................................	66	 143 
3.5.1	Infection	protocol	.................................................................................................................	66	 144 
3.5.2	Cell	harvesting	.......................................................................................................................	66	 145 
3.5.3	Staining	procedure	...............................................................................................................	66	 146 
3.5.4	vRNA	extraction	for	viral	load	........................................................................................	68	 147 
3.6.1	Isolating	PBMCs	.....................................................................................................................	69	 148 
3.6.2	Infection	protocol	.................................................................................................................	70	 149 
3.6.3	Cell	harvesting	and	staining	............................................................................................	70	 150 
3.6.4	Flow	cytometry	analysis	....................................................................................................	72	 151 
 6 
3.7.0	CELL	SUBSET	INFECTION	..........................................................................................................	72	 152 
3.7.1	Isolating	subsets	....................................................................................................................	72	 153 
3.7.2	Monocyte	infection	protocol	............................................................................................	72	 154 
3.7.3	CD4+	T	cell	and	CD8+	T	cell	infection	protocol	.......................................................	73	 155 
3.7.4	Cell	harvesting	and	staining	............................................................................................	73	 156 
3.7.5	Flow	cytometry	analysis	....................................................................................................	76	 157 3.8.0	BLOOD	BRAIN	BARRIER	MODEL	.............................................................................................	76	 158 
3.8.1	Setting	up	of	the	model	......................................................................................................	76	 159 
3.8.2	In	vitro	BBB	model	infection	............................................................................................	77	 160 
3.8.3	Trans-endothelial	electrical	resistance	.......................................................................	80	 161 
CHAPTER	4	.............................................................................................................................	90	 162 
RESULTS	..................................................................................................................................	90	 163 4.1.0	IN	VITRO	MODEL	OF	EV71	INFECTION	..................................................................................	91	 164 
4.1.1	Aims	............................................................................................................................................	91	 165 
4.1.2	EV71	clinical	isolates	..........................................................................................................	91	 166 
	..................................................................................................................................................................	94	 167 
4.1.3	Phylogenetic	analysis	of	EV71	clinical	isolates	.......................................................	96	 168 
Viral	isolate	propagation	and	titring	.....................................................................................	96	 169 
	..................................................................................................................................................................	97	 170 
4.1.4	Measurement	of	viral	replication	using	qRT-PCR	..................................................	98	 171 
	...............................................................................................................................................................	100	 172 
	...............................................................................................................................................................	101	 173 
4.1.5	Examining	the	infectivity	of	EV71	clinical	isolates	.............................................	102	 174 
4.1.6	Examining	the	replication	of	EV71	clinical	isolates	...........................................	105	 175 4.2.0	EX	VIVO	HUMAN	BLOOD	EV71	INFECTION	MODEL	............................................................	106	 176 
4.2.1	Aims	.........................................................................................................................................	106	 177 
	...............................................................................................................................................................	108	 178 
 7 
	...............................................................................................................................................................	109	 179 
4.2.2	EV71	infection	in	primary	human	peripheral	blood	mononuclear	cells	...	110	 180 
	...............................................................................................................................................................	112	 181 
4.2.3	Examining	the	infection	kinetics	in	primary	human	PBMCs	..........................	113	 182 
	...............................................................................................................................................................	114	 183 
4.2.4	Examining	the	replication	kinetics	in	primary	human	PBMCs	......................	115	 184 
	...............................................................................................................................................................	116	 185 
	...............................................................................................................................................................	117	 186 
4.2.5	 Non-virulent	 and	 virulent	 strains	 of	 EV71	 isolates	 generate	 different	 187 
immunophenotype	infectability	profiles	.............................................................................	118	 188 
	...............................................................................................................................................................	122	 189 
	...............................................................................................................................................................	123	 190 
	...............................................................................................................................................................	124	 191 
4.2.6	Differential	replication	kinetics	seen	across	 individual	primary	peripheral	 192 
blood	cell	subsets	..........................................................................................................................	125	 193 4.3.0	IN	VITRO	HUMAN	BLOOD-BRAIN	BARRIER	MODEL	.........................................................	127	 194 
4.3.1	Aims	.........................................................................................................................................	127	 195 
	...............................................................................................................................................................	128	 196 
4.3.2	Cerebral	microvascular	endothelial	cell	susceptibility	to	EV71	infection	and	 197 
replication.	.......................................................................................................................................	129	 198 
	...............................................................................................................................................................	130	 199 
4.3.3	In	vitro	blood-brain	barrier	model	optimisation	.................................................	131	 200 
	...............................................................................................................................................................	132	 201 
4.3.4	EV71	isolate	infection	in	an	in	vitro	blood-brain	barrier	model	..................	133	 202 
	...............................................................................................................................................................	135	 203 
4.3.5	Gene	expression	in	the	endothelial	cells	of	the	BBB	during	neurotropic	and	 204 
non-neurotropic	infections	.......................................................................................................	136	 205 
 8 
4.3.6	 Reduced	 expression	 of	 BBB	 junction	 proteins	 coincided	 with	 the	 initial	 206 
reduction	in	TEER	.........................................................................................................................	137	 207 
4.3.7	Suppression	of	IFN	response	associated	with	down-regulated	BBB	proteins 208 
	...............................................................................................................................................................	138	 209 
4.3.8	 Reduction	 in	 host	 PRR	 expression	 levels	 could	 be	 associated	 with	 BBB	 210 
permeability	....................................................................................................................................	138	 211 4.4.0	IMMUNE	RESPONSE	PATHWAYS	INVOLVED	IN	EV71	PATHOGENESIS	.........................	140	 212 
4.4.1	Aims	.........................................................................................................................................	140	 213 
4.4.2	Examining	the	pathways	via	RNASeq	gene	expression	.....................................	141	 214 
	...............................................................................................................................................................	143	 215 
4.4.3	Genes	of	interest	–	IL-6	....................................................................................................	144	 216 
	...............................................................................................................................................................	145	 217 
4.4.4	Genes	of	interest	–	IL-12b	..............................................................................................	146	 218 
	...............................................................................................................................................................	147	 219 
4.4.5	Genes	of	interest	–	IL-36g	...............................................................................................	148	 220 
	...............................................................................................................................................................	149	 221 
	...............................................................................................................................................................	150	 222 
4.4.6	Genes	of	interest	–ISG15	and	ISG20	...........................................................................	151	 223 
	...............................................................................................................................................................	152	 224 
	...............................................................................................................................................................	153	 225 
4.4.7	Genes	of	interest	–	MADCAM1	......................................................................................	154	 226 
Genes	of	interest	–	RBFOX3	......................................................................................................	154	 227 
	...............................................................................................................................................................	155	 228 
4.4.8	Genes	of	interest	–	RASIP1	.............................................................................................	156	 229 
	...............................................................................................................................................................	157	 230 
4.4.9	Genes	of	interest	–	ANKRD1	..........................................................................................	158	 231 
CHAPTER	5	..........................................................................................................................	159	 232 
 9 
DISCUSSION	........................................................................................................................	159	 233 5.1.0	THE	EFFECT	OF	VIRAL	INFECTIVITY	AND	REPLICATION	ON	SEVERITY	DURING	AN	EV71	 234 INFECTION	...........................................................................................................................................	160	 235 
5.1.1	Phylogenetic	analysis	of	EV71	isolates	show	clustering	according	to	severity 236 
	...............................................................................................................................................................	160	 237 
5.1.2	EV71	virus	isolates	that	cause	mild	symptoms	in	patients	have	low	levels	of	 238 
infectivity	and	limited	levels	of	replication	in	an	in	vitro	infection	model	..........	162	 239 
5.1.3	An	increase	in	viral	infection	and	replication	was	seen	in	EV71	isolates	that	 240 
cause	 moderate	 symptoms	 in	 patients,	 compared	 to	 those	 that	 cause	 mild	 241 
symptoms	.........................................................................................................................................	163	 242 
5.1.4	The	severe	isolates	show	the	highest	levels	infection	and	replication	across	 243 
all	groups	..........................................................................................................................................	164	 244 
5.1.5	Further	studies	proposed	for	this	area	.....................................................................	164	 245 5.2.0	EV71	AND	LEUKOCYTE	INTERACTION	DURING	AN	EX	VIVO	PBMC	INFECTION	........	166	 246 
5.2.1	EV71	infection	in	primary	human	peripheral	blood	mononuclear	cells	...	166	 247 
5.2.2	Viral	infection	kinetics	of	EV71	in	an	ex	vivo	PBMC	system	............................	167	 248 
5.2.3	Viral	replication	kinetics	of	EV71	in	an	ex	vivo	PBMC	system	.......................	170	 249 
5.2.4	Infectivity	of	EV71	in	PBMC	subsets	..........................................................................	172	 250 
5.2.5	Individual	leukocyte	subset	infections	with	EV71	isolates	..............................	175	 251 
5.2.6	Further	studies	proposed	for	this	area	.....................................................................	177	 252 5.3.0	EV71	INFECTION	AND	THE	BLOOD-BRAIN	BARRIER	......................................................	178	 253 
5.3.1	BBB	disruption	in	an	in	vitro	model	..........................................................................	178	 254 
5.3.2	Gene	expression	of	the	BBB	during	an	EV71	infection	vs	a	non-neurotropic	 255 
CHIKV	infection	..............................................................................................................................	183	 256 5.4.0	HOST	RESPONSE	PATHWAYS	AND	THEIR	LINK	TO	EV71	SEVERITY	............................	186	 257 
5.4.1	The	host	response	cascade	.............................................................................................	186	 258 
5.4.2	The	role	of	IL-6	on	EV71	severity	................................................................................	188	 259 
 10 
5.1.3	IL-12b	and	its	downstream	effects	during	EV71	infection	..............................	189	 260 
5.1.4	IL-36g	as	a	novel	cytokine	linked	to	EV71	severity	and	HFMD	......................	191	 261 
5.1.5	The	role	and	regulation	of	ISG15	and	ISG20	during	EV71	infection	...........	192	 262 
5.1.6	The	downregulation	of	MADCAM1	linked	to	EV71	severity	............................	193	 263 
5.1.7	The	effect	of	RBFOX3	on	neural	regulation	............................................................	194	 264 
5.1.8	 Severe	 EV71	 may	 cause	 the	 tight	 junction	 instability	 through	 RASIP1	 265 
downregulation	.............................................................................................................................	195	 266 
5.1.9	The	role	of	ANKRD1	EV71	infection	outcome	severity	......................................	196	 267 NOVEL	FINDINGS	AND	OVERALL	CONCLUSIONS	FROM	THIS	WORK	........................................	198	 268 
REFERENCES	.......................................................................................................................	200	 269 
  270 
 11 
 271 
 272 
Chapter 1 273 
Introduction 274 
  275 
 12 
1.1.0 Background 276 
Hand, foot and mouth disease (HFMD) is a common infection caused by a 277 
number of viruses, commonly from the Picornaviridae family, and notably 278 
enterovirus 71 (EV71), coxsackie A6 (CA6) and coxsackie A16 (CA16) (1, 279 
2). HFMD predominantly affects young children, however older children 280 
and adults can also be affected (3, 4). The main symptoms of the disease 281 
are fever, and blisters on the hands, feet and mouth. Other usual clinical 282 
signs of HFMD include, nausea, vomiting, sore throat, fatigue, malaise, 283 
loss of appetite and irritability. About 3 to 5 days after exposure to the virus, 284 
flat, red or discoloured bumps appear, almost rash-like, on the skin around 285 
the hands, feet mouth and buttocks of the patient. These can often blister 286 
and become vesicular sores (5). This rash is rarely itchy for infants, but it 287 
can be extremely itchy for an adult with the disease. The disease, whilst 288 
quite infectious, is normally self-limiting and symptoms usually disappear 289 
7 to 10 days after disease onset (Fig 1) (5-10). Although HFMD is typically 290 
a mild illness, severe complications can sometimes occur. These include 291 
encephalitis, meningitis, acute flaccid paralysis, cardiorespiratory failure 292 
and can be fatal (Fig 1)(11). 293 
 294 
The coverage of HFMD, with the exception of Polar regions, is global in 295 
distribution (12-21). The disease is most prevalent in the Asian-Pacific 296 
region where it has been endemic since the 1990’s; and has subsequently 297 
caused large-scale epidemics every few years (21-30). Unfortunately, 298 
there are no specific anti-viral treatments for any of the viruses that cause 299 
HFMD. 300 
 13 
301 
EV71 virus enters body 
via faecal-oral route 
Viral replication in 
tonsillar crypt or 
Peyer’s patches 
Onset of symptoms 
and viraemia 
Increased viraemia and 
possible sepsis 
Viral clearance and 
resolution of 
symptoms 
Strong inflammatory 
immune response 
Virus enters host 
CNS 
Neuronal and 
astrocytic cell death 
Cytokine storm 
Large CNS immune 
and inflammatory 
response  
Brainstem Encephalitis 
Damage to medulla 
oblongata 
Increase in 
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Total cardio-respiratory 
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Peyer’s patches 
Blood flow 
Red blood cell 
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Figure 1.  The immunopathophysiology of EV71 and the symptoms it leads to. 
Flow diagram representing the pathogenesis and immune response to an EV71 
infection. Green represents outcomes with mild symptoms that are usually resolved 
in 7-10 days, including photos of patient with hand, foot and mouth disease 
symptoms (left) and a healthy child (right). Orange shows pathophysiology and 
host responses which lead to moderate to severe outcomes and red symbolises 
severe to fatal outcomes. The photographs in this figure were published with 
consent from the parent /legal guardians of the children. 
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Therefore, the treatment strategies for mild HFMD consist of palliative care 302 
including rehydration, analgesics for painful blisters and anti- 303 
inflammatories to reduce swelling (31-33). There is also no specific 304 
treatment of more severe HFMD that can be complicated by 305 
cardiorespiratory collapse. Key treatments are mechanical ventilation and 306 
inotropic support. Empirical treatments such as IVIG and continuous renal 307 
replacement therapy have been used in recent Asian outbreaks, but there 308 
are largely anecdotal (32, 33). 309 
 310 
1.2.0 Epidemiology and Spread 311 
 312 
HFMD usually affects children between the ages of 6 months to 5 years 313 
old; as this is the time when they no longer receive the benefits of passively 314 
transferred maternal antibodies. These antibodies can aid in protecting 315 
them from the etiological agents i.e. EV71 that cause the disease, when 316 
their own immune system is not fully developed to fight the virus on its own 317 
(34). After the first encounter with the virus the child should start producing 318 
antibodies against the viral agent. These antibodies may offer a cross 319 
protective effect the next time the child encounters a HFMD causing virus 320 
(35-37). 321 
 322 
The main etiological agents of HFMD are the coxsackievirus A16 (CA16) 323 
and enterovirus 71 (EV71), both of which are from the Enterovirus A 324 
species of the Enterovirus genus of the Picornaviridae family (38-40). 325 
 15 
Other viruses such as coxsackie A5, A6, A9, A10, B2, and B5 have also 326 
been reported to cause the disease (17, 41-46). Of the two main, etiological 327 
agents that cause HFMD, only EV71 leads to neurological complications. 328 
(Fig 1) (7, 24, 33). Since the almost total eradication of poliovirus, EV71 329 
has become the most important neurotropic Enterovirus in the world. 330 
However, there is still much that is unknown about the interactions of this 331 
virus and more studies are required in this area to fully unravel the 332 
complete mechanism of EV71 (47, 48). 333 
 334 
EV71 has been found all over the world with different symptoms and clinical 335 
manifestations seen during different outbreaks. The virus was first isolated 336 
in California, USA in 1969 from patients suffering from central nervous 337 
system (CNS) infections with cutaneous signs (49). EV71 was next seen 338 
in Europe, in Bulgaria and Hungary where patients suffered from CNS 339 
infections with cardiorespiratory failure and acute flaccid paralysis (50, 51). 340 
EV71 was also starting to be seen in Asia at this time, with Japan reporting 341 
outbreaks of HFMD and CNS infections caused by EV71 (52, 53).   342 
 343 
In 1997 an outbreak of EV71 presenting with HFMD, cutaneous infections, 344 
CNS infections, cardiorespiratory collapse and sudden death was reported 345 
in Malaysia (8, 54). Since then, outbreaks and epidemics of EV71 with 346 
these clinical manifestations have become endemic to the Asian-Pacific 347 
region (21-30).  348 
 349 
 16 
This protracted epidemic has drawn specific scientific interest. These 350 
outbreaks, with their larger variety of symptoms have drawn more 351 
questions that need answering about EV71 and its pathophysiology. 352 
 17 
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Figure 2. The genomic and molecular make up of the EV71 genome.
(A) Diagram showing the EV71 genome, polyprotein and protein products
produced during EV71 replication, size in base pairs (bp) also show. (B)
Picture representation of the T=3 structure of the VP1-3 structural genes of
the EV71 capsid.
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1.3.0 Biology of EV71  354 
1.3.1 Genome Organisation 355 
 356 
EV71 is a positive sense RNA virus, with a genome approximately 7.4kb 357 
long with one open reading frame coding for the 4 structural (VP1-4) and 7 358 
non-structural proteins (2A-C and 3A-D) (55). The genome is initially 359 
translated as a single polyprotein, which is then cleaved into the three 360 
cleavage intermediates P1, P2 and P3 (Fig 2). P1 is cleaved into VP3, VP1 361 
and VP0 (which is then in turn cleaved to form VP4 and VP2). The VP1, 362 
VP2 and VP3 proteins form a surface pentameric subunit together with the 363 
VP4 protein, attached to the inner surface (Fig 2). The capsid is formed by 364 
a quasi-T = 3 symmetry of 60 copies of this subunit to form an icosahedral 365 
capsid (56).  366 
 367 
P2 is cleaved to form the viral protease 2A, and the 2BC polyprotein, which 368 
is then further cleaved in to the two non-structural proteins 2B and 2C. The 369 
protein 2B is thought to be a viroporin (57), which is important for the 370 
replication of the viral genome. It is thought to create a pore in the ER of 371 
the host cell and consequently releases Ca2+ ions in the cell’s cytoplasm, 372 
which may trigger membrane trafficking and viral protein transport (57). 2C 373 
is one of the most complex proteins in the EV71 genome, however its full 374 
function has not been discovered yet. 2C has been shown to play a role in 375 
encapsidation (58), cellular membrane rearrangement (59), immune 376 
evasion (60), RNA replication (60) and uncoating (61).  377 
 378 
 19 
P3 is initially cleaved into 3AB and 3CD, and then further proteolysed to 379 
form the 3A, 3B, 3C and 3D proteins (Fig 2) (62). 3A localises the 380 
replication complex of the virus to the surface vesicle membranes, it also 381 
inhibits ER-to-Golgi apparatus transport in host cells and causes the Golgi 382 
complex to disassemble. This results in the depletion of IFN receptors and 383 
MHC (63). The 3B protein is also known as VPg (viral protein genome- 384 
linked), which acts as an initiator for EV71 replication by covalently linking 385 
the genomic RNA (64). 3C is EV71’s other protease, which is responsible 386 
for most of the cleavage of the junction sites within the EV71 polyprotein 387 
(65). It also acts as part of the replication complex by binding to the 5’UTR 388 
of the viral RNA (66). Another function of the 3C protein is the cleavage of 389 
host immune factors such as TRIF (67) and RIG-I (68), to aid viral immune 390 
evasion. EV71’s 3D protein acts as a RNA-directed RNA polymerase, 391 
which replicates the viral genomic RNA (69). 392 
 393 
EV71 has been divided in to 6 genogroups, A, B, C, D, E and F. The 394 
genogroups B and C can be further divided into the sub-genogroups B0- 395 
B5 and C1-C5.  These genotypes were identified through genetic analysis 396 
of the VP1 gene (40). All of the genogroups of EV71 have an amino acid 397 
(aa) sequence similarity of over 90% to the virus genogroup A prototype 398 
BrCr strain; with B > 92.2%; C > 91.9%; D = 95.2%; E > 93.6% and F > 399 
93.6% (70). They also have a high amino acid sequence similarity within 400 
the subgenogroups individually, with A > 94.9%; B > 95.9%; C > 94.2%; E 401 
= 96.9% and F = 96.9% (information on D not available) (70). While the B 402 
and C subgroups have a global distribution, D, and E and F are restricted 403 
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to India and Africa respectively (70). Further phylogenetic analysis and 404 
Bayesian relaxed molecular clock method experiments suggests than 405 
EV71 originally emerged from CA16 around 1941 (40). 406 
1.3.2 Virus life cycle 407 
 408 
As humans are the only known hosts of EV71, all transmission is assumed 409 
to be human-to-human. The virus can survive on external surfaces for up 410 
to 3 days, so direct human-to-human contact is not always necessary as 411 
the virus can be picked up from these contaminated areas (71). The main 412 
route of transmission is through the faecal-oral route (71), however it can 413 
also be spread through contact with virally contaminated vesicular fluid, 414 
surfaces, fomites and oral secretions as well as respiratory droplets (Fig 1) 415 
(72). EV71 has been also found in faecal samples of symptomatic patients 416 
up to 75 days after infection, and up to 14 days in the throat (73). 417 
 418 
Evidence suggests that the initial phase of replication occurs in lymphoid 419 
tissues of the tonsillar crypt (74) and in the Peyer’s patches of the small 420 
intestine (Fig 1) (71). The virus undergoes further replication in the adjacent 421 
lymph nodes (cervical and mesenteric lymph nodes respectively) and this 422 
often leads to a mild viraemia (75). In the majority of patients, viral infection 423 
is controlled at this point and the patients remain asymptomatic (76). 424 
However, if the viral infection is not controlled, the virus will then reach high 425 
titres, and disseminate to the skin and mucous membranes to cause 426 
HFMD. In a small proportion of patients, EV71 can also enter the central 427 
nervous system and cause severe complications (Fig 1) (72). It has been 428 
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noted that children who had detectable viraemia after 3 days had 429 
significantly more severe complications (Fig 1) (75).  430 
 431 
Retrograde axonal transport has been proposed as the method of entry to 432 
the brain and CNS for EV71, as when mice were inoculated at the hind 433 
limbs with EV71 the virus appeared to be spread from the lower to the 434 
upper spine (77). However, with many receptors for EV71, including one 435 
on lymphocytes (78) retrograde axonal transport may not be the only mode 436 
of entry. After gaining entry to the brain and CNS, EV71 causes neuronal 437 
and astrocytic cell death (Fig 1) (79, 80), which in turn leads to the CNS 438 
immune and inflammatory response and brainstem encephalitis (Fig 1) 439 
(79). This leads to the mass release of certain cytokines, known as a 440 
cytokine storm (81). There have been many cytokines implicated in EV71 441 
brainstem encephalitis which have been discovered to be significantly 442 
increased in patients that suffer from pulmonary oedema. These include 443 
IL-1β, IL-1RA, G-CSF (82), IL-6, IL-10, TNF-α and IFN-γ (Fig 1) (81, 83, 444 
84). The destruction of the brainstem during EV71 infection, including the 445 
vasomotor and respiratory centres leads to a surge of catecholamines and 446 
autonomic dysfunction (85, 86), which may be the cause of 447 
cardiorespiratory problems (Fig 1). 448 
 449 
 It is currently unknown what is the exact cause of cardiac failure and 450 
pulmonary oedema but is thought to be a combination of these elements, 451 
cytokine storm and brainstem destruction.  452 
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1.3.3 Host Receptors 453 
 454 
At least five molecules have been identified as possible cell surface 455 
receptors for EV71. Scavenger receptor B2 (SCARB2) (87), P-selectin 456 
glycoprotein ligand-1 (PSGL-1) (78) sialylated glycan (88), heparan 457 
sulphate (89) and annexin II (Anx2) (90) have been reported to act, 458 
individually, as receptors for EV71. The most characterised of these five 459 
are scavenger receptor class B member 2 (SCARB2) and P-selectin 460 
glycoprotein 1 (PSGL-1) (78, 91). SCARB2 (also known as LIMP-2) is a 461 
highly abundant protein found in the lysosomal membrane, which 462 
participates in the reorganisation and membrane transport of the 463 
endosomal/lysosomal compartment. SCARB2 can acts as a receptor for 464 
all strains of EV71 and is considered the critical receptor for infection (92). 465 
PSGL-1, which is primarily expressed on the surface of leukocytes, is 466 
involved in leukocyte rolling/interacting with the vascular endothelium in the 467 
early stages of inflammation (93). A post translational modification, namely 468 
the tyrosine sulphation at the N-terminus of PSGL-1 was identified as being 469 
crucial for the binding of PSGL-1 to EV71 and for viral replication in 470 
lymphocytes (94). Some EV71 subgroups do not utilise PSGL-1 as a 471 
receptor to enter immune cells, as they cannot bind to the receptor. Only 472 
viruses with a G or Q amino acid at residue 145 of the structural protein 473 
VP1 can bind to PSGL-1 (95). 474 
 475 
Mouse L929 cells that normally do not support EV71 infections, became 476 
highly infected with EV71 after being transfected and overexpressed with 477 
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either SCARB2 or PSGL-1 (92). Although the L-SCARB2 cells were shown 478 
to be more susceptible to EV71 infection than L-PSGL-1 cells, they bound 479 
with a lower amount of EV71 when compared with the L-PSGL-1 cells. This 480 
indicates that the binding ability of the receptor does not determine the 481 
infection efficiency of said receptor (92). 482 
 483 
  484 
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1.4.0 Infection and Immunity 485 
As there is currently no effective treatment available for EV71, 486 
understanding virus/host interactions in greater detail will provide an 487 
increased knowledge base for the successful development of medical 488 
countermeasures (4). 489 
 490 
The innate immune response is one of the body’s earliest ways of fighting 491 
off pathogens (96). This immune response uses specific receptors that can 492 
recognise diverse foreign moieties and then launch an immune response 493 
to try and limit the infection (96). The innate immune response is much less 494 
specific than the adaptive immune response, but much more rapid and 495 
reacts instantaneously upon the discovery of pathogens. The first line of 496 
defence contributes by effectively limiting the infectivity of a pathogen, as 497 
well as activating the adaptive immune response to help destroy and clear 498 
the pathogenic organism (96).  499 
 500 
Host cells, both immune and non-immune contain innate receptors called 501 
pattern-recognition receptors (PRRs), which can recognise 502 
materials/molecules of pathogens, and components of cell damage/death. 503 
These PRRs recognise the pathogens via the detection of PAMPS 504 
(pathogen associated molecular patterns) (97). PRRs can also recognise 505 
molecules from stressed/dying cells, named danger associated molecular 506 
patterns (DAMPs) and launch a response (98). The main receptors of viral 507 
PAMPs are toll-like receptors (TLRs), nucleotide oligomerisation domain 508 
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(NOD) like receptors (NLRs) and retinoic acid inducible gene I (RIG-I) like 509 
receptors (RLRs) (99). 510 
1.4.1 Innate Immunity against EV71 511 
 512 
EV71 is mainly detected via the RLRs; RIG-I, melanoma differentiation- 513 
associated protein 5 (MDA5), and TLR3 (100). The binding of EV71 to the 514 
RLRs sets off a signalling cascade activating mitochondrial antiviral- 515 
signalling protein (MAVS). MAVS associates with tumour necrosis factor 516 
(TNF) receptor associated factor 3 (TRAF3), recruiting TANK-binding 517 
kinase 1 (TBK1) and IκB kinase, leading to the phosphorylation of 518 
interferon regulatory factors 3 and 7 (IRF-3 and IRF-7) (101) (Fig 3). This 519 
phosphorylation causes these two IRF molecules to dimerise, causing the 520 
formation of hetero- and homodimers, which translocate to the nucleus and 521 
bind to interferon stimulate response elements (ISREs). This leads to the 522 
expression of type I interferon genes (101). MAVS activates NF-κB through 523 
a caspase 8/10 dependent pathway (102) (Fig 3). TLR3 also activates NF- 524 
κB by inducing TIR-domain-containing-adapter-inducting Interferon- β 525 
(TRIF), which associates with receptor-interacting protein 1 (RIP1), 526 
activating NF-κB (Fig 3). This coordinated network activates many pro- 527 
inflammatory cytokines, chemokines, enzymes and adhesion molecules to 528 
fight the pathogen (103). 529 
 530 
  531 
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 532 
Figure 3. Signalling cascade of TLR’s and RLR’s during viral infection.
PRRs scan both the intra and extracellular environment for pathogenic
complexes. If found, ligand-activated receptors bind adaptor proteins and recruit
protein kinases and ubiquitin-protein ligases. This causes the regulation of
immune signal transduction to transcription factors through post transcriptional
modification of signalling cascade proteins. Activated transcription factors then
translocate into the nucleus and bind to promoters, stimulating appropriate
antiviral gene transcription. Blue and green circles represent ubiquitination and
phosphorylation, respectively. Black arrows = activation; red lines = deactivation.
Adapted from Heaton et al; JEM 2015
TLR Signalling RLR Signalling
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Interferons (IFN’s) are molecules that are vital to the body’s immune 533 
response in order to help control virus replication and spread (104). Based 534 
on the interaction they have with their receptors, they have been 535 
categorised into three groups; type I, type II and type III. Both type I and 536 
type III IFNs have been suggested to play vital roles in the defence against 537 
viral infections (105). Specific interferon-α (IFN-α; a type I IFN molecule 538 
produced by leukocytes) subtypes have been shown to be inhibitors of 539 
EV71 infection (IFN-α4, 6, 14 and 16) (106). Unfortunately, IFNs have only 540 
been shown to be effective as pre-treatments as in vivo and patient studies 541 
suggest that IFN’s offer little help as a treatment after contraction of the 542 
virus (107). 543 
 544 
Viral proteases are vital for the processing of most viral polyproteins. EV71 545 
relies on its two proteases, 2A and 3C, to cleave viral protein precursors 546 
into their functional forms (Fig 2) (108). These proteases not only cleave 547 
viral proteins, they can also cleave host proteins to aid in immune evasion 548 
(109). Viral protease 2A has been shown to cleave MDA5, the main cellular 549 
receptor for detecting EV71 infection (Fig 3). This cleavage diminishes the 550 
production and activation of IRF-3 and IFN type I (110). The EV71 protease 551 
2A can also cleave MAVS at several sites which again leads to the 552 
disruption of IRF-3 phosphorylation and a decrease in type I IFN 553 
production, leading to increased EV71 propagation, compared to if the 554 
response was active (102). Data has been presented that suggests 2A 555 
interferes with IFNAR I by reducing its expression (111). The reduction in 556 
IFNAR I expression has been postulated as why exogenous IFN has had 557 
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limited effect as a treatment (112). However, this hypothesis is still 558 
contested by some (113), and more evidence will be needed to address 559 
this hypothesis.  560 
 561 
Inhibition of the host interferon response has also been shown by the 3C 562 
protease (68). 3C interacts with the N-terminal domain of RIG-I preventing 563 
the interaction with MAVS and leading to a decrease in nuclear 564 
translocation and expression of IRF-3 and IFN (Fig 3) (68). Similarly, EV71 565 
3C has been shown to bind and degrade IRF-9 (114) and to cleave IRF-7 566 
(115) impairing the ability of these two cellular proteins to stimulate the 567 
production of ISGs and IFN. 568 
1.4.2 EV71 and host replication factors 569 
 570 
The genome of EV71 is uncapped and therefore initiation of translation by 571 
ribosomes is facilitated by the presence of a type I internal ribosome entry 572 
site (IRES) (116). This tertiary RNA structure is a common feature at the 5’ 573 
end of picornaviruses.  Initiation of translation at an IRES requires specific 574 
cellular proteins and their absence can lead to inefficient IRES-dependent 575 
translation. During EV71 and general Picornavirus infection, host cell 576 
factors, known as IRES transacting factors (ITAFs), involved in the 577 
initiation of cap-dependent translation on host mRNAs are degraded by 578 
viral proteases (109). Thus inhibiting cap-dependent host cell translation 579 
and facilitating the translation of viral genomes (which act as an mRNA) 580 
(117). During viral infection, EV71 expresses viral protease 2A that cleaves 581 
eIF4G, part of the eukaryotic initiation factor 4F complex (eIF4F) needed 582 
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for cap dependent translation. Although this results in a significant 583 
decrease in the hosts capped mRNA translation, it increases the 584 
translation efficiency of the EV71 IRES (118). 585 
 586 
Some novel ITAFs for EV71 have also been discovered. Far upstream 587 
element binding protein 1 and 2 (FBP1 and 2) have both been identified as 588 
novel ITAFs for EV71 (119, 120). FBP1 enhances the replication activity of 589 
the virus and IRES-dependent translation. FBP2 however has been shown 590 
to be a negative regulator of IRES activity, by out competing the positive 591 
ITAF hnRNP1 (116). However, EV71 infection triggers proteasomal, 592 
autophagic and caspase activity mechanisms of the host cell, which cleave 593 
FBP2, and these cleavage fragments transform FBP2’s function from a 594 
negative regulator to a positive promoter. (119, 120) 595 
 596 
EV71’s ability to interrupt, intercept and disrupt the host immune response 597 
is critical to the survival and propagation of the virus, and whilst this has a 598 
negative effect for the patients, it gives an insight into possible areas that 599 
could be targeted to disrupt virus biology. 600 
1.4.3 Adaptive Immunity and EV71 601 
 602 
Even though there is still a lack of understanding around the viral infection 603 
process. Especially concerning the viral migration from the primary sites of 604 
infection e.g. tonsils, Peyer’s patches and respiratory mucosa to the brain 605 
and CNS via the circulatory and nervous systems. Previous studies have 606 
identified possible mechanisms of pathogenesis during EV71 infection (77, 607 
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121, 122).  Several of the EV71 specific receptors can be found on certain 608 
human white blood cells. DC-SIGN has been reported on the surface of 609 
immature dendritic cells (123), annexin II, SCARB2 and PSGL-1 have been 610 
shown to be expressed on the surface of dendritic cells, monocytes and 611 
epithelial cells (78, 90, 124). With PSGL-1 also being found on B cells, T 612 
cells and neutrophils (125, 126). EV71 has been found to have the ability 613 
to infect immature dendritic cells in vitro, offering the possibility that it can 614 
migrate from here into the associated tissues and organs e.g. the 615 
brainstem and CNS (123). Furthermore, high levels of EV71 have been 616 
found in the lymphocytes of infected animal models (127) and human 617 
patients (50). This suggests that there is an interaction between these 618 
leukocytes and the virus during severe EV71 infection.  619 
  620 
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1.5.0 Deciphering pathophysiology using in vitro and in 621 
vivo models 622 
1.5.1 In vitro cellular models 623 
 624 
In vitro models whilst being the initial “go to” model for viral experiments, 625 
can come in many different forms and serve many different purposes. The 626 
most basic of these are isolation and viral kinetics, for which 627 
rhabdomyosarcoma (RD) cells are the most utilised for EV71 (128). One 628 
major advantage of in vitro cellular models is that they can be adapted and 629 
modified very easily. This aids the discovery of important proteins and 630 
cellular functions that would otherwise be extremely difficult. The EV71 631 
cellular receptor, SCARB2 was identified utilising in vitro techniques. 632 
Mouse L929 cells, not known to be targeted by EV71 were first transfected 633 
with RD cell genomic DNA and then infected with EV71. Transcriptomics 634 
analysis on highly infected cells identified SCARB2 as the receptor 635 
responsible for this new ability to become infected (87). PSGL-1 was 636 
discovered using Jurkat cells, an immortalised T cell cell line (78). A 637 
retroviral cDNA library from EV71 susceptible Jurkat cells was generated 638 
and then used for expression cloning. Transduction of P3U1 produced four 639 
colonies that bound to EV71 coated dishes, which all encoded PSGL-1 640 
(78). Without this in vitro model, this discovery may not have occurred as 641 
ex vivo primary T cells do not easily proliferate (especially without 642 
stimulation), and therefore this type of experiment would not have been 643 
feasible.  644 
 645 
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Another advantage of using cell lines is they can provide lines that are not 646 
always readily available as primary cells. Primary human monocytes and 647 
T cells often not easily accessible due to availability or ethics, however with 648 
in vitro cell lines such as THP-1 (monocytes) or Jurkat (T cells) these 649 
issues can be easily overcome. THP-1 cells have been used to show the 650 
role of NLRP3 inflammasome activation and IL-1β maturation during 651 
interaction with the EV71 protein 3D (129).  652 
1.5.3 Ex vivo models 653 
 654 
Whilst they are not always readily accessible, primary ex vivo models can 655 
be of huge benefit to investigations as they bridge the gap between 656 
immortalised in vitro cell lines and in vivo animal models. They provide 657 
insights into how the body might react to an infection without any chance 658 
of harm to the host. Understanding EV71’s ability to infect immune cells 659 
and their possible role in EV71 severity and fatalities was not always clear. 660 
However, using ex vivo models allowed studies to investigate the direct 661 
effect EV71 has on these immune cells and any indirect downstream 662 
effects (130). EV71 was shown to directly infect monocytes and 663 
lymphocytes from freshly isolated blood mononuclear cells (PBMCs) and 664 
induce the production of pro-inflammatory cytokines such as TNF-α and 665 
MIF during the course of an infection (130). Ex vivo models have been 666 
used to show how the activation of JNK1/2 and p38 MAPK pathways can 667 
promote EV71 infection in dendritic cells (DCs) (131). 668 
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669 
Cell Line Uses Benefits Drawbacks
Rhabdomyosarcoma 
(RD) - Human Muscle
General viral propagation,
general cell assays, detection
assays, proliferation assays,
viral titre determination
Very easy to grow and proliferate. Easily
infectable with all strains of EV71. Can be used
for a wide variety of different assays and
experiments.
Immortalised cell line, so they have limited
characteristics compared to primary cells. RD cells
are originally from muscle cells which is not a main
target of EV71 so not fully representative.
Vero - African Green 
Monkey Kidney
Same as RD cells
Very easy to grow and proliferate. If infectable,
can be used for a wide variety of assays and
experiments. Grow in a monolayer so can be
used for plaque assays.
Not as effective as RD cells. Not all virus
genotypes/subgenotypes will infect and/or replicate
in vero's, hence why RD cells are the main go to
cell.
Jurkat - Human T 
Cell
To study the effect and role of
EV71 infection in T cells
Have a close phenotype to primary T cells, but
are much easier to grow and cultivate. Do not
require any external stimulation to proliferate
(e.g. IL-2).
They are an immortalised cell line so their
characteristics may deviate from primary T cells
which may result in altered or unrealistic
phenomenoms.
THP-1 - Human 
Monocyte
To study the effect and role of
EV71 infection in Monocytes
Have a close phenotype to primary monocytes,
but are much easier to grow and cultivate. Will
only differentiate if stimulated with PMA, unlike
primary monocytes which will differentiate with
time.
They are an immortalised cell line so their
characteristics may deviate from primary
monocytes which may result in altered or
unrealistic phenomenoms.
SK-N-SH - Human 
Brain
To study the effect and role of
EV71 infection in the brain
and neurons
Have a close phenotype to primary neurons,
but are much easier to grow and cultivate. Will
proliferate spontaneously, compared to primary
neurons which only differentiate and do not
proliferate.
Immortalised cell line. Do not grow uniformly, tend
to grow in clumps. Can become differentiated
which will alter the effect of the virus on the cells
and produce different response.
L929 - Mouse 
Connective Tissue
To study the function of EV71
receptors and their ability to
facilitate infection
Useful for the study of receptors, any infection
seen is due to receptor's interaction with EV71,
false positives are rare as wild type cell line
cannot be infected.
Cannot be infected by EV71 unless transfected
with the appropriate receptors. Can only be used in
the study of EV71 receptors and functionality.
PBMCs – Human 
Peripheral Blood 
Mononuclear Cells  
To study EV71 in primary
blood cells and study the
effect of EV71 on the immune
system and host defence
pathways
Closest cells to replicate host response,
without doing an in vivo experiment. As no
serum or plasma present then it is unlikely
there will be any interference from donor
antibodies.
Show low level infection with EV71. Not always
readily available in the necessary numbers. Ethical
approval needed. Cannot easily proliferate, so long
term studies difficult.
Table 1. Table showing the commonly used cell lines in EV71 experiments, their uses, benefits and drawbacks.
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1.5.4 In vivo animal models 670 
 671 
Interestingly, in vivo mouse models of EV71 have demonstrated an age- 672 
dependent susceptibility to the virus (132-135). Non-transgenic, 673 
immunocompetent mice are resistant to EV71 infection once they are past 674 
the weaning stage, regardless of the route of infection (132-135). In an 675 
effort to develop an EV71 mouse model more similar to the onset of human 676 
disease, mouse-adapted EV71 strains have been generated that are 677 
capable of infecting mice via the oral route, and can cause neuropathology 678 
in the brainstem and spinal cord as well as paralysis of the rear limbs (136- 679 
138). However, these models still have an age limitation and do not cause 680 
the onset of disease after the mice reach 14 days old (136-138). Whilst 681 
these models are not ideal due to their age-limiting factor, they have still 682 
proven to be useful tools in the examination of EV71 pathogenesis. This 683 
model was used in the discovery of type I interferon being an essential 684 
innate defence mechanism in the controlling or EV71 infection and that 685 
EV71 tries to avoid this mechanism by inhibiting type I interferon through 686 
its 3C protease (107, 139).  687 
 688 
To get around this age limitation, immunocompromised models such as 689 
NOD/SCID (133) and AG129 (135) mice have been used which cause 690 
similar features and symptoms seen in the immunocompetent mouse 691 
models but in older mice (133), (135). Whilst this is an advantage, it also 692 
has its drawbacks, namely immunocompromised mice stray further from 693 
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the human model they are trying to replicate and thus give us a less reliable 694 
report on what may be causing these symptoms in humans (140). 695 
 696 
Transgenic mice containing the human EV71 receptors SCARB2 and 697 
PSGL-1 have been generated and been shown to be infected with EV71 698 
to varying degrees (132, 141). Mice expressing the PSGL-1 gene are only 699 
susceptible to mouse-adapted strains of EV71, and whilst this model 700 
exhibited symptoms that were similar to those seen in wild-type mice, these 701 
mice suggest that PSGL-1 cannot provoke EV71 infectivity in mice on its 702 
own (141). Transgenic mice that express the human SCARB2 in their CNS 703 
neurons, lung pneumocytes, hepatocytes and intestinal epithelium (i.e. 704 
similar profile to humans) have been shown to be susceptible to infection 705 
by EV71 after they are 6 weeks of age. These mice display symptoms of 706 
neurotropism, neuropathology, ataxia, paralysis and death, which are 707 
similar to symptoms seen in humans (132). 708 
 709 
Non-human primates have been shown to be susceptible to EV71 infection 710 
and have since been used in various studies (122, 142). Cynomolgus 711 
monkeys show very similar neurological manifestations of symptoms when 712 
infected intraspinally or intravenously, including acute flaccid paralysis, 713 
ataxia and encephalitis. The animals also presented with a broad viral 714 
circulation including spinal cord, cerebrum, brainstem and CNS (122) 715 
(142). However, they do not suffer from blisters or lesions on the skin, nor 716 
do they suffer from pulmonary oedema (122, 142). A Rhesus monkey 717 
model has also been used to assess EV71 infection. These monkeys also 718 
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develop CNS infections after intracranial, intravenous, intratrachial or orally 719 
given virus. Tissue damage and cellular infiltrates in the lungs were noted 720 
in these monkeys, they were not observed in the spleen or pancreas, which 721 
also show high viral load. Although these monkeys did not show vesicular 722 
lesions on the skin or typical neurological symptoms, half of them did suffer 723 
from pulmonary oedema when infected intracranially (143). This is the first 724 
model to show this symptom outside of humans, however it is not known if 725 
the pulmonary oedema is due to CNS damage and inflammation or if it is 726 
a consequence of viral cytolysis in the lungs (143). 727 
 728 
Whilst these animal models are not perfect representations of the disease 729 
or the route in takes in humans, they still provide us with lots of crucial 730 
information on the role of the virus and of the host immune response.  731 
 732 
  733 
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1.6.0 Potential therapeutics for EV71  734 
1.6.1 Antivirals 735 
 736 
Many drugs that have been already developed and used to fight other 737 
Picornaviruses, such as polioviruses and rhinoviruses, were tested for their 738 
abilities to limit EV71 infection. These drugs, ribavirin (144, 145), pleconaril 739 
(144, 146) and rupintrivir (147) have all shown some sort of protective 740 
antiviral effect in mouse models. However, it remains to be seen how this 741 
would be translated to human infections. Also as the EV71 genome is 742 
synthesised through the virus’s 3D polymerase (148), which lacks a 743 
proofreading activity, mutations frequently arise and could quickly lead to 744 
the generation of antiviral resistant viruses (149).  745 
 746 
The recent discovery of the crystal structure of EV71 (56) has shed some 747 
insights into possible drug targets for future antivirals against EV71. The 748 
resolution of this structure by x-ray crystallography showed the presence 749 
of a hydrophobic pocket factor located underneath a depression known as 750 
the canyon. It has been postulated that the binding of molecules to this 751 
pocket region could stabilise the capsid and therefore inhibit the uncoating 752 
process induced by the EV71 receptor (56). Several compounds have 753 
been created which bind to this pocket region and showed effective in vitro 754 
inhibition of EV71 (150-155). However, just a single point mutation was 755 
enough to confer resistance against this type of compound (156).  756 
 757 
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Type I IFN, has been shown as an effective antiviral to treat viral infections 758 
such as HCV (157), so experiments were done to investigate IFNs ability 759 
as an EV71 therapeutic. Studies have shown in both in vivo (107) and in 760 
vitro (106) systems that IFN could increase the survival rate and reduce 761 
EV71 replication (106, 107). However, the viral proteases 2A and 3C have 762 
the ability to degrade IFN and the IFN antiviral pathway and may lead to 763 
the reduction in expression of interferon-α/β receptor (IFNAR) (68, 102, 764 
110, 112, 115). There have been reports of synergistic effects when 3C 765 
inhibitors and IFN are combined (114), but this would have to be combined 766 
with a 2A inhibitor to further inhibit the interruption and degradation of IFN. 767 
1.6.3 Monoclonal antibodies 768 
  769 
As there is no current antiviral treatment, and vaccine development, whilst 770 
currently underway, is not fully approved outside of China, human IVIG has 771 
been used on a presumptive basis as a last resort (158). This treatment 772 
has perceived positive benefits, possibly through modulatory properties or 773 
viral neutralisation, but is not wholly effective and has not been tested via 774 
a randomised controlled trial. IVIG also poses a potential risk of infection 775 
via other pathogens. Humanised mouse monoclonal antibodies eliminate 776 
this risk whilst increasing the specificity against the virus. Humanised 777 
mouse monoclonal antibodies against other viruses such as RSV have 778 
already been approved by the FDA (159, 160).  779 
 780 
There have been several studies that suggest that monoclonal antibodies 781 
could be an effective treatment against EV71 infection, and multiple sites 782 
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on the virus have been found as possible targets. Plevka et al. raised two 783 
antibodies against an empty immature EV71 particle in mice. The structure 784 
of this particle, which is similar to the “A” particle seen when EV71 785 
recognises a host cell before genome release, differs from that of a mature 786 
virus. These antibodies were shown to neutralise EV71 in vitro by 787 
instigating a conformational change after incubation with the mature virus, 788 
transforming the infectious virus into an “A” particle and instigating genome 789 
release (161). 790 
 791 
Another antibody, produced against the EV71 virus like particle (VLP) 792 
showed potent neutralising capabilities in vitro (162) It was later discovered 793 
that the antibody bivalently bound across the 2-fold axis of the EV71 virion, 794 
potentially preventing the conformational changes in viral capsid proteins 795 
required for viral genome release (163).  796 
 797 
Antibodies raised in mice against a conserved VP3 knob region have 798 
shown protective neutralising effect across the different subgroups of EV71 799 
(164). Whilst both antivirals and monoclonal antibodies remain important 800 
tools to fight EV71 infection, a vaccine still serves as our best chance at 801 
eradicating this virus, as shown with the almost total eradication of polio 802 
after the introduction of the Salk and Sabin vaccines (165). 803 
1.6.4 Vaccines 804 
 805 
After the success of the polio vaccines, it was envisioned that EV71, closely 806 
related to polio, would also be an easy target for near eradication via a 807 
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vaccine. Studies in mice demonstrated that the transfer of antiserum 808 
provided protection against EV71, further indicating the attainability of a 809 
vaccine (166). EV71 vaccine candidates have been suggested in many 810 
different forms; from attenuated strains (167), inactivated whole virus 811 
(168), and virus like particles (VLP) (169) to recombinant proteins (170) 812 
and peptide vaccines (171). 813 
 814 
Live attenuated vaccines have been tested in cynomolgus monkeys and 815 
these induced the production of high levels of neutralising antibodies that 816 
provided cross protection across the sub groups (172). However, as with 817 
all live attenuated vaccines, there is the possibility for the virus to mutate 818 
and cause disease. One study showed a vaccine candidate producing mild 819 
neurological symptoms and being neurotropic when injected intravenously 820 
(167). 821 
 822 
DNA vaccines have been attempted for EV71. However, DNA constructs 823 
containing EV71 VP1 gene that elicited specific VP1 immunoglobulin G’s 824 
(IgG’s) and neutralising antibodies conferred low levels of antigenicity 825 
(173). 826 
 827 
Inactivated whole virus vaccines have been shown in mouse models of 828 
EV71 to produce very high levels of virus specific antibodies that are cross 829 
neutralising (174, 175). These successful pre-clinical studies lead the way 830 
for phase I (176) and phase II (177) clinical trials, and since then three 831 
vaccines have moved on to phase III clinical trials, all from China and 832 
 41 
based on the C4 strain (168, 178, 179). These trials involved over 30,000 833 
children and resulted in the prevention of 90% of HFMD and 80% of other 834 
EV71 related symptoms, and the Chinese FDA has approved two of these 835 
vaccines. Although these vaccines have only been approved in China, this 836 
is a very exciting prospect in the eradication of EV71. However, there is 837 
still work to be done on antiviral treatment and therapies for the treatment 838 
of patients and to help unravel the mechanisms behind this disease.  839 
  840 
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1.7.0 The Blood-Brain Barrier 841 
The blood-brain barrier (BBB) is a highly selective, diffusion barrier, formed 842 
by the endothelial cells that make up the cerebral microvessels and 843 
capillaries, and by astrocytes and pericytes on the brain side (180, 181).  844 
Whilst all three cell types are important for the function, structure and 845 
integrity of the BBB, the cerebral endothelial cells are particularly crucial. 846 
Especially as they form the tight junction seal (182), that is the mainstay of 847 
the barrier, and that physically prevents the entry of many dangerous 848 
molecules and components into the brain (183). These tight junctions stop 849 
these possibly neurotoxic substances from entering the brain via the 850 
paracellular route and instead force them towards the transcellular route 851 
(184).   852 
 853 
Endothelial cells of the BBB are uniquely distinctive from other endothelial 854 
cells as their barrier function is majorly enhanced. Cerebral endothelial 855 
cells possess a higher density of tight junction complexes compared to 856 
other endothelial cells, they also lack fenestrations and have a much more 857 
limited level of pinocytic vesicular transport. This combination of attributes 858 
allows them to tightly control the blood-brain barrier (183). However, 859 
sometimes during acute distress e.g. severe viral infections, BBB function 860 
can become impaired and many neurotoxic components could pass 861 
through to the brain side of the barrier and wreak havoc (185).  862 
 863 
EV71 infections have been shown to induce a type I interferon (IFN) 864 
response (186). The dsRNA intermediate synthesised during viral 865 
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replication can be recognised by crucial PRRs, notably RIG-I (187), MDA- 866 
5 (188) and TLR-3 (189), that coordinate to control the innate immune 867 
response including IFN production. MDA5 receptor has been suggested to 868 
be more important than the other PRRs in EV71 infection, although TLR-3 869 
and RIG-I do play roles in initiating the production of downstream effectors 870 
(187, 190). The signal transduction pathways involving these pattern 871 
recognition receptors have been proven to elicit a strong type I IFN 872 
response (191, 192). In which IFN serves as an antiviral agent, which aims 873 
to inhibit or slow down viral replication or upregulate proinflammatory 874 
cytokines for viral clearance (193-195).  875 
 876 
However, during EV71 infection, IFN levels have been shown to be 877 
reduced, indicating that the active suppression of type I IFN response could 878 
be an immune evasion strategy of EV71 (111, 139). Type I IFNs have been 879 
proposed to be protective against BBB permeability during neurotropic viral 880 
invasion (196). Type I IFNs could directly preserve the structural integrity 881 
of the BBB by preferentially activating Rac1 (196, 197). Rac1 is a 882 
cytoskeletal regulatory GTPase that stabilises tight and adherens junctions 883 
to prevent BBB leakiness (197). The activation of Rac1, in turn, limits and 884 
blocks the activation of the antagonist effect of RhoA. RhoA can stimulate 885 
a cascade of inflammatory events, including the formation of stress fibres 886 
that destabilise TJs and promote BBB permeability (198). Furthermore, 887 
type I IFNs can also down-regulate the expression of inflammatory 888 
mediators that could compromise endothelial cell function, such as TNF-α 889 
and IL-1β (199). 890 
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1.8.0 Conclusion   891 
There have been major breakthroughs in EV71 research in the last couple 892 
of decades: from the identification of host receptors, to the discovery of 893 
molecular mechanisms of virus-host interactions, to the phase III trials for 894 
vaccines. Although there is an understanding of EV71 pathogenesis, many 895 
areas of uncertainty remain with many mechanisms still not well 896 
understood and many pathways that have yet to be proven functionally. 897 
There is still a need for an animal model that better mimics the human 898 
disease. The development of such models will enable us to gain a much 899 
better understanding of the path of EV71 infection, and may give us an 900 
insight in to new molecular mechanism that I can target to interrupt the 901 
virus and stop the infection.  902 
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 903 
 904 
Chapter 2 905 
Project Aims 906 
 907 
  908 
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2.1.0 To establish an in vitro infection system to study EV71 viral 909 
kinetics 910 
o Is there any difference between viral isolates that cause mild 911 
disease and viral isolates that cause neurotropic disease? 912 
 913 
 914 
2.2.0 To study the difference in infectivity and immune response in an 915 
ex vivo human blood infection system 916 
o Does immune involvement play a role in this neurotropism? 917 
 918 
 919 
2.3.0 To assess the ability of the different isolates to infect and cross 920 
the blood brain barrier 921 
o Does neurovirulence increase the ability of EV71 isolates to 922 
infect or cross the blood brain barrier? 923 
 924 
 925 
2.4.0 To study the inflammatory pathways involved in EV71 926 
immunopathogenesis 927 
o How do these pathways compare to those found in the 928 
patient samples during outbreaks? 929 
o Do the different severities of disease induce different 930 
pathways? 931 
  932 
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 933 
 934 
Chapter 3 935 
Materials and Methods 936 
 48 
3.1.0 Cell Culture 937 
 3.1.1 Cells used 938 
Cell Type Media Used Incubator Temperature  
CO2 
Conditions 
Additional 
Comments 
Rhabdomyosarcoma (RD) Cells Dulbecco's Modified Eagle's Medium (DMEM) + 10% Foetal Bovine Serum (FBS) 37°C 5%   
VeroE6 Cells Dulbecco's Modified Eagle's Medium (DMEM) + 10% Foetal Bovine Serum (FBS) 37°C 5%   
Human Cerebral Microvascular 
Endothelial Cells/D3 (HCMECs) 
Dulbecco's Modified Eagle's Medium (DMEM) 
+ 10% Foetal Bovine Serum (FBS) + 500ng/ml 
Hydrocortisone + 5ng/ml EGF 
37°C 5% 
Grown on 
fibronectin 
coated flask  
Primary Human Peripheral Blood 
Mononuclear Cells (PBMCs) 
Iscove's Modified Dulbecco's Medium (IMDM) 
+ 10% Human Serum (HS) 37°C 5%   
Primary Human CD14+ 
Monocytes 
Iscove's Modified Dulbecco's Medium (IMDM) 
+ 10% Human Serum (HS) 37°C 5%   
Primary Human CD4+ T Cells Iscove's Modified Dulbecco's Medium (IMDM) + 10% Human Serum (HS) 37°C 5%   
Primary Human CD8+ T Cells Iscove's Modified Dulbecco's Medium (IMDM) + 10% Human Serum (HS) 37°C 5%   
DMEM, FBS – HyClone; Hydrocortisone, Epidermal Growth Factor (EGF), Fibronectin, Claycomb Media, Norepinephrine, L-glutamine – Sigma-Aldrich; 
IMDM – Gibco; HS – Innovative Research, Inc. 
Table 2. Table showing the cell lines used in the following experiments, including information on the media, 
temperature and CO2 conditions used. 
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3.1.2 Cell passaging, propagation and maintenance 939 
 940 
RD Cells – RD cells were grown to 90% confluence in DMEM +10% FBS at 37°C in 941 
5% CO2 in a T150 cell culture flask (Falcon). Once cells reached 90% confluence, they 942 
were washed with 1x Dulbecco’s phosphate buffered saline (DPBS; Gibco) and 943 
trypsinised using 0.125% trypsin-EDTA (Gibco) at 37°C. Cells were dislodged from 944 
the flask then resuspended in fresh DMEM + 10% FBS and centrifuged at 1500rpm 945 
for 5 minutes. The supernatant was then removed and the cells resuspended in fresh 946 
DMEM + 10% FBS, this cell suspension was then added to a new T150 flask with 947 
fresh DMEM + 10% FBS and then placed in to an incubator at 37°C with 5% CO2.  948 
 949 
VeroE6 Cells – VeroE6 cells were grown to 90% confluence in DMEM +10% FBS at 950 
37°C in 5% CO2 in a T150 cell culture flask. Once cells reached 90% confluence, they 951 
were washed with 1x Dulbecco’s phosphate buffered saline and trypsinised using 952 
0.125% trypsin-EDTA at 37°C. Cells were dislodged from the flask then resuspended 953 
in fresh DMEM + 10% FBS and centrifuged at 1500rpm for 5 minutes. The supernatant 954 
was then removed and the cells resuspended in fresh DMEM + 10% FBS, this cell 955 
suspension was then added to a new T150 flask with fresh DMEM + 10% FBS and 956 
then placed in to an incubator at 37°C with 5% CO2. 957 
 958 
HCMEC/D3s – HCMEC/D3s were grown to 90% confluence in HCMEC media (DMEM 959 
+ 10% FBS + 500ng/ml Hydrocortisone + 5ng/ml Epidermal Growth Factor) at 37°C 960 
with 5% CO2 in T150 flasks coated with fibronectin at 500ng/cm2. Once cells reached 961 
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90% confluence, they were washed with 1x DPBS and trypsinised using 0.125% 962 
trypsin-EDTA at 37°C. Cells were dislodged from the flask then resuspended in fresh 963 
HCMEC media and centrifuged at 1500rpm for 5 minutes. The supernatant was then 964 
removed and the cells resuspended in fresh HCMEC media, this cell suspension was 965 
then added to a new fibronectin coated T150 flask with fresh HCMEC media and then 966 
placed in to an incubator at 37°C with 5% CO2. 967 
 968 
HL-1 Cardiomyocytes – HL-1 cardiomyocytes were grown to 100% confluence in 969 
Claycomb media supplemented with 10% FBS + 100μM Norepinephrine + 2mM L- 970 
glutamine at 37°C with 5% CO2 in T75 flasks coated with 0.02% gelatin/0.2ng/cm2 971 
fibronectin. Once cells reached 100% confluence and contracting, they were washed 972 
with 1x DPBS and trypsinised using 0.05% trypsin-EDTA at 37°C for one minute. 973 
Trypsin was then removed and fresh 0.05% trypsin-EDTA was added then incubated 974 
for an additional 2 minutes. An equal amount of soybean trypsin inhibitor (Sigma- 975 
Aldrich) was then added to inactivate the trypsin. Fresh Claycomb media was added 976 
and this suspension was centrifuged at 1500rpm for 5 minutes. The supernatant was 977 
then removed and the cells resuspended in supplemented Claycomb Medium. 1/3 of 978 
the cell suspension was then into a new gelatin/fibronectin-coated T75 flask, and then 979 
placed in to an incubator at 37°C with 5% CO2.  980 
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3.1.3 Cell seeding 981 
 982 
The same protocol as cell passaging, propagation and maintenance was followed until 983 
the resuspension after centrifugation. After resuspension in their respective media 984 
10μl of the cell suspension was removed and added to 20μl of 0.4%TrypanBlue 985 
(Sigma-Aldrich) and mixed via pipette. 10μl of this mixture was then added to a 986 
haemocytometer and 4 corner squares of the 3x3 square. 987 
 988 
Number of cells/ml = 989 
 ( X / D ) * Y   Where  X= Number of live cells counted 990 
     D= Dilution Factor 991 
     Y= 1ml/volume of 1 haemocytometer corner square 992 
e.g. ( 240 live cells / 4 squares ) * 104 993 
=6*105 cells/ml 994 
Calculation for cell seeding 995 
 ( A / B) * N = Tc   Where A= Number of cells needed 996 
     B= Number of counted/ml 997 
     N= Number of wells/flasks to be seeded 998 
 Tv – Tc = Tm    Tc= Total volume of cell suspension 999 
     Tv= Total final volume of all wells/flasks  1000 
     Tm= Total respective media required 1001 
Tc was then resuspended in Tm and the volume required was added to each 1002 
well/flask. The cells were then incubated at 37°C with 5% CO2 overnight.  1003 
 52 
3.1.4 Cell freezing 1004 
The same protocol as cell passaging propagation and maintenance was followed to 1005 
the point of centrifugation. After centrifugation cells were resuspended in freezing 1006 
media (10% Dimethyl Sulphoxide (DMSO; Sigma-Aldrich) and 90% FBS), which had 1007 
been passed through a 0.45μm hydrophilic filter (Sartoris). This was then aliquoted in 1008 
1ml aliquots into screw cap cryovials and placed into an isopropanol filled Mr Frosty 1009 
(Thermo Fischer) and placed into a -80°C freezer to cool the cells at -1°C per minute. 1010 
Once the cells reach -80°C they were placed into a cryobox and stored in a -80°C 1011 
freezer or vapour phase liquid nitrogen tank for short term and long-term storage 1012 
respectively. 1013 
 1014 
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3.2.0 Virus Production and Titring 1015 
3.2.1 Virus isolates 1016 
 1017 
6 EV71 virus isolates were received from Dr Mong How Ooi and Dr David 1018 
Perera, from the paediatrics unit of Sarawak general hospital. They were 1019 
isolated from patients from the 2006 EV71 outbreak in Sarawak, Malaysia. 1020 
They were isolated from 6 separate patients suffering from a varying 1021 
degree of symptoms (Table 1). 1022 
3.2.2 Viral propagation from clinical isolates 1023 
 1024 
Each of the 6 EV71 virus isolates was received in approximately 60ml of 1025 
media. 5ml of each isolate was added to a separate t150 flask of 80% 1026 
confluent RD cells and incubated at 37°C with 5% CO2 for 1.5 hours. After 1027 
the incubation, fresh DMEM + 10%FBS was added to the flask and 1028 
incubated at 37°C with 5% CO2 for 72 hours or until 90% cytopathic effect 1029 
(CPE) was seen. The flask was then freeze thawed 3 times at -80°C. the 1030 
virus was then pre-cleared via centrifugation at 1500rpm for 5 minutes 1031 
before being aliquoted in to cryovials and stored at -80°C. 1032 
  1033 
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3.2.3 Viral propagation 1034 
 1035 
Each EV71 virus isolate was diluted to 5ml at a ratio of 1:20 with DMEM 1036 
serum free (SF) then added to a t150 flask of 80% confluent RD cells and 1037 
incubated at 37°C with 5% CO2 for 1.5 hours. After this incubation, the virus 1038 
was removed and the flask was replenished with fresh DMEM + 10% FBS 1039 
and left to incubate at 37°C with 5% CO2 for 48 hours or until 90% CPE 1040 
was seen. The virus was then pre-cleared via centrifugation at 1500rpm for 1041 
5 minutes before being aliquoted in to cryovials and stored at -80°C. 1042 
3.2.4 Viral titration 1043 
 1044 
The viral titre was determined using a tissue culture infective dose 50 1045 
(TCID50) assay with RD cells. RD cells were seeded on a 96 well plate at 1046 
1.5E4 cells per well. The EV71 isolates were serially diluted in 10-fold 1047 
dilutions until 10-11 in SF DMEM. The dilutions and one row of non-infected 1048 
control were added to the wells at a volume of 80μl and incubated for 1.5 1049 
hours at 37°C with 5% CO2 for 1.5 hours, being rocked every 20 minutes. 1050 
After the 1.5 hours, the wells were refreshed with 100μl of fresh DMEM + 1051 
10% FBS and incubated for 96 hours at 37°C with 5%CO2. After 96 hours, 1052 
the media was removed and the cells were fixed with a 10% formalin 1053 
solution (Sigma-Aldrich) for 1.5 hours. The formalin was then removed and 1054 
the cells were stained with 0.5% crystal violet solution for 30 minutes. The 1055 
crystal violet solution was then washed off and the results were calculated 1056 
using the Reed-Muench method. 1057 
 1058 
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Log10 50% end point dilution =  1059 
log10 of dilution showing mortality next above 50% -  1060 
(difference of logarithms × logarithm of dilution factor).  1061 
 1062 
Difference of logarithms =  1063 
[(mortality at dilution next above 50%)-50%] / 1064 
[(mortality next above 50%)-(mortality next below 50%)]  1065 
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3.2.5 Ultracentrifugation 1066 
 1067 
Viral supernatant was filtered through a 0.45 µm hydrophobic filter to 1068 
remove cell debris. 32ml of this filtered supernatant was then transferred 1069 
to a centrifuge tube (Beckman Coulter). 4ml of a 20% sucrose solution 1070 
made up in 1x TNE buffer (50mM Tris-HCl; Sigma-Aldrich, 100mM NaCl; 1071 
Sigma-Aldrich, 0.5mM EDTA; Promega) was added to form a cushion. 1072 
Each tube was placed into a centrifuge bucket and the mass of bucket and 1073 
tube was measured, virus was added or removed to make sure all samples 1074 
were within 0.1g of each other. The virus was then ultracentrifuged in an 1075 
Optima L-110k ultracentrifuge (Beckman Coulter) at 28000rpm using a 1076 
SW32Ti rotor for 4 hours at 4°C. After ultracentrifugation, the medium was 1077 
removed and the tubes were inverted on to C-fold paper towels until the 1078 
tubes were dry. 100μl of TE buffer (10mM Tris-HCl, 1mM EDTA) was 1079 
added to the tubes and resuspended. The tubes were then covered with 1080 
parafilm and left on ice for 30 minutes. After this time, the virus and TE 1081 
buffer was resuspended and transferred to pre-chilled cryovials and then 1082 
stored at -80°C. 1083 
      1084 
  1085 
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3.3.0 Cell Viability Assays 1086 
3.3.1 CC50 1087 
 1088 
RD cells were seeded in a 96 well plate at 3x104 per well in 200μl of DMEM 1089 
+10% FBS, according to the protocol mentioned above, and left to incubate 1090 
at 37°C with 5% CO2 for 18 hours. Then 100μl of the medium from each 1091 
well was removed and 100μl of the drug/treatment in DMEM + 10% FBS 1092 
was added at the respective concentration to each well. The plate was then 1093 
returned to the incubator and left for 24 hours. The plate was then 1094 
equilibrated to room temperature for 30 minutes in the dark. CellTiter-Glo 1095 
Buffer (Promega) was added to CellTiter-Glo Substrate (Promega). 100μl of 1096 
media was then removed from each well and 100μl of CellTiter-Glo assay 1097 
reagents were added. The contents were then mixed for 2 minutes on an 1098 
orbital shaker at 125rpm to induce cell lysis. The plate was then wrapped 1099 
in tin foil and incubated in the dark at room temperature for 1 hour to 1100 
stabilise the luminescent signal. The luminescence was then read using 1101 
the GloMax-Multi Detection System (Promega) at an integration time of 1.0 1102 
second per well.  1103 
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3.4.0 qRT-PCR Set Up 1104 
3.4.1 Primer and probe design 1105 
 1106 
The VP1 region was chosen as the area to design the primers and probe 1107 
around adapted from Tan et al (200). The nucleotide sequences from the 1108 
six isolates received were aligned and analysed using MegAlign software 1109 
(Lasergene, DNA Star). Conserved regions amongst the six isolates were 1110 
identified and chosen to be used as the forward and reverse primers and 1111 
the probe. These primers (forward – GAGAGCTCTATAGGAGACAGT) 1112 
(reverse – GAGAGCTCTATAGGAGACAGT) and the Fam-labelled 1113 
molecular beacon probe (ACCCACAGGTCAAAACACACA) were 1114 
synthesised by Integrated DNA Technologies. These primers were verified 1115 
against all six isolates using a superscript on-step reverse transcription 1116 
polymerase chain reaction (RT-PCR) with a PlatinumTaq DNA polymerase 1117 
(Qiagen).   1118 
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The reactions were made up in the following ratio. 1119 
The following RT-PCR cycle and conditions were used. 1120 
  1121 
Reagents Vol (μL) 
2x reaction mix 25 
Viral RNA 5 
F+R 1 
Enzyme/RT mix 2 
Water 17 
Total volume 50 
Stage Temperature and Time 
cDNA 
synthesis 
50°C, 20 minutes 
Denaturation 94°C, 2 minutes 
PCR 
94°C, 15 
seconds	 55°C, 30 seconds	 68°C, 1 minute  	 40 cycles 
Final 
Extension 
68°C, 5 minutes 
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3.4.2 RNA standard production 1122 
 1123 
The PCR product was then transformed into plasmid vectors using TOPO 1124 
cloning. The reagents were mixed into the ratio.  1125 
Then incubated at room temperature for 5 minutes and then placed on ice. 1126 
2μl of this reaction mixture was then added to a tube of TOP10 cells and 1127 
gently mixed, then incubated on ice for 30 minutes. The cell mixture was 1128 
then heat shocked for 30 seconds at 42°C and then immediately 1129 
transferred to ice. 250μl of Super Optimal broth with Catabolite repression 1130 
(SOC) media was then added to the tube which was then capped and 1131 
shaken at 200rpm for 1 hour at 37°C. 10-50μl of each transformation was 1132 
spread on separate 2YT plates containing 100μg/ml ampicillin and 1133 
incubated overnight at 37°C. A representative colony was then selected 1134 
from each plate and placed into 50μl of nuclease free water then heated at 1135 
95°C for 5 minutes.  1136 
Reagents Vol (μL) 
PCR product 2 
Salt Solution 1 
TOPO vector 1 
Water 2 
Total Volume 6 
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 These samples were then PCR extended using the following reagents and 1137 
method. 1138 
  1139 
Reagents Vol (μL) 
Template 1 
PCR buffer 12.5 
M13 F+R 1 
Water 10.5 
Total Volume 25 
Stage Temperature and Time 
Denaturation 95°C, 15 minutes 
PCR 95°C, 1 minute; 	 55°C, 30 seconds	 72°C, 1 minute	 30 cycles 
Extension 72°C, 10 minutes 
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After the PCR run, the PCR products were then ran on a 2% agarose 1140 
(Lonza) gel. After confirmation that the colonies contained the correct 1141 
plasmid another colony was picked and grown in 5ml of 2YT/ ampicillin 1142 
medium overnight at 37°C. The bacterial cells were then pelleted via 1143 
centrifugation in a table-top centrifuge at 8000rpm for 3 minutes and the 1144 
supernatant was removed. The plasmid DNA was then purified from the 1145 
cells using a QIAprep Spin Miniprep Kit (Qiagen), following the 1146 
manufactures instructions. The plasmids were then sent to AITbiotech for 1147 
sequencing.  1148 
 1149 
After confirmation of the sequences the plasmid DNA was linearised using 1150 
HindIII restriction enzyme in the following ratio for one hour at 37°C.  1151 
  1152 
Reagents Vol (μL) 
Plasmid (1ug) X 
Cutsmart buffer 5 
Water 44 – X 
HindIII 1 
Total Volume 50 
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The linear DNA was then cleaned using a MinElute Reaction Clean-up Kit 1153 
(Qiagen) following the manufacturer’s instructions. After this clean up the 1154 
DNA underwent in vitro transcription (IVT) using Megascript IVT (Life 1155 
Technologies) in the following reagent ratio. 1156 
Once these reagents were mixed they were incubated at 37°C for 4 hours. 1157 
The reaction was then cleaned up using RNEasy MinElute Clean-up Kit 1158 
(Qiagen) following the manufacturer’s instructions. The viral RNA 1159 
concentration was calculated via a Ribogreen assay (Life Technologies) 1160 
following manufacturer’s instructions and the fluorescence intensity was 1161 
measured using Infinite M200 microplate reader (Tecan) at excitation 1162 
480nm and emission 520nm. After the extrapolation of the concentration in 1163 
ng/ml, the RNA copy number was calculated using 1164 
http://molbiol.edu.ru/eng/scripts/01_07.html. The RNA transcripts were 1165 
Reagents Vol (μL) 
ATP 2 
CTP 2 
GTP 2 
UTP 2 
10x reaction mix 2 
0.1-1ug linear DNA X 
Enzyme 2 
Water Make total volume up to 20μl 
Total Volume 20 
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then diluted to 1x1011 RNA copies/μl, and then serially diluted to create 1166 
standards from 1x109 to 1x101 RNA copies/μl. 1167 
 1168 
3.4.3 Machine set up and program 1169 
 1170 
VP1-targeted qRT-PCR was adapted from Tan et al; 2008(200) with 1171 
forward and reverse primers (GAGAGCTCTATAGGAGACAGT and 1172 
GAGAGCTCTATAGGAGACAGT respectively), and an additional novel 1173 
lab-designed FAM-labeled molecular beacon probe 1174 
(ACCCACAGGTCAAAACACACA) taken from consensus sequence of the 1175 
6 isolates. To assemble the qRT-PCR reaction, 1μl of RNA template was 1176 
mixed with the following reagents: 4.375μl of nuclease-free H2O, 6.25μl of 1177 
2x premix, 0.5μl of forward and reverse primers (final concentration 1178 
400nM) and 0.25μl of each Taqman probe (final concentration 200nM), and 1179 
0.125μl RT mix to a final reaction volume of 12.5μl. The thermal cycling 1180 
conditions were a 30-minute reverse transcription step at 50°C, followed 1181 
by the initial activation at 95°C for 15 minutes. This was then followed by 1182 
the 2-step cycle of 1 cycle at 94°C for 15 seconds followed by 45 1 minute 1183 
cycles at 55°C. Assay exclusivity of EV71-VP1 was confirmed by testing 1184 
viral RNA extracted from the following viruses, and no cross-reactions were 1185 
identified: Dengue viruses (DENV serotype 1-4), Chikungunya virus 1186 
(CHIKV) and O’nyong-nyong virus (ONNV). Analytical sensitivity was also 1187 
determined using quantitated EV71 RNA transcripts and the lower limit of 1188 
detection was estimated as 10 copies for the VP1 gene target. RNA 1189 
transcripts ranging from 10^9 to 10 copies were performed in pentaplicates 1190 
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to construct standard curve for the qRT-PCR assay to estimate the copy 1191 
number of EV71 in samples. All qRT-PCR assays were performed on 1192 
Applied Biosystems (ABI) 7900HT Fast Real-Time PCR System using the 1193 
Quantitect Probe RT-PCR Kit (Qiagen). 1194 
  1195 
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3.5.0 Viral Kinetics 1196 
3.5.1 Infection protocol 1197 
 1198 
Individual EV71 isolate in vitro infections were performed in RD cells at 1199 
multiplicity of infection (MOI) 10. Each infectious mix consisted of virus 1200 
suspension prepared in SF DMEM. RD cells were incubated with the 1201 
infectious mix in 60mm dishes at 37°C for 1.5h with intermittent rocking 1202 
before virus inoculum was removed and replaced with DMEM + 10% FBS. 1203 
Cells were incubated at 37oC and harvested at 0, 3, 6, 12 or 24 hours post 1204 
infection (hpi). Controls were performed with cells undergoing the same 1205 
infection condition in the absence of infectious EV71 virus. These controls 1206 
are referred to as mock-infected samples.  1207 
3.5.2 Cell harvesting 1208 
 1209 
At each time point 140μl of media was removed from its respective dish 1210 
and stored in an eppendorf tube at -80°C to be used for viral RNA 1211 
extraction. 1ml of the media was also removed and stored in a separate 1212 
eppendorf at -80°C for cytokine analysis. The cells were then harvested 1213 
with the remaining media via cell scraping. Half of the cells and media were 1214 
placed into a 5ml polystyrene tube (Falcon) to be used for flow cytometry 1215 
and the other half was stored in eppendorf tubes to be used for total RNA 1216 
extraction.  1217 
3.5.3 Staining procedure 1218 
 1219 
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After the cells were harvested, the 5ml tube was centrifuged at 1500rpm 1220 
for 5 minutes. The supernatant was removed and the cells were 1221 
resuspended in 100μl of LIVE/DEAD fixable aqua dead cell stain 1222 
(Invitrogen; diluted at 1:400 in DPBS) and incubated at room temperature 1223 
in the dark for 20 minutes. Cells were then washed with 2ml FACS buffer 1224 
(DPBS, 2mM EDTA, 5% FBS, 5%HS, 0.1% sodium azide; Sigma-Aldrich) 1225 
and centrifuged at 1500rpm for 5 minutes. After centrifugation, the 1226 
supernatant was removed and the pellet was resuspended in 500μl of 1x 1227 
BD FACS lysing solution to fix the cells. The cells were fixed for 10 minutes 1228 
at room temperature in the dark. They were then washed in 2ml of FACS 1229 
buffer and centrifuged at 1500rpm for 5 minutes. The supernatant was 1230 
again removed and the cells were resuspended in 500μl of BD FACS 1231 
permeabilising solution 2 and incubated at room temperature for 10 1232 
minutes in the dark. The cells were then washed with 2ml of FACS buffer 1233 
and centrifuged at 1500rpm for 5 minutes, and then the supernatant was 1234 
removed. After perming, the cells were incubated with an anti-EV71 1235 
monoclonal antibody raised in mice, which binds to the VP1 region of the 1236 
virus (10F0; Thermo Fischer). The cells were incubated with this antibody 1237 
for 20 minutes in the dark at room temperature. The cells were then 1238 
washed again with 2ml FACS buffer and centrifuged at 1500rpm for 1239 
5minutes. The supernatant was removed and the cells were incubated with 1240 
a goat anti-mouse antibody conjugated with an allophycocyanin 1241 
fluorophore (APC; Life Technologies), which binds to any mouse 1242 
antibodies in the cell suspension. This secondary antibody was incubated 1243 
for 20 minutes at room temperature in the dark. After the 20 minutes the 1244 
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cells were washed with 2ml of FACS buffer and centrifuged at 1500rpm for 1245 
5 minutes. The supernatant was removed and the cells were resuspended 1246 
in 200μl of FACS buffer. 1247 
3.5.4 vRNA extraction for viral load 1248 
 1249 
Viral RNA (vRNA) was extracted from the 140μl viral supernatant using 1250 
QIAamp® Viral RNA Mini Kit (QIAGEN) according to manufacturer’s 1251 
instructions. The extracted vRNA was stored in eppendorf tubes at -80°C.  1252 
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3.6.0 PBMC Infection Model 1253 
3.6.1 Isolating PBMCs 1254 
 1255 
Apheresis cones were received from the Health Sciences Authority blood 1256 
bank Singapore. The blood was expelled from the cone into a 50 Falcon 1257 
tube using a needle without a bevel (BD) and syringe (BD). The cone was 1258 
then washed with 25ml of PBSE (DPBS + 2mM EDTA) into the 50ml tube. 1259 
Ficoll-Paque solution (GE Healthcare) was added to fresh 50ml tube at a 1260 
ratio of 1:2 Ficoll-Paque:diluted blood. The diluted blood was then slowly 1261 
layered on top of the Ficoll-Paque. The tube was then centrifuged at 1262 
3000rpm for 20 minutes with the lowest break and acceleration setting to 1263 
separate the cells via gradient centrifugation. After centrifugation, the top 1264 
plasma layer was removed via aspiration leaving the white disk of PBMCs 1265 
undisturbed. The PBMCs were transferred to a fresh 50ml tube and 1266 
washed with 40ml of PBSE and centrifuged at 1500rpm for 5 minutes and 1267 
then supernatant was removed. 8ml of red blood cell (RBC) lysis buffer 1268 
(155mM NH4Cl, 10mM KHCO3, 0.1mM EDTA; Sigma-Aldrich) was added 1269 
to the cell pellet and the cells were resuspended, and then incubated on 1270 
ice for 5 minutes. The cells were then washed with 40ml of PBSE and 1271 
centrifuged at 1500rpm for 5 minutes. The supernatant was removed and 1272 
the cells were resuspended in 15ml of PBSE. The cells were then counted 1273 
as previously described after a 2-step 50x dilution in trypan blue using 10μl 1274 
of cells.   1275 
  1276 
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3.6.2 Infection protocol 1277 
 1278 
2x106 PBMC were seeded in 500μl of IMDM + 10% HS in a 60mm dish. 1279 
EV71 isolates 1, 3 and 5, plus heat inactivated EV71 and non-infected 1280 
control (mock) were diluted individually to MOI 5 in SF IMDM to make a 1281 
total volume of 500μl. The infection mix was then added to the PBMC and 1282 
incubated at 37°C with 5% CO2  for 2 hours, rocking every 15 minutes. The 1283 
virus was then removed and 3ml of fresh IMDM +10% HS was added and 1284 
the dishes were returned to the incubator for 0, 6, 12 or 24 hours. 1285 
3.6.3 Cell harvesting and staining 1286 
 1287 
At each time point, the cells and media were harvested via scraping and 1288 
transferred, half to 5ml tubes and half to 1.7ml eppendorf tubes. The 1289 
eppendorf tubes were centrifuged in a table-top centrifuge for 5 minutes at 1290 
8000rpm. The supernatant was removed and the cell pellet was 1291 
resuspended in 500μl of TRIzol reagent (Ambion by Life Technologies) and 1292 
stored at -80°C. The 5ml tubes were centrifuges at 1500rpm for 5 minutes, 1293 
140μl and 1000μl of the supernatant were transferred to eppendorf tubes 1294 
and stored at -80°C for vRNA extraction and cytokine analysis respectively. 1295 
The rest of the supernatant was removed and the cells were resuspended 1296 
in 200μl of 1:400 diluted LIVE/DEAD and incubated at room temperature 1297 
for 20 minutes in the dark. The cells were then washed with 2ml of FACS 1298 
buffer and centrifuged at 1500rpm for 5 minutes and then the supernatant 1299 
was removed. The cells were then resuspended in 200μl of BD 1300 
Cytofix/Cytoperm for 10 minutes at room temperature. After fixation, the 1301 
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cells were washed with 2ml of FACS buffer and centrifuged at 1500rpm for 1302 
5 minutes. The supernatant was removed and the cells were then permed 1303 
with 500μl of 0.5% Triton X-100 (BDH VWR) in PBS for 10 minutes at room 1304 
temperature. After permeabilisation the cells were washed with 2ml of 1305 
FACS buffer and centrifuged at 1500rpm for 5 minutes, then the 1306 
supernatant was removed. The cells were then incubated with 100μl of 1307 
10F0 anti-EV71 antibody at 4°C. after this incubation the cells were 1308 
washed with 2ml of FACS buffer and centrifuged at 1500rpm for 5 minutes. 1309 
The supernatant was removed and the cells were resuspended in 100μl of 1310 
goat anti-mouse APC antibody at room temperature for 20 minutes. After 1311 
secondary antibody staining the cells were washed with 2ml of FACS buffer 1312 
and centrifuged at 1500rpm for 5 minutes and the supernatant was 1313 
removed. The cells were then stained with a cocktail of surface marker  1314 
antibodies made up to 100μl in FACS buffer, which consisted of: 1315 
Antibody Colour Manufacturer Volume (μl)/reaction 
CD45 PE-Cy7 eBioscience 2.5 
CD14  PerCP Cy5.5 BD 2.5 
CD3 FITC Biolegend 2.5 
CD19 eVolve 605 eBioscience 2.5 
CD16  APC Cy7 Biolegend 2.5 
CD11c VioBlue Miltenyi 2.5 
HLA-DR PE BD 2.5 
CD56  AF700 BD 2.5 
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They were stained for 20 minutes at room temperature in the dark. After 1316 
staining the cells were washed with 2ml of FACS buffer and centrifuged at 1317 
1500rpm for 5 minutes. The supernatant was removed and the cells were 1318 
resuspended in 200μl of FACS buffer and then acquired via flow cytometry 1319 
on a BD Fortessa analyser using BD FACS Diva software. 1320 
3.6.4 Flow cytometry analysis 1321 
 1322 
All flow cytometry data acquired was analysed using FlowJo v.10 software 1323 
and GraphPad prism x7. 1324 
3.7.0 Cell Subset Infection 1325 
3.7.1 Isolating subsets 1326 
 1327 
Apheresis cones were received from HSA blood bank Singapore. PBMC 1328 
were isolated from these cones as previously described. Monocytes were 1329 
isolated from the PBMC using a negative selection EasySep Human 1330 
Monocyte Enrichment Kit Without CD16 (Stem Cell) following 1331 
manufacturer’s instructions. CD4+ T cells were separately isolated form 1332 
PBMC using a negative selection EasySep Human CD4+ T Cell Isolation 1333 
Kit (Stem Cell) following the manufacturer’s instructions. CD8+ T cells were 1334 
isolated form PBMC using a negative selection EasySep Human CD8+ T 1335 
Cell Isolation Kit (Stem Cell) following the manufacturer’s instructions.   1336 
 1337 
3.7.2 Monocyte infection protocol 1338 
 1339 
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2x106 monocytes were seeded in 500μl of IMDM + 10% HS in a 60mm 1340 
dish. EV71 isolates 1, 3 and 5, plus heat inactivated EV71 and non-infected 1341 
control (mock) were diluted individually to MOI 5 in SF IMDM to make a 1342 
total volume of 500μl. The infection mix was then added to the monocytes 1343 
and incubated at 37°C with 5% CO2 for 2 hours, rocking every 15 minutes. 1344 
The virus was then removed and 3ml of fresh IMDM +10% HS was added 1345 
and the dishes were returned to the incubator for 0, 6, 12 or 24 hours. 1346 
3.7.3 CD4+ T cell and CD8+ T cell infection protocol 1347 
 1348 
2x106 CD4+ or CD8+ T cells were seeded in 500μl of IMDM + 10% HS in 1349 
a 60mm dish. EV71 isolates 1, 3 and 5, plus heat inactivated EV71 and 1350 
non-infected control (mock) were diluted individually to MOI 5 in SF IMDM 1351 
to make a total volume of 500μl. The infection mix was then added to the 1352 
T cells and incubated at 37°C with 5% CO2 for 2 hours, rocking every 15 1353 
minutes. The virus was then removed and 3ml of fresh IMDM +10% HS 1354 
was added and the dishes were returned to the incubator for 0, 6, 12 or 24 1355 
hours. 1356 
3.7.4 Cell harvesting and staining 1357 
 1358 
At each time point, the cells and media were harvested via scraping and 1359 
transferred, half to 5ml tubes and half to 1.7ml eppendorf tubes. The 1360 
eppendorf tubes were centrifuged in a table-top centrifuge for 5 minutes at 1361 
8000rpm. The supernatant was removed and the cell pellet was 1362 
resuspended in 500μl of TRIzol reagent (Ambion by Life Technologies) and 1363 
stored at -80°C. The 5ml tubes were centrifuges at 1500rpm for 5 minutes, 1364 
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140μl and 1000μl of the supernatant were transferred to eppendorf tubes 1365 
and stored at -80°C for vRNA extraction and cytokine analysis respectively. 1366 
The rest of the supernatant was removed and the cells were resuspended 1367 
in 200μl of 1:400 diluted LIVE/DEAD and incubated at room temperature 1368 
for 20 minutes in the dark. The cells were then washed with 2ml of FACS 1369 
buffer and centrifuged at 1500rpm for 5 minutes and then the supernatant 1370 
was removed. The cells were then resuspended in 200μl of BD 1371 
Cytofix/Cytoperm for 10 minutes at room temperature.  1372 
 1373 
After fixation, the cells were washed with 2ml of FACS buffer and 1374 
centrifuged at 1500rpm for 5 minutes. The supernatant was removed and 1375 
the cells were then permed with 500μl of 0.5% Triton X-100 (BDH VWR) in 1376 
PBS for 10 minutes at room temperature. After permeabilisation the cells 1377 
were washed with 2ml of FACS buffer and centrifuged at 1500rpm for 5 1378 
minutes, then the supernatant was removed. The cells were then incubated 1379 
with 100μl of 10F0 anti-EV71 antibody at 4°C. after this incubation the cells 1380 
were washed with 2ml of FACS buffer and centrifuged at 1500rpm for 5 1381 
minutes. The supernatant was removed and the cells were resuspended in 1382 
100μl of goat anti-mouse FITC (monocytes) and goat anti-mouse APC 1383 
(CD4+ and CD8+ T cells) antibody at room temperature for 20 minutes. 1384 
After secondary antibody staining the cells were washed with 2ml of FACS 1385 
buffer and centrifuged at 1500rpm for 5 minutes and the supernatant was 1386 
removed. The cells were then stained with a cocktail of surface marker 1387 
antibodies made up to 100μl in FACS buffer, which consisted of:  1388 
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 1389 
Antibody Colour Manufacturer Volume (μl)/reaction 
CD45 BV786 BD 2 
CD14  BV650 BD 2 
CD16 PerCP Cy5.5 Biolegend 2 
CCR2 APC Biolegend 2 
CD11b PE Cy7 BD 2 
CD169 PE Biolegend 2 
HLA-DR AF700 Biolegend 2 
CD163 Texas Red BD 2 
CD33 APC Cy7 Biolegend 2 
Antibody Colour Manufacturer Volume (μl)/reaction 
CD45 BV786 BD 2 
CD3  PerCP Cy5.5 Biolegend 2 
CD4 FITC Biolegend 2 
CD8 APC VCy7 BD 2 
HLA-DR AF700 eBiosciences 2 
CD45RO BV650 Biolegend 2 
CD45RO BV605 BD 2 
CD56 PE Miltenyi 2 
CD25 PE Cy7 Biolegend 2 
FoxP3 Pacific Blue Biolegend 2 
Monocyte antibody panel 
CD4+ and CD8+ T cell antibody panel 
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They were stained for 20 minutes at room temperature in the dark. After 1390 
staining the cells were washed with 2ml of FACS buffer and centrifuged at 1391 
1500rpm for 5 minutes. The supernatant was removed and the cells were 1392 
resuspended in 200μl of FACS buffer and then acquired via flow cytometry 1393 
on a BD Fortessa analyser using BD FACS Diva software. 1394 
3.7.5 Flow cytometry analysis 1395 
 1396 
All flow cytometry data acquired was analysed using FlowJo v.10 software 1397 
and GraphPad prism x7. 1398 
 1399 
3.8.0 Blood Brain Barrier Model 1400 
3.8.1 Setting up of the model 1401 
 1402 
Cell culture dishes (60mm × 15mm) (Sigma) were coated with 25ng/ml 1403 
fibronectin (Sigma-Aldrich) and incubated for 3 hours at 37°C before its 1404 
removal for cell seeding. hCMEC/D3 (5 × 105) were then seeded and 1405 
incubated at 37°C overnight. During infection, the media overlay is 1406 
aspirated and replaced with a virus suspension that consists of EV71 at a 1407 
virus concentration of multiplicity of infectivity 10 (MOI 10). The cells were 1408 
then incubated at 37°C for 2 hours, with shaking at every 30 minutes. A 1409 
mock infection was also prepared in parallel using hCMEC media for each 1410 
time point. The virus overlay was then removed and replaced with hCMEC 1411 
media. At 0, 6, 12, 24, 48, 72, 96, 120 and 144 hpi, supernatant was 1412 
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removed for viral RNA (vRNA) extraction while the hCMEC/D3 were 1413 
trypsinised and harvested for total RNA extraction and FACS analysis. 1414 
3.8.2 In vitro BBB model infection  1415 
 1416 
0.4μm pore, semi-permeable, polystyrene transwell inserts in the wells of 1417 
12-well plates were coated with fibronectin and incubated for at least 3 1418 
hours at 37oC then removed. hCMEC/D3 (1 x 105) were then seeded onto 1419 
the inserts and incubated at 37oC for 3 days. hCMEC media were also 1420 
added to the luminal and abluminal region such that the hydrostatic 1421 
pressure is kept constant throughout all replicates, as illustrated in (Fig 4).  1422 
 78 
Figure 4. Layout of the BBB monoculture model, with a coat of a 1423 
single confluent layer of hCMEC/D3 on the microporous membrane. 1424 
This figure shows the cross-section of the BBB monoculture model, with 1425 
the different aspects of the model labelled. 1426 
 1427 
The luminal region represents the vascular side of the BBB while the 1428 
abluminal region represents the brain parenchymal side of the BBB. 1429 
Hydrostatic pressure of the luminal and abluminal region is kept constant 1430 
throughout all replicates. (Adapted from Corning®) 1431 
The media in the luminal and abluminal region was then aspirated before 1432 
a virus overlay that consists of CHIKV, ZIKV or EV-71 suspended in 1433 
hCMEC media at MOI 10, was added to the luminal region. The cells were 1434 
then incubated at 37oC for 2 hours. Mock hCMEC/D3 was also prepared in 1435 
parallel with the hCMEC media overlay instead for each time point. A blank 1436 
well was also prepared in parallel, whereby there was no cells seeded onto 1437 
the transwell insert. Fresh media was then added to the abluminal region 1438 
while the virus overlay was also replaced with media, such that the 1439 
hydrostatic pressure is kept constant throughout all replicates, as shown in 1440 
(Fig 4). At 0, 24, 48, 72, 96, 120 and 144 hpi, the supernatant is removed 1441 
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for vRNA extraction from both luminal and abluminal regions while the 1442 
hCMEC/D3 monolayer was trypsinised and harvested for total RNA 1443 
extraction and FACS analysis. 1444 
  1445 
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3.8.3 Trans-endothelial electrical resistance  1446 
 1447 
Trans-endothelial electrical resistance (TEER) is measured using the 1448 
STX2 electrode (World Precision Instruments) connected to a second- 1449 
generation Epithelial Voltohmmeter (EVOM2) (World Precision 1450 
Instruments). The electrodes were sterilized in 100% ethanol before rinsing 1451 
and equilibration with hCMEC media. TEER is measured as illustrated in 1452 
(Fig 5). The electrodes are then positioned in the wells, as illustrated in (Fig 1453 
5), such that the shorter electrode is in the luminal region while the longer 1454 
electrode is in the abluminal region. Readings were taken in triplicates. The 1455 
electrodes were sterilized in formalin for 10 minutes after measurements 1456 
for wells infected with the same virus were completed. TEER was also 1457 
measured for the blank well and the calculated TEER (minus blank) values 1458 
were derived by subtracting the average triplicate values of the blank well 1459 
from the average triplicate values of the well of interest.   1460 
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 1461 
Figure 5. World Precision Instruments STX2 electrodes. This figure 1462 
shows the cross-section of the WPI STX2 electrodes and how they 1463 
measure resistance in a transwell cell system. 1464 
  1465 
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3.9.0 Viruses and Cells.  1466 
EV71 viral isolates 1-6 used in this study were originally isolated from 6 1467 
separate patients from the 2006 outbreak in Sarawak, Malaysia.  1468 
Rhabdomyosarcoma (RD) cells (ATCC CCL-136) are grown and passaged 1469 
in (DMEM; HyClone) supplemented with 10% FBS. Viruses are propagated 1470 
in RD cells, pre-cleared by centrifugation then stored at -80°C. 1471 
 1472 
3.10.0 Tissue culture infective dose 50 (TCID50) Assay 1473 
Viral titre was determined using TCID50 assay with RD cells. RD cells were 1474 
seeded in 96 wells and infected with 80μl of serially diluted EV71 isolates 1475 
in serum-free (SF) Dulbecco’s Modified Eagle Medium (DMEM; HyClone) 1476 
for 1.5h, with intermittent rocking. Then refreshed with 100μl of DMEM with 1477 
10% (vol/vol) foetal bovine serum (FBS; HyClone). Cells were then 1478 
incubated for 4 days at 37°C. Cells were fixed with 10% formalin (Sigma 1479 
Aldrich) before being stained with 0.5% crystal violet (Sigma Aldrich). Titre 1480 
is calculated using the Reed-Muench method (201). Log10 50% end point 1481 
dilution = log10 of dilution showing a mortality next above 50% - (difference 1482 
of logarithms × logarithm of dilution factor). Difference of logarithms = 1483 
[(mortality at dilution next above 50%)-50%]/[(mortality next above 50%)- 1484 
(mortality next below 50%)] 1485 
 1486 
3.11.0 Phylogenetic Analysis 1487 
EV71 subgenogroup B phylogenetic tree generated by maximum- 1488 
likelihood analysis of complete VP1 nucleotide sequences. The tree was 1489 
rooted to the prototype genogroup A strain. Sequences are identified by 1490 
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GenBank accession, country of origin and year of isolation. Viruses 1491 
discussed in this study are underlined. The robustness of the tree was 1492 
evaluated by bootstrap analysis using 1000 pseudoreplicate sequences. 1493 
Bootstrap values >75% of major clades are indicated at relevant branch 1494 
nodes. All branch lengths are drawn to scale and a measurement of relative 1495 
phylogenetic distance is provided by the scale at the bottom of the tree  1496 
 1497 
3.12.0 Infection in RD cells 1498 
EV71 in vitro infections in RD cells were performed at multiplicity of 1499 
infection (MOI) 10, each infectious mix consisted of virus suspension 1500 
prepared in SF DMEM. RD cells were incubated with the infectious mix in 1501 
60mm dishes at 37C for 1.5h with intermittent rocking before virus inoculum 1502 
was removed and replaced with DMEM with 10% FBS. Cells were 1503 
incubated at 37oC and harvested at 0, 3, 6, 12 or 24 hours post infection 1504 
(hpi). Controls were performed with cells undergoing the same infection 1505 
condition in the absence of infectious EV71 virus. These controls are 1506 
referred to as mock-infected samples.  1507 
 1508 
3.13.0 Infection in human peripheral blood mononuclear cells 1509 
Peripheral blood mononuclear cells (PBMCs) were isolated from a blood 1510 
apheresis cone by gradient centrifugation using Ficoll-Hypaque (GE 1511 
Healthcare) as previously described(202, 203). EV71 ex vivo infections in 1512 
PBMCs were performed at multiplicity of infection (MOI) 5, each infectious 1513 
mix consisted of virus suspension prepared in SF Iscove's Modified 1514 
Dulbecco's Medium (IMDM; HyClone). PBMCs were incubated with the 1515 
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infectious mix in 60mm dishes at 37oC for 2h with intermittent rocking 1516 
before virus inoculum was removed and replaced with IMDM with 10% 1517 
human serum (HS; Innovative Research Inc.). Cells were incubated at 1518 
37oC and harvested at 0, 6, 12 or 24hpi. Controls were performed with cells 1519 
undergoing the same infection condition in the absence of infectious EV71 1520 
virus or with heat inactivated virus. Heat-inactivated samples were 1521 
inactivated by being incubating viruses at 80oC for 30 min. These controls 1522 
are referred to as mock-infected and heat-inactivated samples 1523 
respectively.  1524 
 1525 
3.14.0 Infection in Monocytes, CD4+ and CD8+ T Cells 1526 
PBMCs were isolated as described above, and then monocytes, CD4+ and 1527 
CD8+ T cells were isolated from these PBMC using STEMCELL Human 1528 
Monocyte Enrichment Kit Without CD16 Depletion, Human CD4+ T Cell 1529 
Isolation Kit and Human CD8+ T Cell Isolation Kit respectively, following 1530 
the manufacturer’s instructions. Infection was then performed as in PBMCs 1531 
above and cells were harvested at 6 and 12 hpi.   1532 
 1533 
3.15.0 Viral RNA extraction and viral RNA quantification 1534 
Viral RNA was extracted using QIAamp® Viral RNA Mini Kit (QIAGEN) 1535 
according to manufacturer’s instructions. VP1-targeted qRT-PCR was 1536 
adapted from Tan et al; 2008(200) with forward and reverse primers 1537 
(GAGAGCTCTATAGGAGACAGT and GAGAGCTCTATAGGAGACAGT 1538 
respectively), and an additional novel lab-designed FAM-labeled molecular 1539 
beacon probe (ACCCACAGGTCAAAACACACA) taken from consensus 1540 
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sequence of the 6 isolates. To assemble the RT-PCR reaction, 1μl of RNA 1541 
template was mixed with the following reagents: 4.375μl of nuclease-free 1542 
H2O, 6.25μl of 2x premix, 0.5μl of forward and reverse primers (final 1543 
concentration 400nM) and 0.25μl of each Taqman probe (final 1544 
concentration 200nM), and 0.125μl RT mix to a final reaction volume of 1545 
12.5μl. The thermal cycling conditions were a 30-minute reverse 1546 
transcription step at 50°C, followed by the initial activation at 95°C for 15 1547 
minutes. This was then followed by the 2-step cycle of 1 cycle at 94°C for 1548 
15 seconds followed by 45 1 minute cycles at 55°C. Assay exclusivity of 1549 
EV71-VP1 was confirmed by testing viral RNA extracted from the following 1550 
viruses, and no cross-reactions were identified: Dengue viruses (DENV 1551 
serotype 1-4), Chikungunya virus (CHIKV) and O’nyong-nyong virus 1552 
(ONNV). Analytical sensitivity was also determined using quantitated EV71 1553 
RNA transcripts and the lower limit of detection was estimated as 10 copies 1554 
for the VP1 gene target. Copy numbers of EV71 RNA were determined by 1555 
using the Ribogreen RNA specific Quantitation Kit (Invitrogen, Carlsbad, 1556 
USA). RNA transcripts ranging from 10^9 to 10 copies were performed in 1557 
pentaplicates to construct standard curve for the qRT-PCR assay to 1558 
estimate the copy number of EV71 in samples. All qRT-PCR assays were 1559 
performed on Applied Biosystems (ABI) 7900HT Fast Real-Time PCR 1560 
System using the Quantitect Probe RT-PCR Kit (Qiagen, Hilden, 1561 
Germany). 1562 
 1563 
 1564 
 1565 
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3.16.0 Flow cytometry analysis 1566 
Cells from the in vitro infections in RD cells were stained with AmCyan 1567 
LIVE/DEAD Fixable Aqua Dead Stain. Subsequently, cells were fixed with 1568 
1X FACS lysing solution (BD Biosciences). Permeabilisation was achieved 1569 
with 1X FACS permeabilisation solution 2 (BD Biosciences) before staining 1570 
with the EV71 VP1 protein specific mouse monoclonal antibody (Abcam). 1571 
Stained cells were counter-stained with a fluorophore-tagged secondary 1572 
goat anti-mouse IgG (H+L) antibody (Invitrogen). Cells were subsequently 1573 
acquired with Canto II flow cytometer (BD Biosciences) with BD FACSDiva 1574 
software (BD Biosciences). Cells from the ex vivo infections in PBMCs 1575 
were stained with AmCyan LIVE/DEAD Fixable Aqua Dead Stain. 1576 
Subsequently, cells were fixed with 1X FACS lysing solution (BD 1577 
Biosciences). Permeabilisation was achieved with 0.5% Triton X-100 1578 
(Sigma Aldrich) before staining with the EV71 VP1 protein specific mouse 1579 
monoclonal antibody (Abcam). Stained cells were counter-stained with a 1580 
fluorophore-tagged secondary goat anti-mouse IgG (H+L) antibody 1581 
(Invitrogen). Cells were subsequently acquired with Fortessa flow 1582 
cytometer (BD Biosciences) with BD FACSDiva software (BD 1583 
Biosciences). Cell surface staining was then performed with mouse anti- 1584 
human CD45, CD3, CD19, CD14, CD16 (Biolegend), CD56, CD11c and 1585 
HLA-DR (Miltenyi). Cells were subsequently acquired with Fortessa flow 1586 
cytometer (BD Biosciences) with BD FACSDiva software (BD 1587 
Biosciences). The threshold for EV71 positive cells was determined from 1588 
the gating of mock-infected control at the same time point. Junk cells and 1589 
doublets were excluded in all FSC/SSC gating. Amount of EV71 antigen 1590 
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positive cells was determined in total CD45+, T, B, NK cells, monocytes 1591 
and DCs. All analyses were performed using FlowJo version 9.3.2 software 1592 
(Tree Star, Inc.). 1593 
 1594 
3.17.0 Total RNA extraction 1595 
Total RNA was extracted using RNeasy Micro Kit (QIAGEN) according to 1596 
manufacturer’s instructions. The extracted total RNA was subsequently 1597 
quantified with the Nanodrop 1000 spectrophotometer (Thermo Scientific). 1598 
 1599 
3.18.0 RNASeq 1600 
The RNA samples were DNase treated using Ambion Turbo DNA-free Kit, 1601 
and subsequently purified using Ampure XP beads. 2ug of the DNase 1602 
treated RNA was then put through a Ribozero treatment using the 1603 
Epicentre Ribo-Zero Gold Kit (Human/Rat/Mouse) and purified again with 1604 
Ampure XP beads. Successful depletion was then quality tested using 1605 
Qubit and Agilent 2100 Bioanalyzer and all of the depleted RNA was used 1606 
as input material for the ScriptSeq v2 RNA-Seq Library Preparation 1607 
protocol.  Following 14 cycles of amplification, the libraries were purified 1608 
using Ampure XP beads. Each library was quantified using Qubit and the 1609 
size distribution assessed using the AATI Fragment Analyser. These final 1610 
libraries were pooled in equimolar amounts using the Qubit and Fragment 1611 
Analyser data. The quantity and quality of each pool was assessed by the 1612 
Fragment Analyser and subsequently by qPCR using the Illumina Library 1613 
Quantification Kit from Kapa on a Roche Light Cycler LC480II according to 1614 
manufacturer's instructions. The template DNA was denatured according 1615 
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to the protocol described in the Illumina cBot User guide and loaded at 12 1616 
pM concentration. To improve sequencing quality control 1% PhiX was 1617 
spiked-in. The sequencing was carried out on three lanes of an Illumina 1618 
HiSeq 2500 with version 4 chemistry generating 2 × 125 bp paired end 1619 
reads. 1620 
 1621 
3.19.0 Bioinformatics Analysis 1622 
Base calling and de-multiplexing of indexed reads was performed by 1623 
CASAVA version 1.8.2 (Illumina) to produce 30 samples from the 5 lanes 1624 
of sequence data, in fastq format.  The raw fastq files were trimmed to 1625 
remove Illumina adapter sequences using Cutadapt version 1.2.1(204). 1626 
The option “-O 3” was set, so the 3' end of any reads which matched the 1627 
adapter sequence over at least 3 bp was trimmed off.  The reads were 1628 
further trimmed to remove low quality bases, using Sickle version 1.200 1629 
with a minimum window quality score of 20. After trimming, reads shorter 1630 
than 50 bp were removed. If both reads from a pair passed this filter, each 1631 
was included in the R1 (forward reads) or R2 (reverse reads) file.  If only 1632 
one of a read pair passed this filter, it was included in the R0 (unpaired 1633 
reads) file. The reference genome used for alignment was the human 1634 
reference genome assembly GRCh38. The reference sequence was 1635 
downloaded from the Ensembl ftp site 1636 
(ftp://ftp.ensembl.org/pub/release77/fasta/homo_sapiens/dna/Homo_sapi 1637 
ensGRCh38.dna_sm.primary_assembly.fa.gz). The reference annotation 1638 
was also downloaded from the Ensembl ftp site 1639 
(ftp://ftp.ensembl.org/pub/release- 1640 
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77/gtf/homo_sapiens/Homo_sapiens.GRCh38.77.gtf.gz).  The annotated 1641 
file contained 63,152 genes. R1/R2 read pairs were mapped to the 1642 
reference sequence using TopHat2 version 2.1.0 (205) which calls the 1643 
mapper Bowtie2 version 2.0.10 and then compiled using CuffDiff software 1644 
(206).  1645 
 1646 
3.20.0 Data Analysis 1647 
All statistical analyses were performed using either GraphPad Prism 6 or 1648 
R software. Analyses between groups were performed using 2-way 1649 
ANOVA analysis with Bonferri’s multiple comparison test sand Kriskal- 1650 
Wallis analysis (GraphPad) and Friedman’s analysis (R software). A p 1651 
value of less than 0.05 is considered to be statistically significant. 1652 
  1653 
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 1655 
Chapter 4 1656 
Results  1657 
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4.1.0 In Vitro Model of EV71 Infection 1658 
4.1.1 Aims 1659 
 1660 
Before establishing any primary cell models, I first needed to find out if the 1661 
clinical specimens could be propagated, and then needed to examine if 1662 
there were any differences in the infection and replicative profiles of the 1663 
different samples. I propagated the samples in RD cells, up to what I 1664 
deemed an acceptable titre and then measured their viral kinetics over a 1665 
24-hour period. This was done using flow cytometry analysis to detect 1666 
infectivity and qRT-PCR analysis to determine replication. 1667 
4.1.2 EV71 clinical isolates 1668 
 1669 
To examine the impact of different EV71 genotypes on infection, six viruses 1670 
isolated from patients with differing levels of severity of disease during an 1671 
EV71 outbreak in Sarawak, Malaysia were sent to us for analysis. The 1672 
patients, from whom these samples were isolated had EV71 related 1673 
diseases ranging from mild HFMD, to neurological complications, to a 1674 
fatality (82)  (Table 1). These six isolates all belonged to the B5 subgroup 1675 
of EV71. 1676 
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 1677 
Isolate Genotype cluster Date taken Sample type Clinical symptoms 
1 B5-1 09/08/06 Throat swab Herpangina 
2 B5-1 13/0606 Vesicle swab HFMD 
3 B5-2 03/07/06 Throat swab HFMD with Acute meningoencephalitis 
4 B5-2 16/04/06 Vesicle swab HFMD 
5 B5-3 01/04/06 Rectal Fatal 
6 B5-3 20/03/06 CSF HFMD with CNS involvement 
Table 1. EV71 virus isolates from 2006 outbreak in Sarawak, Malaysia. This tables shows the viral isolates we received 
from the 2006 EV71 outbreak in Sarawak, Malaysia. Information includes, EV71 genotype, date the sample was taken, 
region of the body the sample was isolated from, and the symptoms the patient displayed during their infection  
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 1678 
Figure 6. Phylogenetic tree of EV71 virus including the 6 isolates
received from 2006 outbreak in Sarawak, Malaysia.
EV71 subgenogroup B phylogenetic tree generated by maximum-likelihood
analysis of complete VP1 nucleotide sequences. The tree was rooted to the
prototype genogroup A strain. Sequences are identified by GenBank
accession, country of origin and year of isolation. Viruses discussed in this
study are underlined. The robustness of the tree was evaluated by bootstrap
analysis using 1000 pseudoreplicate sequences. Bootstrap values >75% of
major clades are indicated at relevant branch nodes. All branch lengths are
drawn to scale and a measurement of relative phylogenetic distance is
provided by the scale at the bottom of the tree.
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Figure 7. Diagram of viral propagation method.
RD cells were seeded T150 flasks and infected with a 1:5 ratio of EV71 to media mix once the cells had reached 80%
confluency. The cells were then incubated for 2 hours at 37°C with 5% CO2. After these two hours, the virus mix was
removed and fresh media was added. The infected cells were then closely monitored and once 85% CPE was
observed the supernatant was removed via aspiration, pre-cleared via centrifugation at 1500rpm for 5 minutes, before
either being used to re-infect fresh cells for further propagation, or stored at -80°C.
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Concentration of the virus
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Figure 8. Titration of EV71 isolates using TCID50 assay.
This figure shows representative images of the viral titration of the EV71 isolates. A 96 well plate of RD cells seeded at
25E4 cells/well were infected with serially diluted EV71 for 96 hours. Image taken at 96hpi after fixation with 10%
formalin and staining with 0.5% crystal violet. The values were deduced from this assay using the Reed-Muench
method and then converted in to PFU/ml.
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4.1.3 Phylogenetic analysis of EV71 clinical isolates 1681 
 1682 
The isolates were then phylogenetically analysed by a phylogenetic tree, 1683 
generated by maximum-likelihood analysis of complete VP1 nucleotide 1684 
sequences. The tree was rooted to the prototype genogroup A strain. 1685 
Sequences are identified by GenBank accession, country of origin and 1686 
year of isolation. Viruses discussed in this study are underlined. The 1687 
robustness of the tree was evaluated by bootstrap analysis using 1000 1688 
pseudoreplicate sequences. Bootstrap values >75% of major clades are 1689 
indicated at relevant branch nodes (Fig 6). The isolates which caused the 1690 
least severe disease (1 and 2) were grouped together in the phylogenetic 1691 
tree (Fig 6), the two viruses that caused moderate disease (3 and 4) were 1692 
grouped together, separate from isolates 1 and 2 (Fig 6). The severe 1693 
disease-causing isolates, including the fatal isolate (5 – fatal and 6) were 1694 
again together but then separate from the other four isolates (Fig 6). 1695 
Viral isolate propagation and titring 1696 
 1697 
After receiving the isolates from Sarawak, I first propagated each virus to 1698 
passage 2 (P.2) in RD cells. After propagation, the cells were titred using 1699 
a tissue culture infective dose 50 (TCID50) assay. The cells were infected 1700 
for 96 hours then fixed using 10% formalin and stained with 0.5% crystal 1701 
violet (Fig 8). Titres were then deduced using the Reed-Muench method 1702 
and converted to PFU/ml. All isolates reached a titre of at least 1E7 1703 
PFU/ml. 1704 
1705 
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Figure 9. Novel qRT-PCR system for measuring the viral copy number of
EV71 isolates.
EV71 isolates were propagated in RD cells up to P.2 to increase viral load/titre.
Viral RNA was then extracted from the supernatant of the propagation media
and then ran through a novel qRT-PCR system. This figure shows the viral load
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4.1.4 Measurement of viral replication using qRT-PCR 1707 
 1708 
I also created a novel qRT-PCR assay and used it to measure the viral 1709 
copy number. The viral genome was sequenced and the VP1 region of the 1710 
virus was subsequently aligned and analysed using MegAlign software 1711 
(Lasergene, DNA Star). Novel forward and reverse primers and a Fam- 1712 
labelled molecular beacon probe were created from a consensus 1713 
sequence of all six isolates; the primers and probe were a perfect match 1714 
for all six isolates. RNA standards were created using a Ribogreen assay 1715 
and were serially diluted from 1x1011 to create standards from 1x109 to 1716 
1x101 RNA copies/μl. This was used to measure the viral load of the 1717 
propagated viruses to ensure high enough level of viral copy number (Fig 1718 
9).  1719 
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Figure 10. Gating strategy for flow cytometry analysis of viral kinetics of EV71 isolates in
Rhabdomyosarcoma (RD) cells.
This figure shows a representative illustration of the flow cytometry gating strategy of EV71 infected RD cells, using
10F0 (Abcam) mouse monoclonal antibody recognizing the EV71 VP1 antigen (taken at 24hpi). RD cells were
infected with EV71 isolates one to six as well as mock-infected, at MOI 10 and harvested at 0, 3, 6, 12 and 24 hours
post infection (hpi). All infected cells were compared against a mock-infected control at each timepoint.
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Figure 11. Viral kinetics of EV71 isolates in Rhabdomyosarcoma (RD) cells over 24 hours.
Representative histograms of EV71 isolates 1-6 infected RD cells at 0, 3, 6, 12 and 24hpi, collected via flow cytometry
and analysed using FlowJo software. RD cells were infected with EV71 isolates 1-6, at MOI 10 and harvested at 0, 3,
6, 12 and 24 hours post infection (hpi). All infected cells were compared against a mock-infected control at each
timepoint. Each isolate is identified via it’s colour, used in table 1. Mock-infected is coloured black
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Figure 12. Severe EV71 isolates show higher levels of infectivity in RD
cells over 24 hours.
RD cells were infected with the six different isolates of EV71 over 24 hours.
The infected cells was taken at each respective timepoint, fixed, permed and
incubated with an anti-EV71 antibody conjugated with a fluorophore. The
infectivity was then measured via flow cytometry using a mock-infected
sample at each timepoint as a control. This figure shows the graph of infection
kinetics of EV71 isolates one to six at 24hpi in RD cells at MOI 10 (n=3). Data
on this graph was compared against other isolates using 2-way ANOVA with
Bonferroni’s multiple comparisons (*p<0.05, **p<0.01 and ***p<0.001).
EV71 Infectivity in RD Cells 
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4.1.5 Examining the infectivity of EV71 clinical isolates 1723 
 1724 
Once an acceptable titre had been reached across all isolates, the viral 1725 
kinetics of the isolates were assessed over a 24-hour time period, at 0, 3, 1726 
6, 12 and 24 hours post infection, measuring infectivity via flow cytometry 1727 
and replication via qRT-PCR.  Infectivity was assessed by infecting RD 1728 
cells with all isolates, separately, at MOI 10.  1729 
 1730 
An MOI of 10 was chosen for this experiment after inspecting the 1731 
surrounding literature and performing a series of optimisation experiments 1732 
using different MOI’s and time points. MOI’s of 1 and 10 were trialled along 1733 
with time points of 0, 6, 12, 24 and 48 hours post infection These MOIs and 1734 
time points were selected as they have been previously used in 1735 
experiments in similar literature papers (91, 207) . 1736 
 1737 
Cells were harvested at 0, 3, 6, 12, and 24hpi. Virus infectivity was 1738 
determined by measuring the level of intracellular EV71 VP1 antigen (Ag) 1739 
detected by an anti-EV71 VP1 monoclonal antibody via flow cytometry. 1740 
The threshold for EV71 positive cells was determined from the gating of 1741 
mock-infected control at the same time point (Fig 10). Once this was 1742 
established, infection kinetics experiments were performed by infecting RD 1743 
cells with all isolates at MOI 10 across a time course of 0, 3, 6, 12 and 1744 
24hpi (Fig 11). Interestingly, significantly higher levels of EV71 Ag+ cells 1745 
were detected in isolates 5 and 6 infections at 24hpi when compared with 1746 
the other isolates and the mock infected. Isolate 3 also had a significantly 1747 
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higher percentage of EV71 Ag+ cells when compared to isolates 1 and 2 1748 
at 24hpi (Fig 12).   1749 
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Figure 13 Severe EV71 isolates show higher levels of replication in RD
cells over 24 hours.
RD cells were infected with the different isolates of EV71 over 24 hours. The
infectious supernatant was taken at each respective time point, the vRNA was
extracted and then ran through our novel qRT-PCR assay. This graph shows
the level of EV71 isolates one to six viral load, taken at 0, 3, 6, 12, and 24hpi,
and measured using qRT-PCR (n=3). Data on this graph was compared
against other isolates using 2-way ANOVA with Bonferroni’s multiple
comparisons (*p<0.05, **p<0.01 and ***p<0.001).
EV71 Replication in RD Cells 
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4.1.6 Examining the replication of EV71 clinical isolates 1751 
 1752 
To determine virus replication, viral RNA was extracted from the 1753 
supernatant followed by qRT-PCR. Expectedly, similar trends were 1754 
observed in the replication kinetics with significantly higher numbers of 1755 
negative sense VP1 RNA copies observed at 24hpi for isolates 5 and 6 1756 
compared to all the other isolates and the mock-infected sample.  Again 1757 
isolate 3 showed significantly higher levels of negative sense VP1 RNA 1758 
copies as compared to isolates 1, 2 and the mock infected sample (Fig 13).  1759 
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4.2.0 Ex vivo human blood EV71 infection model 1760 
4.2.1 Aims 1761 
 1762 
Once it was found that there was a difference in the viral kinetics of these 1763 
isolates. I next wanted to examine the effect of these viruses in a model 1764 
that was more relatable to the actual disease. Primary human peripheral 1765 
blood mononuclear cells were chosen for this model. As leukocytes are the 1766 
main players in the immune response, I wanted to use a primary source of 1767 
leukocytes. This would help me examine the infectivity and immune 1768 
reaction of EV71 on the host immune system, as well as giving me a view 1769 
into deciphering the pathways and roles of the immune response. Using 1770 
fresh PBMCs, which contain no plasma or serum, gives the added 1771 
advantage (e.g. over whole blood) that the donor’s antibodies will not play 1772 
any role during the experiments. There will also be minimal levels of any 1773 
other factors that may interfere with the experimental process such as 1774 
cytokines and chemokines.  1775 
 1776 
Due to the limited amount of primary PBMC donors, 3 virus isolates that 1777 
representing the best range of symptoms were selected for further studies. 1778 
A mild (HFMD only - Isolate 1), moderate (HFMD and meningoencephalitis 1779 
- Isolate 3) and severe (fatal - Isolate 5) strain of EV71 were chosen. Viral 1780 
load, infectivity, immunophenotyping and RNASeq analysis was 1781 
subsequently performed on the samples.  1782 
 1783 
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Cells seeded at 
density optimized 
for infection
Cells infected at 
specific infection 
MOI
Virus incubated 
with cells for 2 
hours
Infection media removed and fresh media added
0h Timepoint
Harvest supernatant and 
cells at specific time 
points, and process
Figure 14. Diagram of infection protocol for all infection experiments.
Cells were seeded at their optimal density depending on which infection experiment was being carried out. The
cells were then infected with the specific virus at the specific MOI respective to that experiment. The cells were
then incubated for 2 hours at 37°C with 5% CO2. After these two hours, the virus mix was removed and fresh
media was added. Once the fresh media was added, this is the 0h time point. Just to note, at 0h post infection
the virus has been in contact with the cells for 2 hours, so this is why infection and viral load can be seen at 0h
post infection.
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Figure 15. Gating strategy for flow cytometry analysis of CD45+ EV71 infected cells.
PBMCs were infected with EV71 isolates 1, 3 and 5, as well as heat inactivated EV71 and a mock-infected control, at
MOI 5 over 24 hours. The PBMCs were harvested at each respective timepoint, then fixed, permed and stained with
an anti-EV71 antibody and respective cell surface marker antibodies, then analysed using flow cytometry. This figure
shows a representative illustration of the flow cytometry gating strategy of EV71 infected PBMCs, taken at 6hpi.
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Figure 16. Infection percentages of CD45+ gated cells from PBMCs
infected with EV71 isolates of differing severity.
PBMCs were infected with EV71 isolates 1, 3 and 5, as well as heat inactivated
EV71 and a mock-infected control, at MOI 5 over 24 hours. The PBMCs were
harvested at each respective timepoint, then fixed, permed and stained with an
anti-EV71 antibody and respective cell surface marker antibodies. The cells
were gated in to CD45+ cells, and then EV71 Ag+ percentage was compared to
the mock-infected control at the specific timepoint. This figure shows a
representative dot plots of the EV71 Ag gate of CD45+ EV71 infected PBMCs
(taken from 6hpi).
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4.2.2 EV71 infection in primary human peripheral blood mononuclear cells 1787 
 1788 
PBMCs were isolated from human blood apheresis cones and infected with 1789 
EV71 isolates 1, 3 and 5, along with heat-inactivated and mock-infected 1790 
controls at MOI 5 across a time course of 0, 6, 12 and 24hpi.  1791 
 1792 
An MOI of 5 was chosen for this experiment after inspecting the 1793 
surrounding literature and performing a series of optimisation experiments 1794 
using different MOI’s and time points. MOI’s of 1, 5 and 10 were trialled 1795 
along with time points of 0, 12, 24, 48 and 72 hours post infection These 1796 
MOIs and time points were selected as they have been previously used in 1797 
experiments in similar literature papers (130, 131). 1798 
 1799 
At each time point the PBMCs were harvested, fixed, stained for dead cells, 1800 
permed, stained with a mouse anti-EV71 antibody, then stained with an 1801 
anti-mouse antibody conjugated with a fluorophore, then finally stained 1802 
with antibodies against certain cell surface markers. This was then 1803 
analysed using flow cytometry. Infectivity in the PBMCs was determined 1804 
by initially gating out the dead and duplet cells using a fixable Live/Dead 1805 
stain and an FSC-W/FSC-H gate respectively, before gating the CD45+ 1806 
cells and measuring the level of intracellular EV71 VP1 Ag. The threshold 1807 
for EV71 positive cells was determined from the gating of the mock-infected 1808 
control at the same time point (Fig 15). Each infection was completed to 1809 
n=10. The neurovirulent isolates (isolates 3 and 5) were shown to be more 1810 
infectable in PBMCs as compared to the non-neurovirulent isolate (isolate 1811 
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1) (Fig 16). Significantly higher levels of EV71 VP1 Ag were detected in the 1812 
neurovirulent isolates of EV71 (3 and 5) as compared with the non- 1813 
neurovirulent strain (isolate 1), the heat-inactivated virus and the mock- 1814 
infected controls (Fig 13). All the data within these graphs were compared 1815 
using Friedman analysis (*p<0.05, **p<0.01 and ***p<0.001). 1816 
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Figure 17. Infection percentages of EV71 isolates of differing severities in
CD45+ cells from PBMCs over 24 hours.
PBMCs were infected with EV71 isolates 1, 3 and 5, as well as heat inactivated
EV71 and a mock-infected control, at MOI 5 over 24 hours. The PBMCs were
harvested at each respective timepoint and analysed via flow cytometry. The
cells were gated in to CD45+ cells, and then EV71 Ag+ percentage was
compared to the mock-infected control at the specific timepoint. This figure
shows the summary graphs of the infection percentages of CD45+ cells infected
by the different EV71 isolates (n=10). Dotted line represents mock-infected
control. Data within these graphs were compared using Friedman analysis
(*p<0.05, **p<0.01 and ***p<0.001).
EV71 Infectivity in PBMCs 
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4.2.3 Examining the infection kinetics in primary human PBMCs 1818 
 1819 
Differing trends were seen across the isolates over the time-course of 1820 
infection in PBMCs. Isolate 1 showed limited infectivity across all time 1821 
points during the PBMC infection, barely passing the background baseline 1822 
set by the mock-infected control. There was a non-significant increase from 1823 
6 to 24hpi, however this still did not exceed 2% infection (Fig 17). 1824 
 1825 
Isolate 3 showed high levels of initial infectivity, peaking after the initial 1826 
incubation period at 0hpi. However, it then had steadily decreasing levels 1827 
of EV71 VP1 Ag detected as the time course progressed, with 0hpi having 1828 
significantly higher levels of infection over 6, 12 and 24hpi (Fig 17). As 1829 
previously shown in Fig 14 at 0hpi the cells have already been incubated 1830 
with the virus for two hours, which is enough time for EV71 to begin binding 1831 
to its receptors and start the internalisation process. This is why these 1832 
levels of infection can be seen at 0hpi.  1833 
 1834 
Isolate 5 was the only isolate to show increasing levels of infectivity across 1835 
the time points. With initially low levels of infectivity at 0hpi, there was a 1836 
non-significant increase between 6hpi. Infectivity peaked at 12hpi, with a 1837 
significantly higher point of infection than any other time point. Before 1838 
decreasing at 24hpi to a level below the 6hpi level of infectivity (Fig 17).  1839 
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Figure 18. Viral load of EV71 isolates of differing severities in CD45+ cells
from PBMCs over 24 hours.
PBMCs were infected with EV71 isolates 1, 3 and 5, as well as heat inactivated
EV71 and a mock-infected control, at MOI 5 over 24 hours. The infectious
supernatant was collected at each time point from each isolate. The vRNA was
extracted and then analysed via a novel qRT-PCR assay. This figure shows the
summary graphs of the viral loads of PBMCs infected by the different EV71
isolates (n=10). Data within these graphs were compared using Friedman
analysis (*p<0.05, **p<0.01 and ***p<0.001).
**
**
**
***
***
***
EV71 Replication in PBMCs 
 115 
4.2.4 Examining the replication kinetics in primary human PBMCs 1841 
 1842 
As well as harvesting the cells, the supernatant was also taken from the 1843 
infectious mix at each time point. The viral RNA was extracted from this 1844 
supernatant and then the level was measured using a novel qRT-PCR 1845 
assay. Similar trends to the infectivity kinetics were also observed in the 1846 
viral load from the PBMC infection. Isolate 1 showed significantly lower 1847 
levels of VP1 RNA copies detected across all time points as compared with 1848 
isolates 3 and 5. They were significantly higher than the mock-infected 1849 
sample at each time point, but there was no significant increase across any 1850 
of the time points (Fig 18). 1851 
 1852 
Isolate 3 again showed significantly high initial levels of VP1 RNA copies, 1853 
peaking at 0hpi. There was a significant decrease between 0 and 6hpi. The 1854 
viral load then plateaued between 6 and 12hpi, before decreasing again at 1855 
24hpi. This decrease across all time points shows that there was limited 1856 
replication during the isolate PBMC infection (Fig 18). 1857 
 1858 
Isolate 5 was the only isolate that seemed to show replicative capacity 1859 
during this PBMC infection. There was no increase between 0 and 6hpi, 1860 
however there was then a significant increase in viral load between 6 and 1861 
12hpi. Showing that isolate 5 has the capacity to replicate in human 1862 
PBMCs. There was then a significant decrease in viral load between 12 1863 
and 24hpi, suggesting 6-12hpi is the peak time for replication in PBMCs for 1864 
this isolate (Fig 18). 1865 
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Figure 19. Flow cytometry gating strategy for immunophenotyping PBMCs after EV71 infection.
After infection with EV71 and harvesting at specific time points, the PBMCs were fixed, permed, stained with
antibodies for EV71 and then stained with antibodies for cell surface markers. The cells are gated on size and
granularity to remove debris. Then gated for single cells and Live/Dead (shown on Figure 7). The leukocytes are
then gated using CD45+ cells. From these cells T cells and B cells are gated using a CD3/CD19 gate. T cells are
CD3+/CD19-. B cells are CD3-/CD19+. The rest of the panel is gated from the CD3-/CD19- gate. Monocytes are
gated from this using CD14/SSC-A, CD14+ cells are the monocytes, these can be further gated into CD14+/CD16-
or CD14+/CD16+ monocytes (not shown). The CD14-/SSC-A gate is then gated using CD16/SSC-A. CD16+ cells
are further gated using CD56/SSC-A in to CD56lo and CD56high NK cells. The CD16- gate is further gated using a
HLA-DR/CD11c gate. With HLA-DR+/CD11c+ cells being cDCs and HLA-DR+/CD11c- cells being pDCs. This figure
shows a representative image of the gating strategy used to isolate the immune cell subsets after EV71 infection in
PBMCs via flow cytometry (taken at 12hpi)
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Figure 20. Infection levels in leukocyte subsets of PBMCs after infection
with EV71 isolates over 24 hours.
EV71 infected PBMCs were harvested, fixed, permed and stained with EV71
and surface marker antibodies, and then analysed via flow cytometry. They were
then gated as shown in figure 11. Each subset was then gated against the EV71
Ag and the percentage infectivity was analysed, as compared to the mock-
infected. This figures show representative dot plots of the infection levels for the
T cells, B cells, monocytes, NK cells and the other cells, gated from EV71
infected PBMCs. Image taken from 6hpi.
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4.2.5 Non-virulent and virulent strains of EV71 isolates generate different 1868 
immunophenotype infectability profiles 1869 
 1870 
To further examine the role of PBMCs in EV71 infection severity, 1871 
immunophenotyping was performed on the infected PBMCs. This allowed 1872 
for an in-depth analysis of the infection profiles and kinetics of the immune 1873 
subsets. The cells were further gated from the CD45+ leukocyte population 1874 
(Fig 15) into the subset populations of PBMCs using the cell surface 1875 
markers, CD3, CD19, CD14, CD16, CD56, CD11c and HLA-DR. These 1876 
markers separate the cells into: 1877 
  1878 
• T cells - CD45+/CD3+/CD19- 1879 
• B cells - CD45+/CD3-/CD19+ 1880 
• Monocytes - CD45+/CD3-/CD19-/CD14+ 1881 
o CD45+/CD3-/CD19-/CD14+/CD16+ 1882 
o CD45+/CD3-/CD19-/CD14+/CD16- 1883 
• NK cells - CD45+/CD3-/CD19-/CD14-/CD16+/CD56+ 1884 
o CD45+/CD3-/CD19-/CD14-/CD16+/CD56lo 1885 
o CD45+/CD3-/CD19-/CD14-/CD16+/CD56hi 1886 
• cDCs - CD45+/CD3-/CD19-/CD14-/CD16-/HLA-DR+/CD11c+ 1887 
• pDCs - CD45+/CD3-/CD19-/CD14-/CD16-/HLA-DR+/CD11c-  1888 
 1889 
Important respective cell surface markers are in bold (Fig 19).   1890 
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Figure 21. Infectivity in leukocyte subsets of PBMCs after infection with
EV71 isolates over 24 hours.
EV71 infected PBMCs were harvested, fixed, permed and stained with EV71
and surface marker antibodies, and then analysed via flow cytometry. They were
then gated as shown in figure 11. Each subset was then gated against the EV71
Ag and the percentage infectivity was analysed, as compared to the mock-
infected. This figure shows summary graphs of the level of infection in T cells, B
cells and monocytes gated from PBMCs infected with the EV71 isolates (n=10).
Dotted line represents mock-infected baseline. Isolate 1 not shown as no
infection seen. Data within these graphs was compared using Friedman analysis
(*p<0.05, **p<0.01 and ***p<0.001).
Hours Post Infection (hpi)
EV71 Infectivity in PBMC Leukocyte Subsets 
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From this more in-depth gating, it was observed that there are three main 1892 
infectable subsets within the PBMCs; T cells, B cells and monocytes (Fig 1893 
20), which show higher levels of infection compared to the other subsets. 1894 
These other subsets such as DCs and NK cells were infectable but showed 1895 
lower/limited levels of infectability (Fig 20). It is also seen that isolate 1 1896 
(non-virulent) shows limited infection across all of the immune cell subsets, 1897 
when compared with the virulent strains (isolate 3 and 5). It has a profile 1898 
closer to the heat inactivated and mock-infected samples (Fig 20). 1899 
 1900 
Isolate 3 showed a similar infectivity trend in T cells as in the total PBMCs. 1901 
There was a significantly high initial level of EV71 VP1 Ag+ cells detected 1902 
at 0hpi. There was then a steady decrease to 6hpi then 12 and 24hpi (Fig 1903 
21). This trend was also seen in the other lymphocyte population, the B 1904 
cells. Again, with significantly high levels of EV71 Ag+ cells being detected 1905 
at 0hpi, and then a steady decline over the 24 hours (Fig 21).  Isolate 3 1906 
infected monocytes; however, showed a slightly different pattern to that of 1907 
the isolate 3 infected lymphocytes and infected PBMCs. Although a similar 1908 
initial high infectivity at 0hpi was observed, there was a larger decrease in 1909 
EV71 Ag+ cells between 0 and 6hpi, and then plateau with a 1910 
similar/constant level of infectivity across the remaining time points (Fig 1911 
21). 1912 
 1913 
Each of the leukocyte subsets showed different infection profiles after 1914 
infection with EV71 isolate 5, as well as showing completely different trends 1915 
from the other isolates. The isolate 5 infected T cells subset showed a 1916 
 121 
similar pattern of infection to isolate 5 infected total PBMCs. This was a 1917 
steady, significant increase in infection from 0hpi to 12hpi, where the 1918 
infection peaked, before a decrease in infection at 24hpi (Fig 19). The B 1919 
lymphocyte subset showed an earlier increase in infectivity than T cells. 1920 
With low levels of infection at 0hpi, suddenly peaking to significantly higher 1921 
levels at 6hpi, before steadily decreasing at 12 and 24hpi (Fig 21). EV71 1922 
isolate 5 infected monocytes showed a completely different trend to either 1923 
of the lymphocyte subsets. It maintained a constant, relatively high, level 1924 
of infectivity across the 24-hour time course (Fig 21). Both isolate 3 and 1925 
isolate 5 showed significantly higher levels of infection in T cells, B cells 1926 
and monocytes as compared to the heat inactivated virus and the mock- 1927 
infected control.  1928 
  1929 
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Figure 22. Replication of EV71 isolates of differing severities in monocytes
isolated from PBMCs over 24 hours.
Isolated human primary monocytes were infected with EV71 isolates 1, 3 and 5,
as well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 6 and 12hpi. This figure is a summary graph of viral load taken
from EV71 isolate 1, 3 and 5, heat inactivated and mock infected human
monocytes at 6 and 12hpi (n=4). Data within this graph was compared using
Friedman analysis (*p<0.05).
EV71 Infectivity in Monocytes 
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Figure 23. Replication of EV71 isolates of differing severities in CD8+ T
cells isolated from PBMCs over 24 hours.
Isolated human primary CD8+ T cells were infected with EV71 isolates 1, 3 and
5, as well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 6 and 12hpi. This figure is a summary graph of viral load taken
from EV71 isolate 1, 3 and 5, heat inactivated and mock infected human CD8+
T cells at 6 and 12hpi (n=4). Data within this graph was compared using
Friedman analysis (*p<0.05).
EV71 Infectivity in CD8+ T Cells 
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Figure 24. Replication of EV71 isolates of differing severities in CD4+ T
cells isolated from PBMCs over 24 hours.
Isolated human primary CD4+ T cells were infected with EV71 isolates 1, 3 and
5, as well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 6 and 12hpi. This figure is a summary graph of viral load taken
from EV71 isolate 1, 3 and 5, heat inactivated and mock infected human CD4+
T cells at 6 and 12hpi (n=4). Data within this graph was compared using
Friedman analysis (*p<0.05)
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4.2.6 Differential replication kinetics seen across individual primary 1933 
peripheral blood cell subsets 1934 
 1935 
To deeper explore the role of the individual immune cell subsets a further 1936 
infection using isolates 1, 3 and 5 as well as heat inactivated virus and a 1937 
non-infected mock control, was performed on isolated monocytes, CD4+ 1938 
and CD8+ T cells. Viral RNA was isolated from the supernatant of these 1939 
infections at 6 and 12hpi and then analysed through qRT-PCR. 1940 
 1941 
After examination of the viral load taken during infection, isolate 1 again 1942 
showed significantly lower levels of VP1 RNA copies across the time points 1943 
when compared with the other two isolates in monocytes (Fig19), CD8+ T 1944 
cells (Fig 23) and in CD4+ T cells (Fig 24). Isolate 3 showed no significant 1945 
change in viral load across the between 6 and 12 hours post infection 1946 
during the isolated monocyte infection. However, the level was significantly 1947 
higher than the mock-infected, heat inactivated and isolate 1 infections (Fig 1948 
22). There was also no significant change in viral copy number during the 1949 
isolate 3 infection of isolated CD8+ T cells (Fig 23), this was again, 1950 
however, significantly higher than the isolate 1, heat inactivated and mock- 1951 
infected samples. A similar trend is also seen in the isolate 3 infected CD4+ 1952 
T cells, with no significant change across the time points but being 1953 
significantly higher than isolate 1 and the controls (Fig 24).  These 1954 
outcomes substantiate the results seen in the whole PBMC infection. 1955 
 1956 
Isolate 5 showed limited replication in monocytes across the 6 and 12h 1957 
time points (Fig 22). This lack of significant change in viral copy number is 1958 
 126 
also seen in the CD8+ T cells (Fig 23). Both are significantly higher than 1959 
isolate 1 and the controls however. The CD4+ T cell infection is where 1960 
isolate 5 differs from the other isolates. There was a significant increase in 1961 
EV71 VP1 RNA copies in isolate 5 infected CD4+ T Cells between 6 and 1962 
12hpi (Fig 24), which was not seen in any of the other subsets. This 1963 
significant change points to the CD4+ T cells being the major players in 1964 
EV71 replication in PBMCs. This increase in replication is also at the same 1965 
time point as the isolate 5 infection in whole PBMCs (Fig 16). 1966 
 1967 
  1968 
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4.3.0 In Vitro Human Blood-Brain Barrier Model 1969 
4.3.1 Aims 1970 
 1971 
As EV71 can be a neurotropic virus, and the mechanism of entry to the 1972 
brain is not fully clarified, I wanted to examine the ability of the different 1973 
isolates to cross/breakdown the blood-brain barrier, to see if this could play 1974 
a possible role in EV71 pathogenicity. I also wanted to examine the genes 1975 
and pathways that could play a role, to figure out why EV71 can cross the 1976 
blood brain barrier, and to do this I needed a non-neurotropic virus to which 1977 
I could compare EV71, for this I chose Chikungunya virus. 1978 
  1979 
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Figure 25. EV71 infection and replication in a 60mm dish in vitro infection of
HCMEC/D3 cells.
HCMEC/D3s were seeded in 60mm dishes and infected with the different isolates
of EV71 at MOI 10. At each time point the cells were harvested and analysed for
level of infection via flow cytometry. The cell supernatant was also harvested and
the viral RNA was extracted and the viral load was assessed via qRT-PCR. All
samples were compared to a mock infected sample at the same time point.
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4.3.2 Cerebral microvascular endothelial cell susceptibility to EV71 1981 
infection and replication. 1982 
 1983 
Before I began to test on a BBB model, I first wanted to know if HCMEC/D3 1984 
cells were susceptible to EV71 infection. The cells were seeded in 60mm 1985 
dishes and infected with isolates 1, 3 and 5 of EV71 at MOI 10 and 1986 
incubated for up to 144 hours. At each time point the cells were harvested 1987 
and analysed for level of infection via flow cytometry. Isolate 1 showed 1988 
limited infectivity during this infection, with most time points being similar 1989 
to the mock infected sample, and the peak of infectivity only just reaching 1990 
over 2% infectivity at 48hpi (Fig 25). Isolate 3 had a much greater level of 1991 
infection however. The level of infection gradually increased across the 1992 
time points, reaching a peak at 96hpi, suggesting it has a much greater 1993 
ability to infect these cells (Fig 25). Isolate 5 reached a similar level of 1994 
infectivity to isolate 3, however it achieved this infection level at a much 1995 
faster rate peaking at 12hpi, suggesting an even greater suitability to these 1996 
cells (Fig 25).  1997 
 1998 
As well as harvesting the cells from the infection, I also harvested the 1999 
supernatant from and extracted the viral RNA so I could analyse the viral 2000 
load of these infections. The results showed a similar trend to the infection 2001 
profiles. Isolate 1 showed limited replication compared with the other two 2002 
isolates, with one main peak just after 48hpi (Fig 25). Isolate 3 showed a 2003 
higher level of replication, gradually increasing and peaking just after 96hpi 2004 
(Fig 25). Isolate 5 showed a similar level of replication to isolate 3, but with 2005 
its large increase in replication seen just after 12hpi (Fig 25). 2006 
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Figure 26. Setting up of monolayer HCMEC/D3 in vitro blood brain barrier
model.
Human cerebral microvascular endothelial cells were seeded on a 12-well
transwell semi-permeable membrane insert at 1E5 per insert. They were left to
grow and the TEER was measured every 24 hours. This is a summary graph
showing the TEER level after the blank value had been deducted.
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4.3.3 In vitro blood-brain barrier model optimisation 2008 
 2009 
The next step in this experimental procedure was to optimise the BBB 2010 
model I would be using. The model needed to be able to withstand the 2011 
amount of time the infection would run for, without the barrier losing 2012 
integrity, as this would compromise the results. HCMEC/D3 cells were 2013 
seed on 12-well transwell inserts, which were then placed into a 12 well 2014 
plate. The cells were then left to grow, and the transendothelial electrical 2015 
resistance (TEER) was measure every 24 hours (Fig 26). The BBB did not 2016 
reach optimal strength until 72 hours after initial seeding, which meant that 2017 
the infection should not take place before this time point. The TEER value 2018 
did not significantly change from this point onwards, until the experiment 2019 
was stopped at 240 hours after the initial seeding (Fig 26). From 72h to 2020 
240h would be enough time for all the time points I wanted to use for these 2021 
experiments. 2022 
 2023 
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Figure 27. EV71 isolate infection of a HCMEC/D3 in vitro blood brain barrier model.
Human cerebral microvascular endothelial cells were seeded on a 12-well transwell semi-permeable membrane insert
at 1E5 per insert. They were left for 72 hours to adhere and form a barrier. They were then infected with different
isolates of EV71 and measured for TEER and viral load every 24 hours. All TEER measurements are shown after
blank value has been deducted, and are then compared to mock infected value. All viral load shown were taken from
the abluminal side. Mock viral load was undetectable. Data within these graphs was compared using students test
(*p<0.05, **p<0.01 and ***p<0.001).
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4.3.4 EV71 isolate infection in an in vitro blood-brain barrier model 2025 
 2026 
After the optimisation of the BBB, I again seeded HCMEC/D3 cells on a 2027 
12-well transwell semi-permeable membrane insert at 1E5 per insert. They 2028 
were left for 72 hours to adhere and form a barrier. I then infected the 2029 
barrier with different isolates of EV71 and measured for TEER and viral 2030 
load every 24 hour up to 144hpi. The level of TEER is an indicator of the 2031 
barrier’s strength and integrity, whilst the viral load (taken from the 2032 
abluminal side) measures the ability of the virus to pass through the BBB.  2033 
 During infection with isolate 1, the BBB suffers very little damage; 2034 
and there is no reduction in TEER seen up to 96hpi (Fig 27). At 120hpi and 2035 
144hpi there is a small decrease in TEER however it is not a significant 2036 
drop (Fig 27), suggesting isolate 1 does not cause any serious breakdown 2037 
of the BBB. This is mirrored in the viral load analysis with a very low level 2038 
of virus being able to pass through the BBB (Fig 27), suggesting that its 2039 
integrity is still intact.  2040 
 2041 
Isolate 3 causes much more damage to the BBB. The decrease in TEER 2042 
starts at 72hpi, with a significant decrease seen at 96hpi onwards (Fig 27). 2043 
This suggests that the barrier is losing its integrity and is losing some of its 2044 
barrier function. This can also be seen in the viral load, with a much greater 2045 
level of vRNA being detected in the abluminal side of the isolate 3 infection, 2046 
compared with isolate 1. 2047 
 2048 
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The highest level of damage is seen during the infection with isolate 5. A 2049 
significant decrease in TEER was seen at 72hpi, which continued until 2050 
144hpi, at which point the barrier was almost completely destroyed (Fig 2051 
27). This deterioration in barrier function can also be seen in the viral load 2052 
data, with extremely high levels of vRNA detected early on in the infection 2053 
(Fig 27). Suggesting severe detrimental damage to the BBB has been 2054 
inflicted. 2055 
 135   2056 
Figure 28. Heatmap gene expression analysis of total RNA taken from CHIKV and EV71 infected in vitro
HCEMC/D3 BBB model.
The in vitro BBB was infected with CHIKV or EV71, at each timepoint cells were harvested and the total RNA was
extracted from them. They were then analysed for there gene expression and compared against mock infected and a
house keeping gene β-actin. The time points chosen here represent initial infection (0hpi), first drop in TEER (72hpi) and
peak TEER drop (144hpi). A total of 24 genes were screened, including 7 receptor genes (AXL receptor, Tyro-3, PSGL-1,
SCARB2, RIG-I, MDA-5 and TLR-3) 6 genes encoding for tight junction proteins (Claudin-2, Claudin-5, Occludin) and
adhesion factors (CD99, CD98 and CD44), 6 IFN production genes (IRF-3, IRF-5, IFN-α, IFN-β, IFN-γ and IFN-γ receptor)
and 5 IFN-associated genes (ISG-15, CCL-5, CXCL9, CXCL10 and CXCL11) at the selected time points using the
Quantifast™ SYBR-Green assay. Fold change in the mRNA expression level is then derived using GADPH as the house-
keeping gene and normalized to mock population, calculated using the ΔΔ Ct method. A heatmap was generated, based
on the fold change values and viewed in MeV 4.9.0 . Any up-regulation of gene expression is indicated in red while any
down-regulation of gene expression is indicated in blue. Scale is normalized from -1 to 1 in MeV 4.9.0.
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4.3.5 Gene expression in the endothelial cells of the BBB during 2057 
neurotropic and non-neurotropic infections 2058 
 2059 
To investigate the pathways involved in the disruption of the BBB during 2060 
EV71 infection, I examined the gene expression profiles of important 2061 
infection immune response or BBB tight junction related genes during an 2062 
EV71 infection. Namely virus receptors and PRRs AXL receptor, Tyro-3, 2063 
PSGL-1, SCARB2, RIG-I, MDA-5 and TLR-3, 6 genes encoding for tight 2064 
junction proteins (Claudin-2, Claudin-5, Occludin) and integrin-mediated 2065 
inter-endothelial adhesion factors (CD99, CD98 and CD44), 6 IFN 2066 
production genes (IRF-3, IRF-5, IFN-α, IFN-β, IFN-γ and IFN-γ receptor) 2067 
and 5 IFN pathway associated genes (ISG-15, CCL-5, CXCL9, CXCL10 2068 
and CXCL11). To compare the EV71 neurotropic infection, I used a non- 2069 
neurotropic viral infection (Chikungunya virus; CHIKV) and a mock infected 2070 
control.  2071 
 2072 
EV71 and CHIKV infections produced two very distinct gene expression 2073 
profiles when the hCMEC/D3 in vitro BBB model was infected by the 2074 
viruses. CHIKV upregulated many of the different gene classes across all 2075 
the time points during the infection, to cause a sustained pro-inflammatory 2076 
response (Fig 28). However, conversely, EV71 down-regulated the mRNA 2077 
expression level of many pro-inflammatory genes screened when TEER 2078 
first significantly decreases at 72hpi (Fig 28). EV71 also sustained the 2079 
down-regulation and suppression of the pro-inflammatory response all the 2080 
way until 144hpi (Fig 28).  2081 
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4.3.6 Reduced expression of BBB junction proteins coincided with the 2082 
initial reduction in TEER   2083 
 2084 
To determine if the drop in TEER in the BBB model represents a genuine 2085 
breach in the integrity of the barrier function, key BBB proteins such as 2086 
integrin-mediated inter-endothelial adhesion factors CD99, CD98 and 2087 
CD44, and tight junction proteins Claudin-2, Claudin-5 and Occludin, were 2088 
screened to identify any changes in their expression levels.  2089 
 2090 
During EV71 infection there was a down-regulation of the mRNA 2091 
expression levels of key tight junction proteins and adhesion factors during 2092 
the first TEER drop at 72hpi and 144hpi respectively. Particularly, EV71 2093 
infection resulted in the down-regulation of Occludin, Claudin-2, CD99 and 2094 
especially CD98. Although there was a slight up-regulation of Claudin-5 2095 
and CD44 from 0hpi to 72hpi (first TEER drop), they were down-regulated 2096 
again at 144hpi (Fig 28). CHIKV had a contrasting expression profile of 2097 
these genes. There was a sustained or increased level of gene expression 2098 
of the adhesion factor and tight junction proteins Claudin-5, Occludin, 2099 
CD99, CD98 and CD44, at 72h after CHIKV infection. EV71 continued to 2100 
down-regulate all of the BBB proteins except Claudin-2 at 144hpi. These 2101 
results from the mRNA expression level of blood-brain barrier proteins 2102 
during an EV71 infection suggest that the initial breach in BBB integrity 2103 
may be due to a virus-induced down-regulation of BBB adhesion and tight 2104 
junction proteins, which is likely to be sustained during EV71 infection. 2105 
 138 
4.3.7 Suppression of IFN response associated with down-regulated BBB 2106 
proteins 2107 
 2108 
A consistently low mRNA expression level of IFNs, its transcription factors 2109 
and downstream IFN-associated cytokines was seen during EV71 2110 
infection, from 0 through 72 and 144hpi (Fig 28). Specifically, IFN-α, IFN- 2111 
β, IFN-γ, IFN-γ receptor, IRF-3, IRF-5, ISG-15, CCL-5, CXCL9, CXCL11 2112 
and CXCL10, were all down-regulated at 72hpi. This pattern of suppressed 2113 
IFN responses was sustained until 144hpi, except for a slight up-regulation 2114 
in IRF-5 and IFN-β (Fig 28). This result of down-regulated IFN responses 2115 
is juxtapose to CHIKV infection, where a potent IFN-mediated pro- 2116 
inflammatory response was induced across all the time points, including 2117 
the up-regulation in expression levels of IRF-3, IFN-α, CXCL-9, IFN-β, ISG- 2118 
15, CXCL-11 and CCL-5 at both 72hpi and 144hpi (Fig 28). This suggests 2119 
that the down-regulation of the IFN response coincides with increased BBB 2120 
permeability.  2121 
4.3.8 Reduction in host PRR expression levels could be associated with 2122 
BBB permeability  2123 
 2124 
Genes encoding for host PRRs, that could mediate downstream IFN 2125 
responses, were screened to see if the suppression of IFN response due 2126 
to EV71 infections could be due to upstream factors of the IFN response.  2127 
 2128 
Upon EV71 infection, the mRNA expression level of two host PRRs, 2129 
namely MDA-5 and TLR-3, was down-regulated across the time points, 2130 
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72hpi and 144hpi (Fig 28). However, the mRNA expression level of RIG-I 2131 
was slightly up-regulated at 72hpi but became significantly down-regulated 2132 
at 144hpi (Fig 28). Again, these results contrast with the expression level 2133 
of the PRRs during CHIKV infection, which are up-regulated across the 2134 
time points. 2135 
  2136 
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4.4.0 Immune Response Pathways Involved in EV71 2137 
Pathogenesis  2138 
4.4.1 Aims 2139 
 2140 
During any infection, multiple pathways are activated, either by the host in 2141 
response to the pathogen, or by the pathogen itself trying to extend its own 2142 
survival. Whilst these pathways are usually activated with host survival in 2143 
mind, they can often cause more and larger complications. I wanted to 2144 
examine the different pathways used by EV71 during infection, and to see 2145 
if there is any difference between the pathways activated during infection 2146 
with the isolates of differing severity.   2147 
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4.4.2 Examining the pathways via RNASeq gene expression 2148 
 2149 
To examine any possible differences in pathways involved in EV71 2150 
pathogenesis I needed to use a high-throughput, wide ranging technique 2151 
to cover as many options as possible, before narrowing in on the interesting 2152 
results. Otherwise I could be at risk of missing out possible key pathways 2153 
as they aren’t included in my experimental scope. To cover these bases, I 2154 
decided to use RNASeq analysis to examine the pathways.  2155 
 2156 
Primary human PBMCs were infected with the different EV71 isolates at 2157 
MOI 5 and incubated for 0, 6, 12 or 24hpi, as described in previous 2158 
chapters. At each time point, the cells were harvested, and their total RNA 2159 
was extracted. After the RNASeq was ran, the data was analysed using 2160 
TopHat and CuffDiff analysis tools. This combined and compared the data 2161 
from the four separate donors used for each isolate, at each specific time 2162 
point. From this the fold changed compared with the mock was deduced, 2163 
and the fold increase or decrease analysed for any noteworthy results. 2164 
Results were deemed of interest if the fold change was greater than 1.5 or 2165 
less than -1.5 compared with the mock.   2166 
 2167 
Unfortunately, due to time and resource constraints only a very basic level 2168 
of initial analysis after the TopHat and CuffDiff analysis was able to be 2169 
performed. The results from the analysis were collated for each time point 2170 
for all isolates in a tabular format. The “no results” were removed from the 2171 
results, and the remaining genes were filtered on their level of fold change 2172 
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(greater than 1.5 or less than -1.5). Before removal of any no results, or 2173 
filtering based on fold change was performed, the number of genes 2174 
analysed was approximately 16, 000.  2175 
 2176 
After the initial filtration of results and the individual time points, the genes 2177 
that scored above and below 1.5 and -1.5 fold change respectively were 2178 
then compared across the different time points to find any patterns or data 2179 
of interest. The genes that were seen to have high/low levels across all the 2180 
time points, or showed an interesting trend across the time points were 2181 
picked for further analysis and interpretation. This analysis narrowed the 2182 
initial search down to 33 genes of interest.   2183 
 2184 
If extra time and resources allowed, extra high throughput analysis would 2185 
have been performed on this data to reveal more information of interest in 2186 
this research area. I would have initially run a volcano plot on the different 2187 
time points to find the most statistically significant data and analyse this 2188 
across the time points. This could have been followed up with DAVID 2189 
analysis, or ingenuity pathway analysis (IPA), which could have helped to 2190 
identify new markers of interest, potential biomarkers or biological 2191 
pathways that could lead to new areas of interest in EV71 severity studies. 2192 
  2193 
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Figure 29. Gene expression level of the IL-6 gene during EV71 infection,
measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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4.4.3 Genes of interest – IL-6 2195 
 2196 
One of the first genes of interest I found was interleukin-6. This well-known 2197 
pro-inflammatory cytokine has been previously associated with the 2198 
development of encephalitis, when seen in high levels, in patients infected 2199 
with EV71. Isolate 1 shows little increase in IL-6 across all time points (Fig 2200 
29.), there was a slight increase above the mock level, but only on similar 2201 
terms with the heat inactivated virus (Fig 29).  2202 
 2203 
On the other hand, the more severe isolates, 3 and 5, show much greater 2204 
levels of IL-6 gene expression, increasing almost 3-fold over the first 6h 2205 
(Fig 29). There was a further small increase at 12hpi for both isolates (Fig 2206 
29). This was where isolate 3 peaks and before returning to a lower level 2207 
of fold increase (Fig 29). Isolate 5, however, kept a consistent fold increase 2208 
across 12 and 24hpi (Fig 29). This extended, increased level of IL-6 2209 
upregulation, could play an important role in the increased pathogenesis of 2210 
this isolate.  2211 
  2212 
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Figure 30. Gene expression level of the IL-12! gene during EV71 infection,
measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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4.4.4 Genes of interest – IL-12b 2214 
 2215 
IL-12b is the beta subunit of IL-12, which is a cytokine that has been shown 2216 
to induce the differentiation of T cells, and stimulate the production of IFN- 2217 
g and TNF-a. During EV71 infection with the different isolates, there was 2218 
large increase in IL-12b seen in all of the isolates at 6hpi, most notably in 2219 
isolates 3 and 5 (Fig 30). At 12hpi there was still a notable fold change in 2220 
IL-12b gene expression in isolates 3 and 5, however it is much lower than 2221 
at 6hpi. There was no fold increase for any note seen at 12hpi for isolate 1 2222 
(Fig 30). The fold change was completely depleted at 24hpi for all isolates 2223 
(Fig 30). 2224 
  2225 
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Figure 31. Gene expression level of the IL-36! gene during EV71 infection,
measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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4.4.5 Genes of interest – IL-36g 2227 
 2228 
IL-36g belongs to the IL-1 cytokine family, and has be reported to be 2229 
stimulated by IFN-g, TNF-a and IL-1b. Interestingly, the expression of this 2230 
cytokine has been linked with psoriasis like lesion. Expression of this could 2231 
therefore be linked to the HFMD sores seen in patients, and an increase in 2232 
the expression of this cytokine could provide evidence as to why certain 2233 
patients suffer from a more sever for of HFMD.  2234 
 2235 
There was a small increase in fold change in IL-36g during isolate 1 2236 
infection, starting at 6hpi, this level of increase was consistent across all 2237 
the time points, from 6hpi onwards (Fig 31). This limited level of increase 2238 
could indicate why the patient only suffered a mild case of HFMD, and did 2239 
not produce any more severe symptoms.  2240 
 2241 
Isolate 3 showed a greater level of fold change compared with isolate 1, 2242 
this increased level of gene expression was seen at 6hpi (Fig 31). This 2243 
higher fold increase stayed consistent for the rest of the time course. This 2244 
adds further evidence that IL-36g could play an important role in the 2245 
severity of HFMD and its relating complications.  2246 
 2247 
Isolate 5 showed the highest level of fold change across the 3 isolates, 2248 
again, starting at 6hpi, then increasing and peaking at 12hpi, before 2249 
plateauing at 24hpi (Fig 31). This adds further evidence that IL-36g could 2250 
be implicated in the severity of EV71, especially concerning HFMD.  2251 
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Figure 32. Gene expression level of the ISG15 gene during EV71 infection,
measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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Figure 33. Gene expression level of the ISG20 gene during EV71 infection,
measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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4.4.6 Genes of interest –ISG15 and ISG20 2254 
 2255 
ISG15 and ISG20 belong to a family of genes known as the interferon 2256 
stimulated genes. Their expression is induced in response to type I IFNs. 2257 
Type I IFNs are usually an antiviral response mounted by the innate 2258 
immune system. As such, a high and increasing level of ISG15 and ISG20 2259 
should be expected in response to the increasing level of type I IFN. Whilst 2260 
an initial increase was seen across all isolates at 6hpi, a continued large 2261 
increase was not (Fig 32 and Fig 33). However, as mentioned earlier, EV71 2262 
has mechanism and methods to restrict and inhibit the release and 2263 
activation of IFN and its downstream receptors. This theory could well be 2264 
coming in to play again here, containing the level of ISG15 and ISG20.  2265 
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Figure 34. Gene expression level of the MADCAM1 gene during EV71
infection, measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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Figure 35. Gene expression level of the RBFOX3 gene during EV71
infection, measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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4.4.7 Genes of interest – MADCAM1 2269 
 2270 
MADCAM1 codes for the protein addressin, these proteins are ligands for 2271 
the homing receptors of lymphocytes. Their function is to direct 2272 
lymphocytes into inflamed and mucosal tissues. Isolates 1 and 3 show little 2273 
change in the expression of their MADCAM1 levels, they stay consistently 2274 
between 1 and -1-fold increase (Fig 34). However, isolate 5 largely 2275 
downregulated the expression levels of MADCAM1 across all time points 2276 
(Fig 34). This could possibly suggest that isolate 5 uses this 2277 
downregulation as an immune evasion technique to avoid detection by 2278 
leukocyte, thus giving it more time for replication and a greater chance of 2279 
survival and spread.  2280 
 2281 
Genes of interest – RBFOX3 2282 
 2283 
RBFOX3 is an alternative splicing factor, which regulates the cells of the 2284 
immune system, mostly related to neuronal regulation. This was seen to 2285 
have no significant change across isolates 1 and 3, both keeping between 2286 
1 and -1-fold change across the whole time course (Fig 35). However, 2287 
isolate 5 was majorly downregulated at 6hpi, and continued to be largely 2288 
downregulated at 12hpi (Fig 35). This suppression may be part of the 2289 
pathway that is linked with neurogenic dysregulation, which lead to the 2290 
systemic failure of the patient’s cardio and respiratory systems.    2291 
 2292 
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Figure 36. Gene expression level of the RASIP1 gene during EV71
infection, measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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4.4.8 Genes of interest – RASIP1 2295 
 2296 
RASIP1 is the Ras-interacting protein1 gene. It acts as a regulator of 2297 
GTPase signalling, and adhesion. It is also important in supressing RhoA 2298 
signalling. RhoA has been linked to instability in endothelial cell tight 2299 
junctions, and it has been suggested that it can interfere with the stability 2300 
and integrity of the BBB. 2301 
 2302 
Isolate 1 showed a slight downregulation in the level of gene expression 2303 
for RASIP1 however, it was not a significant downregulation, and was 2304 
almost on par with the heat inactivated control (Fig 36). Isolate 3 however 2305 
showed high early levels of downregulation, starting at 0hpi and increasing 2306 
to 6hpi before it decreased in downregulation at 12hpi to a non-significant 2307 
level (Fig33). Isolate 5 showed a similar pattern to isolate 3, with an 2308 
increased level of downregulation at 0hpi. However isolate 5 showed a 2309 
higher level of downregulation all the way through to 12hpi before it 2310 
decreased in downregulation and significance (Fig 36). 2311 
 2312 
This downregulation in the two isolates that caused neurological 2313 
complications, lends itself to the theory that sever EV71 infection can lead 2314 
to an increase in RhoA activation, leading to a decrease in BBB stability 2315 
and integrity.  2316 
 2317 
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Figure 37. Gene expression level of the ANKRD1 gene during EV71
infection, measured as fold change against the mock infected sample.
Isolated human primary PBMCs were infected with EV71 isolates 1, 3 and 5, as
well as heat inactivated EV71 and a mock-infected control, at MOI 5 and
harvested at 0, 6, 12 and 24hpi. The total RNA was extracted and RNASeq was
ran on this RNA. The results were then analysed using TopHat and CuffDiff. The
gene expression level was compared with the mock infected sample at the
respective time point and the fold changed was calculated.
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4.4.9 Genes of interest – ANKRD1 2320 
 2321 
ANKRD1 is the gene that encodes the protein cardiac adriamycin- 2322 
responsive protein (CARP) which is a transcription involved in conditions 2323 
of stress. It is thought that CARP may have a negative effect on contractile 2324 
function. The more severe viral isolates, 3 and 5, showed increased levels 2325 
of the ANKRD1 gene expression compared with isolate 1 (Fig 37). This 2326 
increase could be linked to the pathway which is connected to EV71 related 2327 
heart failure. 2328 
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5.1.0 The Effect of Viral Infectivity and Replication on 2334 
Severity During an EV71 Infection 2335 
5.1.1 Phylogenetic analysis of EV71 isolates show clustering according to 2336 
severity  2337 
 2338 
In vitro infections have long been used to examine the infection and 2339 
replication kinetics of viruses (208, 209). As there is currently limited 2340 
knowledge on why there is such a difference in pathogenicity in EV71 2341 
infections, I wanted to discover whether the different isolates of the virus 2342 
had any role in this. 2343 
 2344 
After sequencing the virus isolates taken from the outbreak of EV71 in 2345 
Sarawak, Malaysia in 2006 (32) used in these experiments, it can clearly 2346 
be seen that different groups are emerging (Fig 6). Patterns between the 2347 
severity of the outcomes in the patients can be seen in the phylogenetic 2348 
tree, with patient who suffer milder symptoms due to EV71 infection are 2349 
seen grouped together. Further phylogenetic evidence could show or 2350 
suggest areas that could be further explored as areas relating to the 2351 
severity of the patient’s disease. 2352 
 2353 
It is not only the mild symptom groups that can be seen grouped in the 2354 
phylogenetic tree. Patients who suffered from “moderate” symptoms, which 2355 
include more severe cases of HFMD and slight neurological complications, 2356 
are also grouped together. This suggests that there is viral element to the 2357 
 161 
severity of disease during EV71 infection, that it is not just simply down to 2358 
the host response to the virus. 2359 
 2360 
To add further evidence to this, the severe symptoms group, which 2361 
includes severe neurological complications, cardiopulmonary issues and 2362 
fatalities were also found to be clustered together after analysis. This 2363 
signifies that the virus could play a pivotal role in the patients’ outcome 2364 
severity.  2365 
 2366 
This data is a starting point that could be used to further understand the 2367 
areas of the EV71 genome that may be important in pathogenesis. 2368 
Obviously, the initial information has a few flaws. This data was only 2369 
collected from one outbreak in one country, and during this outbreak only 2370 
subgroup B5 was seen. The other subgroups may have different 2371 
areas/regions in the genome that convey pathogenesis. A much broader 2372 
phylogenetic investigation would need to be carried out in order to test if 2373 
any differences or patterns could be found across all the subgroups. 2374 
 2375 
Another possible route to take, rather than diversifying the investigation, 2376 
would be to look deeper into the genetic analysis of these six isolates and 2377 
find regions or motifs that may be responsible for the differences in 2378 
pathogenesis seen in these six patients. 2379 
 2380 
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5.1.2 EV71 virus isolates that cause mild symptoms in patients have low 2381 
levels of infectivity and limited levels of replication in an in vitro infection 2382 
model 2383 
As the virus’ ability to infect and replicate can play an important role in the 2384 
efficacy to colonise the host I looked at each isolates ability to infect, and 2385 
replicate in, human cells in a controlled in vitro viral kinetics assay.  2386 
 2387 
EV71 isolates 1 and 2, which both produced mild symptoms in the 2388 
respective patients during the 2006 outbreak, were both seen to have 2389 
limited infectivity over the 24h time course. This inability to produce an 2390 
effective infection in an environment where there is no competition gives 2391 
us an insight into a possible reason for the mild symptoms seen in the 2392 
patients. If the virus only produces a limited infection in this system then it 2393 
is predicted that it will also have a poor infection efficacy in vivo. This 2394 
inability to infect has a twofold effect on viral pathogenesis (210).  2395 
 2396 
Firstly, if the virus cannot enter the cell then it cannot replicate, as all 2397 
viruses require their host’s replicative machinery to proliferate. Without 2398 
access to this apparatus, there will be no increase in viral load. Lack of 2399 
virus will lead to lessened immune response meaning a decrease in 2400 
adverse effects and symptoms. The second part to this limitation is, the 2401 
virus’ inability to enter the host’s cells will lead to an increase in exposure 2402 
to endogenous cells, cytokines or particles that can destroy the virus. The 2403 
longer the virus is out in the open, the more likely it is to be destroyed. An 2404 
increase in viral clearance leads to a faster resolution of symptoms. 2405 
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5.1.3 An increase in viral infection and replication was seen in EV71 2406 
isolates that cause moderate symptoms in patients, compared to those that 2407 
cause mild symptoms 2408 
 2409 
Both of the moderate isolates show an increased level of infectivity as 2410 
compared to the isolates that cause mild disease. This further 2411 
substantiates the theory that the infection capacity of the virus is linked to 2412 
the severity of the disease in patients.  2413 
 2414 
The level of replication, shown via viral load, also shows a significant 2415 
increase between the two groups. The higher level in replication could be 2416 
down to two factors. The increase in infectivity would lead to an increase 2417 
in virus presence in the cells, meaning an increase in the virus interacting 2418 
with the host machinery. Naturally more cells hijacking and using the 2419 
replicative machinery of the host would translate in to an increase in viral 2420 
replication. The second factor is that it could be a more effective replication 2421 
from the moderate virus due to subtle mutations between the isolate 2422 
groups. This could lead to a greater viral load, which could in turn lead to 2423 
a higher level of infectivity as there is a higher number of viruses. More 2424 
viruses mean a greater virus to cell ratio, which leads to an increased 2425 
chance in the virus entering the cell.  2426 
 2427 
It is likely that both these factors play a role as there is a similarly significant 2428 
increase in both replication and infection between mild and moderate 2429 
isolates, suggesting there isn’t one specific factor driving the other (210).  2430 
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5.1.4 The severe isolates show the highest levels infection and replication 2431 
across all groups      2432 
 2433 
This theory is further demonstrated by the viral kinetics of the most severe 2434 
isolates. Isolate 5 and 6 show significantly higher levels of both infection 2435 
and replication than all the other isolates. This significant elevation in viral 2436 
load could be the reason that there is increased pathogenesis in vivo. An 2437 
increased viraemia in patients can lead to significant, systemic infection 2438 
and severe complications. Higher levels of viraemia means that the virus 2439 
is more likely to come into contact with different tissues and organs with in 2440 
the host. When this is combined with an increased ability to infect the host 2441 
cells, the probability of severe infection is likely to be hugely increased. 2442 
This increased level of infectivity and replication could be the reason 2443 
infections with these isolates lead to neurological complications (210, 211).  2444 
5.1.5 Further studies proposed for this area 2445 
 2446 
As there seems to be such a distinctive grouping between the isolates of 2447 
different severity I would look to further this area of study by taking a more 2448 
in depth look at the genome sequences of the different clades, and the 2449 
individual isolates. Then try to map these to either the known gene epitopes 2450 
or a 3D structure of the EV71 virus to see if there are any major mutations 2451 
between the groups. Any changes in protein sequences or structure could 2452 
point to a reason why there is such a difference in severity between these 2453 
isolates. As well as that it could lead to a possible drug target that may help 2454 
reduce the severity of the symptoms in patients.  2455 
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The regions I would initially want to look at if I continued with this area of 2456 
research would be: the VP1 region, which has already shown, specific 2457 
regions of interest for receptor binding and infection levels (95). I would 2458 
also look at the VP1/VP2/VP3 canyon as this has been shown to play an 2459 
interesting role in receptor binding and integration (155). 2460 
 2461 
The other areas I would be interested in looking at would be the 2A and 3C 2462 
viral protease regions. As these have been shown in several studies to be 2463 
able to have a large effect on the virus’s immune evasion strategies (67, 2464 
68, 102, 110, 115, 139, 212). Any mutations or patterns in this region could 2465 
prove crucial to the virus’s ability to minimise detection and therefore 2466 
continue to proliferate and cause damage to the host. 2467 
 2468 
If the link between the virus and the severity of the outcome can be found 2469 
this could not only lead to huge improvement in the ability to predict the 2470 
most at risk patients. It could also provide us with possible avenues that 2471 
could be explored in the realms of drug targets and therapeutic treatments 2472 
to limit the severity of conditions the virus can cause.  2473 
 2474 
      2475 
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5.2.0 EV71 and Leukocyte Interaction During an Ex Vivo 2476 
PBMC Infection 2477 
5.2.1 EV71 infection in primary human peripheral blood mononuclear cells 2478 
 2479 
As I had established an infection in an in vitro setting, and found significant 2480 
differences in between the virus isolates, I wanted to look at more 2481 
representative model of infection. Many studies have shown that 2482 
leukocytes are the key players in host defence response, so I decided to 2483 
use an ex vivo model to further study the intricate differences between 2484 
these viruses. During the isolation procedure for PBMCs, all plasma and 2485 
serum is removed, thus eliminating any chance of reactive antibodies from 2486 
the donors interfering with the results. There will also be minimal levels of 2487 
any other factors that may interfere with the experimental process such as 2488 
cytokines and chemokines. 2489 
 2490 
As there was a limited number of donor’s blood cones received per week, 2491 
and a limited number of cells that could be retrieved from each cone, 2492 
combined with the number of cells needed per sample and the number of 2493 
conditions (time points, plus samples, plus controls) meant only three 2494 
viruses could be selected. To get the best coverage of the three severities, 2495 
I chose isolates 1 (mild; herpangina), isolate 3 (moderate; HFMD with 2496 
meningoencephalitis) and isolate 5 (fatal). I wanted to see if PBMCs could 2497 
be infected by the different isolates, and if there were any distinct 2498 
differences between the infection profiles of the isolates. To examine these 2499 
differences, I decided to use flow cytometry to measure the infectivity of 2500 
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the isolates in PBMCs and qRT-PCR to measure the replication of the 2501 
virus.  2502 
5.2.2 Viral infection kinetics of EV71 in an ex vivo PBMC system  2503 
 2504 
After isolating the PBMCs from fresh apheresis cones, they were infected 2505 
with the different isolates. At the respective time point, the samples were 2506 
harvested, the cells kept for flow cytometry and total RNA extraction, and 2507 
the supernatant for vRNA and cytokine analysis. The initial area I wanted 2508 
to investigate was the infectability of the total PBMC population. Using flow 2509 
cytometry, the cells were gated on their size and granularity to remove any 2510 
debris, then on their height to width ratio to remove any doublet cells which 2511 
may affect the results. Dead cells were then removed via a live/dead stain. 2512 
The cells that remained should be whole, live, single cells. These cells were 2513 
then gated on the CD45 cell surface marker, which is also known as the 2514 
common leukocyte antigen. It is found on all white blood cells and is a way 2515 
to separate them out from other cells such as red blood cells and platelets. 2516 
The CD45 positive cells for finally gated on their positivity for the anti-EV71 2517 
ab. 2518 
 2519 
Isolate 1 showed very limited infectivity after gating. It was almost 2520 
comparable with the mock infected and heat inactivated virus in terms of 2521 
infectability. This was unsurprising as isolate 1 had a poor infectability in 2522 
the immortalised cell line RD cells, which are known for being highly 2523 
susceptible to EV71 infection. So, infecting primary cells such as fresh 2524 
PBMCs would be quite unlikely, as these are known to be much more 2525 
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difficult to infect compared to immortalised cell lines. This limited ability to 2526 
infect either immortalised or primary cells could be a strong indicator as to 2527 
why this isolate only caused a mild onset of disease symptoms during the 2528 
initial patient infection. This may be due to an inability to bind to the 2529 
receptors efficiently which would cause a marked decrease in the virus’s 2530 
ability to infect the cells. If less virus can enter the cell, this would also lead 2531 
to a decrease in viral replication and viral replication speed compared to 2532 
other isolates as there would be less viral RNA available for transcription 2533 
and translation.  2534 
 2535 
A different pattern of infection was seen in PBMCs during isolate 3 2536 
infection. This isolate managed to have a high level of initial infection, which 2537 
decreased across the time course. This suggests that the virus isolate does 2538 
not struggle to enter the cell, however it cannot efficiently replicate once 2539 
inside. If it cannot replicate than it cannot increase its viral copy number, 2540 
and will also struggle to leave the cell. If the virus is then trapped inside the 2541 
cell, it is likely to be subject to the cells innate defences and degraded.  2542 
This would then lower the viral load and, in time, the effectiveness of the 2543 
virus. This could be the explanation why this virus caused a moderate and 2544 
not a severe illness (210). The viruses lessened ability to replicate meant 2545 
that it could cause initial problems for the patient, however it could not 2546 
reach the severe systemic effects of other isolates (213).  2547 
 2548 
Isolate 5 showed a different trend again to both isolates 3 and 5. There was 2549 
an initially low infection which steadily increased peaking at 12hpi before 2550 
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decreasing. This was the first isolate to show signs of an increase in 2551 
infectivity across the time points. This increase in infectivity could suggest 2552 
that isolate 5 shows an ability to replicate in these cells. Which could give 2553 
an indication as to why it caused severe symptoms in the patient. The 2554 
ability to replicate inside the cells not only means that the virus can 2555 
increase its own number, it also gains control over the host cell’s replication 2556 
centre. Giving it the ability to limit host RNA synthesis, as well as increasing 2557 
its only RNA synthesis which can lead to the supress and downregulation 2558 
of certain crucial immune factors (109). It can also lead to upregulation of 2559 
pathways and factors that are beneficial to the virus’s survival (109). 2560 
 2561 
This data would suggest that the infection of the cell may not be the be all 2562 
and end all to pathogenesis with EV71. As the moderate isolate (isolate 3) 2563 
is seen to be much more infectious, however it showed lower severity in 2564 
the patient. This may be due to the replication ability of the virus. It could 2565 
also be due to the receptor which this isolate preferentially binds to enter 2566 
the cell. It has previously been shown that PSGL-1 has a greater efficiency 2567 
for binding to EV71 (91). However, the virus cannot undergo the initiation 2568 
of uncoating as efficiently and therefore cannot enter the replication cycle 2569 
as proficiently compared to binding with SCARB2 (91). This would be an 2570 
interesting area of further study. I would look at knocking down/inhibiting 2571 
SCARB2 and PSGL-1 in PBMCs (or an immortalised cell line first), and see 2572 
what effect this would have on the infection and replication levels of the 2573 
different isolates. This could be combined with phylogenetic analysis of the 2574 
virus to identify any areas of sequencing difference in the receptor motifs. 2575 
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5.2.3 Viral replication kinetics of EV71 in an ex vivo PBMC system  2576 
 2577 
I next assessed the isolates’ replication capacity via qRT-PCR. Isolate 1’s 2578 
replication profile tallied with its infection profile. There was limited 2579 
replication across the time points. This adds further evidence as to why it 2580 
only produced a mild set of symptoms in the patient during the initial 2581 
infection. As stated previously a limited ability to infect and replicate would 2582 
inhibit the virus from spreading easily throughout the body, especially into 2583 
areas that are normally extremely difficult for pathogens to enter, e.g. the 2584 
brain. This would lead to only local symptoms being able to present, and 2585 
preventing the chance of a systemic infection. 2586 
 2587 
This result adds further volume to the theory that the virus and not only the 2588 
host response is responsible for the severity of EV71 infection, as each 2589 
infection was carried out with cells from the same donor. This means there 2590 
should be no donor to donor variation across the isolations during the 2591 
infection, and the only difference in response seen should be due to the 2592 
virus. 2593 
 2594 
The lack of replication seen in isolate 1, added to the lack of infectivity 2595 
would suggest that there may be two (or possibly be more) areas in the 2596 
genome where this isolate varies from the more severe isolates. The initial 2597 
areas I would be interested in would be the binding sites for PSGL-1 and 2598 
SCARB2, as I believe slightly mutations in this area may be the reason for 2599 
the limited level of infection. For the second area, I would look at the viral 2600 
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proteases 2A and 3C. Mutations in these sequences may lead to the 2601 
protease having limited/diminished cleavage abilities, which would not only 2602 
limit the virus’s ability to process its proteins and form the necessary 2603 
additional machinery required for viral replication. It would also decrease 2604 
the virus’s mechanisms in its immune evasion strategies, meaning it would 2605 
be an easier target for immune discovery and destruction.  2606 
 2607 
One other area I would also think about exploring would be the viral protein 2608 
3D, which is the virus’s RNA polymerase. If there was a mutation or defect 2609 
in this gene it could lead to a lesser amount of the viral RNA being 2610 
transcribed, therefore less protein being translated and less viral particles 2611 
being produced inside the cell. This would inevitably lead to a lower level 2612 
of infectivity. If this were found to be the case, this could explain why there 2613 
is not only lower levels of infectivity and replication seen for isolate one in 2614 
the PBMC model, but in the in vitro RD cell viral kinetics model as well.  2615 
 2616 
The replication profile of isolate 3 was also similar to its infection profile. 2617 
With a high initial viral load, which slowly decreased across the time points. 2618 
This again points to the virus’s ability to infect the cells but not replicate 2619 
within them efficiently. This result furthers the evidence that the isolates 2620 
ability to proficiently infect cells but not replicate in them could be the cause 2621 
of the limited capacity of this virus to cause a full systemic and potentially 2622 
fatal attack. 2623 
 2624 
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As mentioned previously the high level of infection but low level of 2625 
replication seen in the isolate 3 PBMC infection could be due to a number 2626 
of factors. The one I would be most interested in pursuing would be looking 2627 
at the mutations in the proteases 2A and 3C. This may be the reason there 2628 
is a slow decrease in the level of infection across the time course. However, 2629 
as there is still a higher level of infection, this would suggest that the 2630 
mutation is not as severe as with isolate 1. 2631 
 2632 
As with the other two isolates, isolate 5 showed large similarities between 2633 
its infection and its replication kinetics. Again, it was the only isolate to 2634 
show an increase across the time points. This, proving that it is the only 2635 
isolate to show positive replication in PBMCs. As mentioned earlier, this 2636 
ability is likely to be a causative factor in the proficiency of this virus. 2637 
Increasing the viral load, as well as controlling host replication is very likely 2638 
to enhance this virus’s ability to spread throughout the body, and increase 2639 
its pathogenesis. 2640 
5.2.4 Infectivity of EV71 in PBMC subsets 2641 
 2642 
To further investigate the effect of EV71 on the leukocyte population, and 2643 
how this relates to severity, I used flow cytometry to examine different 2644 
PBMC cell subsets during EV71 infection. Using specific, cell surface 2645 
markers, I separated the CD45 positive cells into: T Cells, B cells, 2646 
monocytes, NK cells, cDCs and pDCs. These subset populations were 2647 
then gated on the EV71 antigen positivity. This allowed me to pick out the 2648 
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specific populations that seemed most susceptible to EV71 infection, and 2649 
those which are most likely to have the biggest effect on outcome severity. 2650 
 2651 
Isolate 1 barely gets higher than the mock infected and heat inactivated 2652 
virus samples. The adds more evidence to the previous theory that this is 2653 
a leading cause behind its limited pathogenesis. It also highlights that there 2654 
are no specific cell subsets that are majorly susceptible to infection with 2655 
isolate 1. 2656 
 2657 
In both isolate 3 and isolate 5 there seems to be 3 main subsets that are 2658 
responsible for the majority of the infection. T cells, B cells and monocytes 2659 
seem to be the leukocyte subtypes that are most susceptible to EV71 2660 
infection. NK cells, cDCs and pDCs still show some level of infection 2661 
however it is not as high as the other subsets. Within these subsets 2662 
different patterns can be seen, both between the individual subsets and 2663 
between the isolates. During infection with isolate 3, T cells and B cells 2664 
showed the same infection pattern as the total PBMCs, which was a high 2665 
initial infection, and then a slow steady decrease in infection levels across 2666 
the time points. A slightly different trend was seen in the monocytes 2667 
infected. They show the same high initial infection, but then have a sudden 2668 
large decrease at 6hpi, and then stay at this level for the rest of the time 2669 
course. This was probably not reflected in the total PBMC infection result 2670 
as monocytes only make up approximately ten percent of the total number 2671 
of PBMCs, whereas T and B cells usually make up about seventy percent. 2672 
This information justifies the process of further splitting the cells into 2673 
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subsets, as it is something that wouldn’t have been seen in the total 2674 
population but due to this drilling down, it can be seen. 2675 
 2676 
Three separate patterns can be seen during isolate 5 infection of PBMCs. 2677 
T cells show a similar pattern to the total PBMC infection, with a gradual 2678 
increase in infection until 12hpi, then a decrease at 24hpi. T cells are the 2679 
highest cell population within PBMCs, usually accounting for 40-60 percent 2680 
of the total cell number. So, the fact that the total infection pattern and this 2681 
subset profile are so similar is not surprising. B cells show their own 2682 
distinctive infection profile during isolate 5 infection. They have a much 2683 
lower initial infection percentage, but then peak at 6hpi before decreasing 2684 
across 12 and 24hpi. This different infection level could indicate that B cells 2685 
have an earlier role to play in the infection process. This profile however 2686 
doesn’t compare with the replication kinetics of isolate 5, which would 2687 
suggest that B cells don’t have a major role in the replication of EV71 in 2688 
PBMCs. It could be argued that because of their lower total number that a 2689 
change would be less detectable as it would be masked by any T cell 2690 
profile. However, given that B cells make up 20-30 percent of the total cell 2691 
number, and that there is large increase in infection between 0 and 6hpi, 2692 
you would expect to see an increase in the replication between this time 2693 
points. Yet, there is no increase, in fact there is a slight, although not 2694 
significant, decrease in the replication between these time points. Which 2695 
suggests that there is only a limited amount of replication occurring in the 2696 
B cells.  2697 
 2698 
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Monocytes during isolate 5 infection show a completely different trend to 2699 
both T and B cells. They show a much higher early level of infection, which 2700 
is then slightly decreased at 6hpi, but stays constant for the rest of the time 2701 
course. This may suggest one of two things. Firstly, the virus, may be 2702 
entering the cell, not be able to replicate, but also not be destroyed, almost 2703 
entering a state of dormancy. On the other hand, it could be that the virus 2704 
is replicating just enough to keep a steady infection of the monocytes, 2705 
without drastically increasing its population, or being eradicated in large 2706 
numbers. 2707 
 5.2.5 Individual leukocyte subset infections with EV71 isolates 2708 
 2709 
To have a more in-depth assessment of the infection profile of the EV71 2710 
isolates, I wanted to look further into the specific subsets that seem to be 2711 
key to EV71 infection and pathogenesis. As T cells and monocytes seem 2712 
to be the most infectable and most replicative, they were the ones I 2713 
focussed on. First the PBMCs were isolated in the same way as previous, 2714 
then the individual subsets were isolated via negative selection with 2715 
magnetic beads. The T cells were isolated into CD4 positive and CD8 2716 
positive cells respectively. These isolated cells were then subjected to the 2717 
same infection procedure under the same conditions as the initial PBMC 2718 
infection.  2719 
 2720 
Isolate 1 again showed limited level of replication in these cells, which 2721 
confirms with the infection data, that it is not very capable of mounting a 2722 
sustainable infection in PBMCs, and this could be a major factor in why it 2723 
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has a limited level of pathogenesis within the patient, and only produced a 2724 
mild onset of symptoms. Isolate 3 showed no significant change in the level 2725 
of viral load. Suggesting a limited level of replication in monocytes. The 2726 
further backs up the evidence that despite its ability to infect cells in the 2727 
host, its lessened replication capabilities prevent it from maximising it 2728 
pathogenicity, and stops it from progressing to a severe systemic disease. 2729 
Isolate 5 also has a limited level of replication in monocytes, this adds to 2730 
the infection data seen in the total PBMC infection, and adds more 2731 
evidence to the theory that whilst monocytes are able to sustain an 2732 
infection with isolate 5, they are not the main proponents of EV71 infection 2733 
in a severe outcome patient. 2734 
 2735 
In CD8 positive T cells, isolate 1 again continues the trend of limited 2736 
replication, and isolate 3 shows a much higher viral load than isolate 1, but 2737 
still there was a decrease across the time points, again suggesting limited 2738 
replication within these cells. Isolate 5 shows a different pattern than 2739 
expected here, compared with the total PBMC infection. Both the viral load 2740 
of the total PBMCs and infection profile of the total T cell subset shows that 2741 
there is an increase and a peak at 12hpi. However, this is not seen during 2742 
the CD8 positive T cell only infection. There could be two reasons for this, 2743 
one is that the CD8 T cells need other factors from other cells to stimulate 2744 
infection and replication. Yet, the more likely reason is that CD8 T cells are 2745 
not the main subset of T cells involved in EV71 isolate replication. As there 2746 
is only a plateau in replication this would suggest that CD4 T cells are the 2747 
main players in replication. 2748 
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 2749 
In fact, CD4 positive T cells do show a significant increase in replication 2750 
across the time points. Isolate 5 infected T cells were the only cell subset 2751 
tested to show a significant positive replication of EV71 across the time 2752 
course. This suggests that the more severe virus isolates have developed 2753 
an ability to replicate within these cells. This ability could be one of the 2754 
reasons why they have an increased pathogenic ability. Whether, it is form 2755 
controlling the hosts ability to synthesise its own mRNA, thus reducing its 2756 
ability to eliminate the virus, or cause a large increase in the production of 2757 
cytokines. Or whether it can use the cell as a Trojan horse, to enter parts 2758 
of the host’s system, that it previously could not enter. 2759 
5.2.6 Further studies proposed for this area 2760 
 2761 
I would like to see the subset infection expanded to see more time points, 2762 
and to include the B cell subset, as I believe it would be interesting to see 2763 
if there was any replication in B cells, and why there was such a significant 2764 
increase at the earlier time point. I also think an interesting area to explore 2765 
would be to examine the pathways affected in the different subsets by this 2766 
infection. Especially during significant increases in replication, just to see 2767 
exactly which pathways are becoming affected. This could give an 2768 
indication in to possible pathways that are increasing the severity of the 2769 
disease, and offer either a possible biomarker for severity, or a pathway in 2770 
which we could disrupt to lessen the severity for the patient. 2771 
 2772 
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As well as expanding the infection to include extra time points and a B cell 2773 
infection, I would also try to confirm the infective nature of the virus in the 2774 
individual subsets. I did originally attempt this using flow cytometry; 2775 
however, the cells were too sensitive to the permeabilisation buffer, and 2776 
analysis via flow cytometry was not possible. To assess the infectivity level 2777 
of EV71 in these subsets I would run a Western blot on the infected cells 2778 
to detect the virus particles as proof of infection. Although this would not 2779 
be able to give the same level of quantification of infection as flow 2780 
cytometry, it will serve as proof of infection and should be able to offer 2781 
some level of measurement of viral infection across the isolates based on 2782 
the band thickness and intensity. 2783 
5.3.0 EV71 Infection and the Blood-Brain Barrier 2784 
5.3.1 BBB disruption in an in vitro model 2785 
 2786 
The blood brain barrier is a physical, highly selective, diffusion barrier, that 2787 
can prevent components carried by the blood, such as pathogens, and 2788 
neurotransmitters from entering the brain. A major component of this 2789 
barrier is the high abundance and density of tight junction proteins 2790 
populating the endothelial cells of the cerebral blood vessels and 2791 
capillaries. These proteins have been well established and characterised 2792 
in upholding the integrity of the BBB and limiting the paracellular passage 2793 
of these dangerous components through. However, during severe infection 2794 
and stress, the BBB is known allow some of these neurotropic pathogens 2795 
to gain access to the brain and CNS, to cause potentially fatal neurological 2796 
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complications. For example, EV71 has been shown to cause a wide range 2797 
of neurological complications, from encephalitis and meningitis to acute 2798 
flaccid paralysis and neurogenic pulmonary oedema in certain cases. How 2799 
these pathogens cross this tightly regulated barrier still remains unclear.  2800 
 2801 
To attempt to understand how EV71 can enter the brain and cause these 2802 
neurological complications, I set up an in vitro blood brain barrier model. 2803 
The aim of which was to study, assess and try to identify the crucial factors 2804 
or genes relevant in the viral transverse or barrier breakdown of the BBB. 2805 
This was then compared with a non-neurovirulent virus, which was infected 2806 
on the same model. The two viruses were then compared both in their 2807 
ability to disrupt the BBB via TEER measurement and in their gene 2808 
expression of specific markers. TEER reflects the ionic conductance of the 2809 
paracellular pathway in an endothelial monolayer by measuring the 2810 
resistance in Ohms (Ω) (214). Consequently, a decrease in resistance 2811 
(TEER) indicates a higher ionic conductance of the paracellular pathway 2812 
and hence implies there is damage to the structural integrity of the BBB. 2813 
 2814 
The initial BBB model infection the three EV71 virus isolates used in the 2815 
PBMC infection model. they were added to the BBB and the stability and 2816 
integrity of the BBB was measured over time via TEER and viral load 2817 
analysis. Isolate 1 showed limited TEER reduction across the time course, 2818 
with a slight decrease in TEER starting at 120hpi, however it was not 2819 
significant, there was also a slight increase in abluminal viral load across 2820 
the time points. These results suggest that there was minimal damage 2821 
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done to the BBB, as there was no significant reduction in its resistance. 2822 
The minimal increase in abluminal viral load suggest there was possibly 2823 
some para or transcellular viral transfer, however this low level could be 2824 
attributed to the functionality of the immortalised cell line being used. The 2825 
immortalisation procedure of hCMEC/D3 was found to have led to the lower 2826 
expression of many surface molecules, such as claudin-5, occludin and 2827 
JAM2, as well as Glut1, than primary cerebral endothelial cells (215, 216). 2828 
Therefore, a certain degree of baseline paracellular leakiness would 2829 
always be present.  2830 
 2831 
Infection with isolate 3 showed a much bigger disruption of the BBB with 2832 
TEER significantly decreasing at 96hpi, and there had been a large 2833 
disruption of the barrier’s integrity by144hpi, this evidence was backed up 2834 
by a much larger increase in abluminal viral load. There are no cells on the 2835 
abluminal side in this model, so there cannot be any replication coming 2836 
from that side, so all the increase must be coming as para or transcellular 2837 
viral transfer from the luminal side. This significant decrease in BBB 2838 
resistance, disruption to the BBB and increase in abluminal viral suggest 2839 
that this virus has the ability to cross the BBB. This could be a major factor 2840 
in this isolates ability to cause a more severe disease than isolate 1. 2841 
 2842 
During infection with EV71 isolate 5, there is a large drop in TEER and a 2843 
sharp increase in viral load in the abluminal region, which indicates that 2844 
paracellular flux of virions from the luminal to the abluminal side is very 2845 
likely. Isolate 5’s increase in viral load in both the luminal and abluminal 2846 
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regions suggest that EV71 could be able to cross the BBB transcellularly, 2847 
as well as via the paracellular route. This isolate shows a similar ability to 2848 
disrupt the BBB to isolate 3. However, isolate 5 disruption seems to occur 2849 
much faster and causes a higher level of BBB disruption. This speed and 2850 
increase destruction could be the reason why this isolate causes the most 2851 
severe onset of symptoms, which lead to systemic issues, and ultimately, 2852 
a fatality. 2853 
 2854 
During infection with CHIKV, no change in TEER was noted, indicating that 2855 
there was no disruption of the BBB, meaning the paracellular flux of virions 2856 
from the luminal side to the abluminal side is unlikely. This assessment 2857 
was further supported by a consistent unchanged viral load in the abluminal 2858 
region, meaning that there was no increase in virus particles entering the 2859 
brain side of the barrier. This could be due to the inability of CHIKV in even 2860 
establishing infection in the first place as shown by the absence of a 2861 
detected infected population, much less replication as shown by the 2862 
consistent viral load in the luminal region. 2863 
 2864 
This inability of CHIKV to cause any BBB damage and pass into the 2865 
abluminal side could be due to the polarised infection ability of CHIKV. 2866 
More specifically, CHIKV has been shown to preferentially infect 2867 
endothelial cells on the abluminal side of the BBB as oppose to the luminal 2868 
side (217-219). The E1, E2 and E3 glycoproteins of the CHIKV envelope 2869 
contain N-glycans, which have been suggested to act as apical sorting 2870 
signals, leading to the preferential release of the virus into the luminal 2871 
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domain. Therefore, CHIKV has a lower proclivity to cause neurological 2872 
infections as it struggles to transcellularly traverse across the BBB.  2873 
Furthermore, as there was no increase in viral load in either the luminal 2874 
and abluminal region throughout the infection time course, this suggests 2875 
there was a lack of viral replication and infection. So, these results from the 2876 
in vitro BBB model suggest that CHIKV is highly unlikely to cross the BBB 2877 
either paracellularly or transcellularly in an in vivo setting. 2878 
 2879 
If I was to repeat this experiment I would add in another condition which 2880 
would be a positive control such as the West Nile virus, which has been 2881 
proven to infect the BBB and cause damage to the barrier (220). This would 2882 
prove a good comparison to compare the level of infection, TEER readings 2883 
and gene expression profile against as it would show the comparative level 2884 
of EV71 BBB disruption. 2885 
 2886 
Flow cytometry was attempted after the infection experiment to measure 2887 
the infection level of the isolates in the BBB model. However, despite 2888 
several attempts, the cells could not be removed from the insert membrane 2889 
without damaging them and rendering them unusable for flow cytometry. If 2890 
I were to repeat the experiment, instead of attempting flow cytometry I 2891 
would use one of the three inserts (all experiments were done as technical 2892 
triplicates) for confocal microscopy or IHC staining. This would not only 2893 
allow visualisation of proof of infection, as well as a certain level of 2894 
quantification it would also allow the viewing of the level of destruction of 2895 
the tight junctions of the BBB. This would be achieved by the staining of 2896 
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the TJ proteins. With the other two inserts, I would remove the cells and 2897 
use them in a western blot experiment to test for the presence of viral 2898 
particles to add further proof and quantification of infection. 2899 
5.3.2 Gene expression of the BBB during an EV71 infection vs a non- 2900 
neurotropic CHIKV infection 2901 
 2902 
Next, I looked at the gene expression levels within these infections to 2903 
assess if there were any genes that could be playing a role in the regulation 2904 
or disruption of the BBB. Due to certain restraints, only data for isolates 5 2905 
and CHIKV was able to be collected. A number of genes were screened, 2906 
relating to different functions related to the BBB. these included 7 receptor 2907 
genes, 6 genes encoding for tight junction proteins and adhesion factors, 2908 
6 IFN production genes and 5 IFN-associated genes. 2909 
 2910 
There was an overall down-regulation in the mRNA expression of the tight 2911 
junction and inter-endothelial adhesion proteins of the BBB, during the 2912 
initial disruption in BBB integrity at 72hpi, detected by the first significant 2913 
decrease in TEER. This down-regulation of TJ and adhesion protein genes 2914 
was consistent throughout EV71 infection and seemed to be further 2915 
downregulated at 144hpi, which could give an explanation to the continual 2916 
large decrease in TEER. Downregulation of other tight and adherens 2917 
junction proteins may also play a role in the disruption and permeability of 2918 
the BBB for example, cadherin is known to associate with ZO-1, another 2919 
TJ protein, to regulate TJ assembly (221). As well as function as an 2920 
adhesive membrane protein that links the intracellular actin cytoskeleton to 2921 
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intermediary proteins such as catenins to form inter-endothelial cell 2922 
contacts (183).  2923 
 2924 
Conversely CHIKV showed a continued up-regulation of these TJ and 2925 
adherens protein genes throughout the infection time course, giving further 2926 
evidence that CHIKV does not cause increased BBB permeability. Also, 2927 
that there could be a direct link between EV71 infection and disruption of 2928 
the BBB via the downregulation/destruction of the TJ and adherens 2929 
junction proteins. 2930 
 2931 
CHIKV showed an expected up-regulation of type I interferons and 2932 
downstream effectors throughout the infection time course, which also 2933 
coincided with an up-regulation in the expression level of BBB TJ and AJ 2934 
proteins. It has been widely reported that CHIKV is a known trigger of high 2935 
IFN responses as a potent anti-viral response. This has been shown in 2936 
various immortalised and primary cell lines such as HEK293T, 2937 
macrophages, fibroblasts, pDCs (222, 223)  2938 
 2939 
EV71 infection showed a quite opposite effect, it led to the continuous 2940 
suppression of type I IFN responses throughout the time course of the 2941 
infection. This downregulation indicates that the suppression of the type I 2942 
interferon response could play an interesting role in the increased 2943 
permeability of the BBB. The suppression of type I IFNs has been 2944 
previously reported during EV71 infection, where the virus downregulates 2945 
IFNAR expression levels to evade immune responses by the host (111, 2946 
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139). The method of action for this has been suggested that the EV71 2A 2947 
protein is involved in the cleavage of IFNAR. The disruption of this receptor 2948 
has further knock on effects down the line, such as blocking the IFN 2949 
mediated phosphorylation of STAT, which would therefore inhibit 2950 
downstream cytokines, chemokines and other interferon stimulated genes. 2951 
Another pathway for the suppression of type I IFN by EV71 that has been 2952 
reported is the cleavage of the IFN transcription factor IRF-7 by the EV71 2953 
viral protease 3C. The cleavage of IRF-7 directly prevents the activation of 2954 
IFN promoter transcription (115). 3C has also been reported to inhibit the 2955 
nuclear translocation of IRF-3, which like IRF-7 is an important promoter of 2956 
transcription for type I IFNs (Lei et al, 2010). 2957 
 2958 
There is evidence to suggest that the downregulation and suppression of 2959 
type I IFNs could increase the permeability of the blood-brain barrier, by 2960 
virtue of disrupting the balance of two small, regulatory, antagonistic 2961 
GTPases, called Rac1 and RhoA. Rac1 which inhibits the molecule cofilin 2962 
and recruits cortacin, to stabilise cortical actin fibres, has been shown to 2963 
be activated and enhanced by type I IFNs. This adds stability to the TJs 2964 
and AJs within the endothelial cell, this giving greater structural integrity to 2965 
the BBB. The RhoA GTPase, through its Rho kinase, destabilises the 2966 
barrier proteins of endothelial cells by up-regulating myosin light chain 2967 
kinase-dependent contraction of stress fibres Which leads to the 2968 
weakening of the BBB by decreasing the stability of the tight and adherens 2969 
junctions. Type I IFNs have also been shown to inhibit the RhoA GTPase 2970 
(224). 2971 
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 2972 
This adds further evidence to suggest that type I IFN responses could form 2973 
a protective response against BBB permeability. EV71 shows the ability to 2974 
suppress these responses. This could be viewed as a virulence factor 2975 
which certain neurotropic viruses could utilise to further destabilise the TJ 2976 
and AJs within the BBB, leading to the ability of the virus to transverse into 2977 
the brain. This indicates that as well as their many antiviral and immune- 2978 
active properties IFNs could also be a protective pathway against BBB 2979 
breakdown and disruption. 2980 
5.4.0 Host Response Pathways and Their Link to EV71 2981 
Severity 2982 
5.4.1 The host response cascade 2983 
 2984 
During any attack by a foreign body, the host normally mounts a response 2985 
to eliminate the pathogen and stop any damage being done to the host, 2986 
that may occur as a direct or side product of the foreign body’s invasion. 2987 
Most of the time, the body mounts an appropriate response. The pathogen 2988 
is dealt with and the host can carry on as normal. However, sometimes the 2989 
host mounts an underwhelming response, and the pathogen is not cleared, 2990 
or the host unleashes too big of a response and causes itself damage in 2991 
the process. There can be many reasons for these responses, for example 2992 
pathogen immune evasion or over expression and production of cytokines. 2993 
If these specific pathways can be deciphered; and the reasons why certain 2994 
 187 
viruses or isolates cause much more severe infections can be ascertained, 2995 
then opportunities will arise for products that can limit or stop these effects. 2996 
 2997 
To attempt to assess the pathways that could be linked to EV71 severity, I 2998 
analysed the total RNA from a human primary PBMC EV71 infection, using 2999 
isolates of differing severity. It is well established that leukocytes are the 3000 
key players in host immune responses. As such, PBMCs are a great way 3001 
to study the host immune pathways. Due to the technique for isolating 3002 
PBMCs, all the plasma and serum is removed, Therefore, there can be no 3003 
cross contamination from outside influences, such as cytokine levels 3004 
present in serum. 3005 
 3006 
To analyse the extracted total RNA, I decided to use RNASeq, as it would 3007 
provide me with a high throughput, wide ranging analysis, that would not 3008 
pigeon-hole in to certain genes but give me the full picture. This stops any 3009 
genes being missed or overlooked and provides me with a in depth look at 3010 
the total gene expression. 3011 
 3012 
There are some downsides to using RNASeq on these sorts of samples, 3013 
as well as the many benefits. For example, the samples are from PBMC 3014 
infections, there are no single cell type populations, they are all of mixed 3015 
lineages, so any increases in gene expression in a specific cell type may 3016 
be masked or negated by a large baseline expression of the same gene in 3017 
a different cell type with in the PBMC population. Another disadvantage is 3018 
that it only shows mRNA expression levels, which do not always concur 3019 
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with the active protein expression levels. This means further experiments 3020 
may be necessary to add a proof of concept. 3021 
 3022 
5.4.2 The role of IL-6 on EV71 severity 3023 
 3024 
IL-6 is one of the major pro-inflammatory cytokines linked with stimulating 3025 
the immune response during an infection. It is secreted by macrophages 3026 
and T cells to initiate this response. Usually in response to PAMPs, which 3027 
bind to PRRs and induce the intracellular signalling cascade, which results 3028 
in the inflammatory cytokine production. IL-6 signals through its IL-6 3029 
receptor, which consists of the ligand binding part, CD126 and CD130, 3030 
which is the signal transduction component. Once IL-6 has bound and 3031 
activated its receptor, it then initiates a signalling cascade through the 3032 
JAK/STAT pathway.  3033 
 3034 
IL-6 has already been reported to play a major role in the severity of EV71 3035 
infection (81, 225, 226). There has been evidence shown that that high 3036 
levels of IL-6 could possibly overwhelm the host immune defence leading 3037 
to a chronic inflammatory disease (227). There have been numerous 3038 
clinical studies that have suggested overproduction of IL-6 may be 3039 
responsible for severe EV71 brainstem encephalitis (81, 84, 187, 228-230). 3040 
One experiment showed that patient treated with IVIG resulted in a rapid 3041 
decrease in both serum and CNS levels of IL-6, however, there was no 3042 
significant change in anti-EV71 titres (228). These findings suggest that an 3043 
EV71 induced systemic inflammatory reaction could be the result of the 3044 
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overproduction of IL-6. Furthermore, this overproduction may be a 3045 
contributing factor in the severe complications such as encephalitis and 3046 
cardio-respiratory failure.  3047 
 3048 
My findings give further evidence to this theory, showing largely increased 3049 
expression of IL-6 in the more severe isolates, both of which were taken 3050 
from patients who suffered neurological complications.  3051 
 3052 
As a next step in proving this theory, I would run a simple IL-6 ELISA on 3053 
the cell samples, this could add further evidence to the theory that high IL- 3054 
6 levels play a role in EV71 severity, as well as adding to our knowledge 3055 
that this mRNA expression increase was translated into protein expression 3056 
levels. If the ELISA proves high levels of IL-6 are established, it would be 3057 
interesting to see what effect, if any, could be seen on IL-6 levels during a 3058 
BBB infection with EV71, and if there was an increase in IL-6 levels as 3059 
severity increased, as there may be an interesting link between the immune 3060 
response and the BBB.   3061 
 3062 
5.1.3 IL-12b and its downstream effects during EV71 infection 3063 
 3064 
IL-12b is a subunit of IL-12 which acts on NK and T cells. It is naturally 3065 
produced by DCs, macrophages and neutrophils after antigenic 3066 
stimulation. IL-12 is known to stimulate the production of IFN-g and TNF-a 3067 
from T cells and NK cells. These two cytokines are part of two of the main 3068 
antiviral pathways  in the immune system. IFN-g is a type II interferon which 3069 
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is an important activator of macrophages and induces MHCII molecule 3070 
expression.  It has the ability to directly inhibit viral replication, and has 3071 
extremely important immunostimulatory effects. TNF-a is cytokine 3072 
produced mainly by macrophages, that is involved in systemic 3073 
inflammation. It is produced to regulate immune cells, but can also induce 3074 
fever, inhibit viral replication and cause inflammation. Increased 3075 
expression of IL-12 can lead to the overproduction of IFN-g and TNF-a, 3076 
which, along with IL-6 are the main players in systemic inflammation (231). 3077 
Systemic inflammation can lead to a cytokine storm, which can lead to 3078 
severe neurological complications, and organ failures, such as pulmonary 3079 
oedema and cardiac arrest. My results suggest that the more severe 3080 
isolates have an upregulated expression of IL-12b which could be driving 3081 
this systemic inflammation, through the IFN-g and TNF-a channels (232). 3082 
 3083 
The next step I would take in regards to this experiment would be to run an 3084 
ELISA for IL-12 to see if this increase in IL-12b expression was directly 3085 
relatable into an increase in IL-12 protein expression. If there was an 3086 
increase in IL-12 expression levels, I would next run a qPCR experiment 3087 
on the levels of IFN-g and TNF-a to get a more in depth look to see to what 3088 
extent this pathway has been activated, and to see if this has led to an 3089 
increase in product of IFN-g and TNF-a.  3090 
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5.1.4 IL-36g as a novel cytokine linked to EV71 severity and HFMD  3091 
 3092 
IL-36g is a member of the IL-1 cytokine family, which has be reported to be 3093 
stimulated by the  cytokines IL-1b, IFN-g and TNF-a. This cytokine has 3094 
been linked to psoriasis lesions, as well as being induced during HSV 3095 
infection. This link between three of the main, induced inflammatory 3096 
cytokines reported during EV71; its expression being linked to skin lesions; 3097 
its induction by HSV; and that EV71 infection causes similar style lesions 3098 
on patients during HFMD, may be the initial findings to a novel pathway 3099 
during EV71 infection. This theory is furthered when my results, which 3100 
show that the more severe isolates cause a large upregulation in IL-36g 3101 
gene expression (233). As more IL-1b, IFN-g and TNF-a are produced, 3102 
there will be an increase in the expression of IL-36g, this increase leads to 3103 
a more severe form of HFMD, which in turn creates a greater production of 3104 
inflammatory cytokines, which could eventually lead to systemic 3105 
inflammation and complications. 3106 
 3107 
As IL-36 requires  proteolytic cleavage of its inactivate pro form before it 3108 
becomes the active cytokine, the mRNA expression levels would have to 3109 
be validated by a protein expression study, such as an ELISA or a Western 3110 
blot for the active cytokine, before this theory can be confirmed. I believe 3111 
this could open an interesting area of investigation into EV71 severity, and 3112 
not only the severity, but also the lesions caused by EV71 infection.  3113 
 3114 
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As well as running an ELISA, I would also run a qPCR test on both IL-36 3115 
and IL-36g to get a more focussed view on the expression level of these 3116 
cytokines and tie this in with the ELISA data. If this data proved interesting, 3117 
this could be furthered with a mouse model. I would like see a IL-36 knock- 3118 
out mouse, to see if this would cause any change in the level of severity of 3119 
infection compared to a wild type mouse. This model could provide very 3120 
useful information on the pathways involved during EV71 infection and 3121 
involved in the increase of pathogenesis. 3122 
 3123 
5.1.5 The role and regulation of ISG15 and ISG20 during EV71 infection 3124 
 3125 
Interferon is one of the innate immune responses first line of defence 3126 
against viral pathogens. The pathogens are recognised via PRRs which 3127 
leads to the production of IFNs, these IFNs then signal, through the 3128 
JAK/STAT pathway to induce IFN stimulated genes (ISGs). During viral 3129 
infection, you would expect to see a large increase in IFNs during the early 3130 
stages of infection, which would translate into large increases in ISGs. 3131 
However, due to EV71’s immune evasion techniques mentioned in the 3132 
previous chapter, EV71 has the ability to downregulate  type I IFNs through 3133 
its viral proteases. My results add further evidence to this to this theory. 3134 
There is an initial large increase in ISG15 and ISG20 gene expression 3135 
between 0 and 6hpi. This would normally be expected to continue to rise, 3136 
however, there is no more significant increase in ISG15 and ISG20 3137 
expression (234). They plateau from 6hpi until the end of the time course 3138 
suggesting there is no more increase in IFN stimulation. 3139 
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 3140 
This theory could be further tested with the addition of a positive infectious 3141 
control. A virus that is known to infect PBMCs (Sendai virus for example). 3142 
The infection profile of this virus could be compared to the EV71 profile, 3143 
you would expect the positive control virus to cause a high level of ISG15 3144 
and ISG20 expression, which would constantly increase across the time 3145 
points. This comparison could add further weight to the theory that EV71 3146 
severity is linked to the virus’s ability to evade immune detection.   3147 
5.1.6 The downregulation of MADCAM1 linked to EV71 severity 3148 
 3149 
MADCAM1is the gene which encodes for the protein addressin. 3150 
Addressins act as ligands for the homing receptors of lymphocytes, and 3151 
with the aid of their receptors, determine the tissue the lymphocyte will next 3152 
enter. They are normally used to direct leukocytes into mucosal and 3153 
inflamed tissue. As mucosal and inflamed tissues are normally the primary 3154 
infection sites for EV71 e.g. Peyer’s patches and tonsils, this protein is 3155 
likely to home lymphocytes to these virally infected areas to remove and 3156 
destroy the viruses. However during EV71 infection with isolate 5, the 3157 
severe isolate, the expression of this protein is downregulated. This 3158 
suggests a possible theory that this downregulation of MADCAM1 is a 3159 
further technique of immune evasion by EV71 (235). This downregulation 3160 
is not seen in the other two milder isolates, suggesting that early detection 3161 
avoidance, whilst in the primary infection and replication sites, may lead to 3162 
a more severe infection outcome.  3163 
 3164 
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This theory would need a few more experiments to strengthen its case. 3165 
Firstly it would need to be determined if this decrease in mRNA expression 3166 
would lead to a decrease in protein expression (via ELISA), as it is the 3167 
protein that is the ligand for the homing receptor. If this was downregulated 3168 
the next step would be to measure the gene and protein expression levels 3169 
in mucosal endothelial cells as these would be the cells that actually 3170 
release the ligand to attract lymphocytes to the site of infection. If there was 3171 
a down regulation in the protein expression of MADCAM1 in these cells 3172 
then this could be added to the well populated list of EV71 immune evasion 3173 
techniques.  3174 
5.1.7 The effect of RBFOX3 on neural regulation 3175 
 3176 
RBFOX3 is a gene which encodes for the RNA-binding FOX protein, which 3177 
is involved regulation of alternative splicing of pre-mRNA. It plays a 3178 
prominent role in the regulation of adult brain function and is expressed at 3179 
its highest in the CNS (235). During the infection with the EV71 isolates, 3180 
RBFOX3 was significantly downregulated when the PBMCs were infected 3181 
with isolate 5. This downregulation could suggest that there may be a 3182 
disruption in this pathway. This disruption could be lead to a dysregulation 3183 
of brain function, this combined with a systemic inflammation could cause 3184 
an increased level of neurological complication.  3185 
 3186 
As mentioned with many of the other genes found to be up/downregulated 3187 
during thisev71 PBMC infection, although the mRNA downregulation is a 3188 
good starting point, this needs to be further qualified by a protein 3189 
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expression study. As RBFOX3 plays its regulatory role as a protein, the 3190 
protein level, as well as the mRNA level would have to be down regulated 3191 
for this to have any effect. It is currently unclear as to what RBFOX3 3192 
function and role is in brain regulation, however it is thought to play a role 3193 
in neurogenesis and synaptogenesis (236). If neurons have been damaged 3194 
during EV71 infection, either due to direct viral lysis or through 3195 
immune/cytokine damage, new neurons would be needed to help with the 3196 
recovery of the brain. If a key part in this neurogenesis pathway has been 3197 
downregulated, then this could be a reason why this isolate has much more 3198 
severe effects.  3199 
5.1.8 Severe EV71 may cause the tight junction instability through RASIP1 3200 
downregulation 3201 
 3202 
The RASIP1 gene codes for the protein Ras-interacting protein 1. This 3203 
protein acts a critical regulator for adhesion and GTPase signalling. It also 3204 
regulates RhoA GTPase activity by suppressing RhoA signalling. RhoA, 3205 
mentioned in the previous chapter, acts through its Rho kinase to 3206 
destabilise the barrier proteins of endothelial cells by up-regulating myosin 3207 
light chain kinase-dependent contraction of stress fibres. This causes a 3208 
weakening of the endothelial tight junctions in the BBB leading to decrease 3209 
in the BBB integrity. During the PBMC infection with EV71, isolates 3 and 3210 
5 both downregulated the RASIP1 gene (237). This downregulation would 3211 
cause a decrease in suppression of the RhoA GTPase, leading to decrease 3212 
in BBB stability. As previously stated, type I IFNs have been shown to 3213 
inhibit the RhoA GTPase. Whether this downregulation of RASIP1 is linked 3214 
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to IFN suppression is unknown, however this could be an interesting 3215 
pathway to examine to look at BBB integrity.  3216 
 3217 
I believe an interesting area of further research to look at would be to link 3218 
these results to the RhoA/Rac1 and IFN results seen with the BBB 3219 
infection. A good starting point would be to look the RASIP1, RhoA and 3220 
Rac1 mRNA expression levels via qPCR in both the PBMC and BBB 3221 
infection models, before moving on to the protein expression levels.  3222 
5.1.9 The role of ANKRD1 EV71 infection outcome severity 3223 
 3224 
ANKRD1 encodes for the protein cardiac ankyrin repeat protein (CARD), it 3225 
is a transcription factor involved in conditions of stress to the heart. During 3226 
times of stress ANKRD1 is upregulated to induce CARP production which 3227 
has been shown to be a remodelling and repair protein after disease or 3228 
injury. During EV71 PBMC infection, ANKRD1 was upregulated during the 3229 
more severe isolates’ infection (238). This would suggest that the gene is 3230 
being produced as a defence mechanism in case there is cardiac 3231 
compromise. Some studies have also suggested, that whilst CARP 3232 
performs a repairing role, it can actually have a negative effect on 3233 
contractile function. This could be a step in the pathway that leads to 3234 
cardiac dysfunction and pulmonary oedema during sever EV71 infection.  3235 
 3236 
One suggestion I would have if I was going to run further experiments in 3237 
this area would be to try and look at the RNASeq data from just the infected 3238 
PBMCs (i.e. remove the uninfected PBMCs). As these PBMC infections 3239 
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yielded quite low levels of infectivity and replication, some of the effects 3240 
that the virus is having on the immune system and gene expression levels 3241 
may be masked or diluted by the non-infected cells, or by cells that have 3242 
not come in to high levels of contact with the virus. This could be done by 3243 
sorting the cells using FACS, however this would require fixing the cells 3244 
first which would decrease the amount of RNA available for extraction. 3245 
Nonetheless it would be very interesting to see if any new or different 3246 
changes in gene expression could be seen in these concentrated infected 3247 
cells. I hypothesise that there may be several more pathways of interest 3248 
that could be uncovered with this experiment.  3249 
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 Novel Findings and Overall Conclusions From This 3250 
Work 3251 
Viral infectivity and replication play a big role in outcome severity 3252 
• Viruses that cause a greater level of severity in patients have 3253 
significantly increased levels of infection and replication in vitro. 3254 
Virus isolates from patients with severe outcomes have higher levels 3255 
of infectivity 3256 
• Isolate 1 showed limited infectivity during the PBMC infection 3257 
• Isolates 3 and 5, which both came from patients suffering 3258 
neurological complications, showed significantly higher levels of 3259 
infection in PBMCs 3260 
Only the isolates from the most severe patients can replicate in an ex 3261 
vivo PBMC system 3262 
• Only isolate 5 showed signs of positive replication during the 3263 
infection 3264 
Certain subsets of PBMC show higher susceptibility  for infection 3265 
• Monocytes, T cells and B cells showed significantly higher levels of 3266 
infection than the other subsets.  3267 
CD4+ T Cells are the main instigators of EV71 replication in PBMCs  3268 
• Only CD4+ T cells showed an increase in replication during severe 3269 
EV71 infection 3270 
Severe EV71 isolates show an increased ability to disrupt the BBB 3271 
• Both isolate 3 and 5 show greater levels BBB disruption, with isolate 3272 
5 being the most destructive 3273 
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EV71 can downregulate BBB tight junction and adherens junction 3274 
proteins 3275 
• TJ and AJ gene expression was down regulated during EV71 3276 
infection, compared to mock infected and a non-neurotropic virus 3277 
infection 3278 
EV71 can downregulate immune response genes which may lead to 3279 
a weakened BBB 3280 
• The downregulation of IFN and IFN related genes may lead to 3281 
instability in the BBB junction proteins 3282 
Severe EV71 infection leads to the upregulation of IL-6 3283 
• Isolate 3 and 5 show higher levels of IL-6 gene expression 3284 
IL-36g could be a involved in a novel pathway related to infection 3285 
severity 3286 
 3287 
Immune avoidance could play an early role in EV71 severity 3288 
• The downregulation of MADCAM1 may lead to immune avoidance 3289 
and increased pathogenicity 3290 
  3291 
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